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ABSTRACT 
 
 
 
Identification and characterisation of novel vaccine targets for the 
control of trypanosomiasis 
 
 Trypanosoma brucei is a unicellular protozoan parasite that causes human 
sleeping sickness and animal trypanosomiasis in sub-Saharan Africa. The parasite 
alternates its life cycle between a mammalian host and an insect vector (Glossina 
spp.). Within tsetse flies, trypanosomes undergo a series of developmental changes, 
which allow the parasite to adapt to the different tsetse tissues. Remodelling of the 
parasite surface glycocalyx is completed when the abundant variant surface 
glycoproteins (VSG) are expressed by the infectious metacyclic trypomastigote form 
(MCF) in the tsetse salivary glands. Although the role of the metacyclic VSG coat 
remains unknown, it is assumed this coat is important for parasite transmission and 
that it may mask or prevent the surface exposure of invariant proteins, in analogy with 
the blood stages. However, investigating metacyclic biology has been hindered as 
MCFs have been impossible to culture in vitro and harvesting enough parasites from 
infected tsetse salivary glands to perform biochemical analyses is challenging. In this 
thesis, I used a combination of several biochemical, genetic and cell biology 
methodologies to search for suitable transmission-blocking vaccine candidates to 
help control trypanosomiasis caused by T. brucei parasites. 
 
 A proteomics approach was used to identify parasite soluble factors found in 
T. brucei-infected tsetse saliva that may be crucial for transmission or early infection 
stages of the host. I confirmed that infected saliva is enriched with T. brucei surface 
proteins, including VSGs, Brucei Alanine-Rich Proteins (BARP) and a small, novel 
family of five GPI-anchored glycoproteins presently designated Metacyclic Invariant 
Surface Proteins (MISP). Notably, misp genes are highly transcribed in salivary gland-
associated trypanosomes, but are predominantly expressed in the metacyclic stage. 
The crystal structure of the MISP360 isoform, together with molecular modelling, 
suggests that the MISP N-terminal ectodomains adopt a three-helical bundle 
conformation that is projected above the metacyclic VSG coat, thus exposing 
immunogenic epitopes. When misp genes were silenced by RNAi, a tsetse infection 
phenotype was not observed although these proteins may be important for parasite 
transmission rather than infection establishment. Collectively, these data suggest the 
T. brucei metacyclic trypomastigote surface is not just densely covered with a VSG 
coat, but rather it is more variable and allows for the co-expression of invariant GPI-
anchored glycoproteins, like BARP and MISP, the latter which is more abundant and 
completely accessible to the hosts’ antibodies. Due to these unique characteristics, 
MISP are predicted to be a strong vaccine candidate against trypanosomiasis. 
  
 In order to perform further functional studies on MISP, a system to generate 
T. brucei MCFs in vitro, based on the overexpression of trypanosomal RNA-binding 
protein 6 (RBP6), was developed. In a previous transcriptomic study, designed to 
characterise T. brucei genes involved in parasite migration to the tsetse salivary 
glands and/or metacyclogenesis, RBP6 was also identified among the top hits. Top 
candidates included a gene encoding for a hypothetical protein with an identifiable 
MYND-like zinc finger domain, three different folate transporter genes, and glutamate 
dehydrogenase. These genes were characterised in vitro and in vivo after they were 
expressed in a mutant parasite strain that fails to establish a salivary gland infection. 
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Strikingly, over expression of rbp6 did not rescue the infection phenotype but the gene 
encoding for a MYND-like protein restored salivary gland infectivity and metacyclic 
formation. The T. brucei MYND-like protein function is unknown, but the presence of 
a zinc finger domain, together with its cytosolic localisation, suggest it may be involved 
in the regulation of parasite gene expression. 
 
 Since most of the T. brucei surface proteins are known to be N-glycosylated, 
I conducted a series of preliminary experiments to address the in vivo essentiality of 
parasite N-glycosylation in the tsetse. First, among all oligosaccharyltransferase 
genes (sst3a-c), sst3b is the main isoform expressed during T. brucei development in 
the tsetse. Given its glycan specificity, this suggests that oligomannose N-glycans are 
likely the predominant oligosaccharide in the insect stages. Second, functional studies 
suggest that protein N-glycosylation may be essential for parasite establishment in 
the tsetse salivary glands. Collectively, these results suggest that the T. brucei N-
glycosylation pathway could be exploited to generate new transmission-blocking 
approaches. Lastly, I developed a new methodology for imaging tsetse tissues in 
great detail. We can now generate complete 3D reconstructions of tissues using laser 
scanning confocal microscopy, to study, for instance, the interactions between 
trypanosomes and tsetse or determine changes in the architecture of tsetse tissues 
with different stressors. 
 
 In summary, this thesis focused on the T. brucei stages that colonise the tsetse 
proventriculus and salivary glands to identify key molecules involved with parasite 
differentiation and transmission.  This work carries potential implications for 
transmission-blocking approaches against African trypanosomiases, mainly (but not 
exclusively) caused by T. brucei. The discoveries of MISP, the hypothetical zinc finger 
protein MYND and the essentiality of N-glycosylation have revealed important targets 
for development in the tsetse, which can be studied at a higher level using our new 
imaging methods.   
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1.1 General Introduction 
  
 Neglected tropical diseases (NTDs) are a group of 20 human infections (WHO, 
2018) affecting over a billion people, with major incidence in tropical and sub-tropical 
countries across the globe. Most NTDs are vector-borne and are caused by a broad 
range of infectious pathogens such as bacteria, viruses, protozoa and helminths. The 
burden of NTDs especially affects human populations from low-income countries with 
poor sanitation and in proximity with the disease vectors and livestock. Disease 
control relies on a combination of public health approaches such as vector control, 
screening of populations and mass drug administration. In summary, most NTDs, 
including those caused by kinetoplastid parasites like Leishmaniasis and African 
trypanosomiasis, have a huge impact in the people, economy and development of 
endemic countries (Feasey et al., 2010). 
 
 
1.2 Human African Trypanosomiasis 
 
1.2.1 Importance of the disease 
 
 African trypanosomiasis is a group of vector-borne diseases caused by  
protozoan parasites and mainly transmitted by tsetse flies, which affect both human 
and livestock in sub-Saharan African countries where the vector is found (Barrett et 
al., 2003; Malvy and Chappuis, 2011). Human African trypanosomiasis (HAT) cases 
have declined every year since 2010 due largely to a program of active screening and 
treatment of the human population in endemic areas, together with an efficient vector 
control program (2,184 cases reported in 2016, WHO). However, it is thought that 
these numbers are a vast underestimation since many cases occur in rural areas with 
no access to healthcare (Fevre et al., 2008; Simarro et al., 2012). Animal African 
trypanosomiasis (AAT or Nagana disease), however, continues to cause huge 
economic losses in the agricultural sector with more than 1 million cattle dying of AAT 
each year (Giordani et al., 2016). Despite the low number of reported HAT cases, 
over 70 million people continue to be at risk and so more efforts need to be made 
towards its elimination, for which the World Health Organization (WHO) has 
overambitiously set for the year 2020.  
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1.2.2 Epidemiology  
    
There are currently several parasitic diseases in sub-Saharan Africa known 
as African trypanosomiasis, which affect both humans and animals. HAT, commonly 
known as sleeping sickness, can be caused by two morphologically identical 
subspecies of the unicellular parasite Trypanosoma brucei; i.e. T. brucei gambiense 
and T. brucei rhodesiense (Simarro et al., 2010). These subspecies have different 
geographic distribution (Figure 1.1) and present distinct clinical manifestations. T. b. 
gambiense is found in Central and West Africa, causing a slow chronic form of the 
disease, in where humans are thought to be the main reservoirs of this anthroponotic 
disease. T. b. gambiense HAT was responsible for the ~95% of cases in 2016 (WHO), 
75% of them reported in the Democratic Republic of the Congo. On the other hand, 
T. b. rhodesiense prevails in South and East Africa and causes an acute and virulent 
form of the disease which is mainly zoonotic with multiple animal reservoirs. Only in 
Uganda there is transmission of both subspecies (Picozzi et al., 2005) and, although 
human co-infections have not been reported, T. b. rhodesiense cattle reservoirs have 
been recently described to migrate towards T. b. gambiense endemic areas in North 
Uganda, which could potentially lead to co-infections. Cattle are particularly affected 
by AAT, which is mainly caused by T. congolense, T. vivax and T. evansi. AAT is one 
of the main causes of death for cattle in sub-Saharan Africa, burdening meat and milk 
production which translates in losses of billions of US dollars and halting 
development. AAT spreads beyond the sub-Saharan Africa (Figure 1.1) since 
species like T. vivax or T. evansi, which do not have a complete life cycle in the tsetse, 
can be mechanically transmitted by non-tsetse insect vectors such as horseflies 
(Tabanus spp.) or stable flies (Stomoxys spp.) (Giordani et al., 2016).   
 
HAT is primarily transmitted to humans through the bite of the tsetse fly 
biological vectors, although transmission may eventually occur through blood 
transfusion (Herwaldt, 2001; Hira and Husein, 1979), congenital or even sexual routes 
(De Kyvon et al., 2016; Lindner and Priotto, 2010; Rocha et al., 2004). All 31 Glossina 
species, classified as forest, savannah and riverine types according to habitat, have 
the potential to transmit African trypanosomes and their geographical distribution 
defines the distribution of HAT (Cecchi et al., 2008; Jordan, 1993). The most 
significant tsetse species responsible for T. b. gambiense HAT transmission are the 
riverine G. palpalis and G. fuscipes (Grebaut et al., 2016), whereas the savannah 
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species G. morsitans, G. pallidipes and riverine G. f. fuscipes are the main 
responsible for transmitting T. b. rhodesiense HAT (Shereni et al., 2016). 
 
 
 
Figure 1.1. Geographical distribution of trypanosome species causing human 
African trypanosomiasis and animal African trypanosomiasis in the African 
continent. Distribution of T. b. gambiense and T. b. rhodesiense based on the 
number of reported cases in 2016 (left). Distribution of T. evansi, T. vivax and T. 
congolense. The striped white-dotted area represents the habitat distribution of 
Glossina spp. Modified from WHO (HAT) and Giordani et al. 2016 (AAT). 
 
 
1.2.3 Clinical presentations  
 
The clinical presentations for sleeping sickness vary depending on the 
parasite subspecies, stage of the disease and the response of the host. Both forms 
of the disease are usually fatal if they remain untreated, although individuals may 
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eventually become asymptomatic or self-heal (Jamonneau et al., 2000; Jamonneau 
et al., 2002; Jamonneau et al., 2012). The diseases typically go through two clinical 
stages. In the haemolymphatic stage (stage 1) the parasites remain in the blood and 
lymph, and in some cases, they can invade the adipose tissue and the skin (Trindade 
et al., 2016; Capewell et al., 2016;). Symptoms include intermittent fever, headache 
and skin rash among others (Blum et al., 2006; Duggan and Hutchinson, 1966). To 
progress to the meningoencephalitic stage (stage 2), the parasites cross the blood-
brain barrier invading the central nervous system (CNS) (Masocha et al., 2007) 
leading to neurological alterations that may include sleep disorders, behavioural 
changes, coma and death (Buguet et al., 2001). Recent studies on mice suggest that 
these sleeping disturbances (from which the disease is named) are a result of the 
manipulation of the host’s circadian rhythm by the parasite (Rijo-Ferreira et al., 2018; 
Rijo-Ferreira et al., 2017a; Rijo-Ferreira et al., 2017b). While T. b. gambiense HAT 
takes years to progress (Checchi et al., 2008a; Checchi et al., 2008b), the T. b. 
rhodesiense disease is typically acute and progresses to the stage 2 within weeks 
and death within 6 months (Odiit et al., 1997).  
 
 
1.2.4 Diagnosis 
  
 Disease diagnosis requires specific tests since the clinical symptoms are 
usually unspecific. The diagnosis of T. b. gambiense HAT often starts with the card 
agglutination test for trypanosomiasis (CATT) (Chappuis et al., 2002; Magnus et al., 
1978), which can be done on capillary blood or serum, and it is fast enough to allow 
large-scale screening of populations in endemic areas (Robays et al., 2004). 
However, due to its sub-optimal sensitivity (Jamonneau et al., 2015),  parasitological 
validation by microscopic examination of capillary blood or serum is usually required 
(Lutumba et al., 2005a). Since parasitaemia levels can be below the detection 
threshold, concentration methods may be required such as the microhaematocrit or 
anion-exchange centrifugation techniques (Woo, 1970) (Mumba Ngoyi, 2014). In 
contrast, diagnosis of T. b. rhodesiense infections relies on the unspecific clinical 
manifestation and the history of exposure of the patient because there is no 
serological test available. Microscopy tests, however, are more reliable as the 
parasite densities in blood and lymph are usually high.  The identification of stage 2 
patients for both T. b. gambiense and T. b. rhodesiense diseases by microscopic 
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examination of the cerebrospinal fluid after lumbar puncture is of great importance as 
treatments differ between stages (Kennedy, 2008; Mumba Ngoyi et al., 2013).  
 
 
1.2.5 Treatment 
 
 There is no preventive or therapeutic vaccine against African trypanosomiasis 
mainly because of antigenic variation, the phenomenon by which the parasite evades 
the host’s immune system by periodically changing the variant surface glycoproteins 
(VSGs) coat (Horn, 2014). The only treatments for the diseases rely on the 
administration of five drugs in accordance to the parasite subspecies and stage of the 
infection. Pentamidine isethionate is used intramuscularly as a high-efficacy first-line 
treatment of stage 1 T. b. gambiense infections (Bronner et al., 1991). Intravenous 
infusion of suramin (Gustafsson, 1987), although effective against both subspecies, 
it is only used to treat stage 1 T. b. rhodesiense to prevent strong allergic reactions in 
patients co-infected with onchocerciasis in T. b. gambiense-endemic areas. To treat 
T. b. gambiense stage 2, a combination of nifurtimox (orally) and eflornithine 
(intravenously) therapy (NECT) is frequently used (Priotto et al., 2009). Lastly, 
intravenous melarsoprol is only used to treat stage 2 T. b. rhodesiense infections 
because of its high rate of severe side effects, including death (Schmid et al., 2005). 
The majority of these drugs have moderate rates of unpleasant side effects and low 
fatality rates, being melarsoprol the exception with the highest rates (Franco, 2012; 
Priotto et al., 2009; Schmid et al., 2012) . Remarkably, two new drugs (fexinidazole 
and SCYX-7158) that are currently in advanced phases of clinical trials can 
significantly improve these treatments (Jacobs et al., 2011; Tarral et al., 2014). They 
are orally administered in a few doses to treat both stages of T. b. gambiense and T. 
b. rhodesiense infections, removing the need for stage determination by lumbar 
puncture. Drug resistance has been described as a result of mutations in the parasite 
genome, especially against pentamidine and melarsoprol (Alsford et al., 2013; Graf 
et al., 2013; Munday et al., 2014). New combined therapies such as the NECT are in 
part designed to prevent drug resistance by using several drugs with different modes 
of action.  
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1.2.6 Disease control 
 
 HAT is mainly controlled due to a combination of active surveillance, screening 
and treatment methods, and vector control (Abel et al., 2004; Barrett, 2006; Lutumba 
et al., 2005b). Ceasing these activities may result in a re-emergence of the disease 
in endemic areas (Smith et al., 1998; Van Nieuwenhove et al., 2001). For instance, in 
the 1960s the number of sleeping sickness cases was similar to the current ones, but 
after control strategies halted there was resurgence (Abel et al., 2004; Lyons, 1992). 
The most effective approach for controlling T. b. gambiense HAT is case detection 
during big-scale screening and treatment, which aims to reduce the number of human 
reservoirs (Barrett, 2006). However, some studies suggest that domestic animals, not 
considered in most epidemiological studies, may be also reservoirs for T. b. 
gambiense (Kagbadouno et al., 2012; Njiokou et al., 2006; Simo et al., 2006). In 
addition, the recent discovery of the human skin (Capewell et al., 2016) and adipose 
tissue (Trindade et al., 2016) as parasite reservoirs, and asymptomatic carriers 
(Jamonneau et al., 2012) may be of great importance to improve the efficacy of 
current control methods. The control of T. b. rhodesiense HAT is mainly based on the 
control of domestic animals as the key disease reservoir (Enyaru et al., 2006; Welburn 
et al., 2001; Wendo, 2002), although wild animals also play a role in the epidemiology 
and are more difficult to tackle in control approaches. Additionally, vector control 
strategies which intend to reduce the incidence of tsetse in these foci are of great 
importance too. The use of insecticide-treated tsetse-attractive traps or “tiny targets” 
is the main vector control method currently used (Courtin et al., 2015), although aerial 
(and animal) insecticide spraying and sterile insect technique (or SIT) can also reduce 
tsetse populations depending on the geographical area and Glossina species (Shaw 
et al., 2013; Shaw et al., 2015; Torr et al., 2007). 
 
 WHO has appointed HAT for elimination as a public health problem (i.e. <1 
annual case/10,000 people in a given focus) by 2020. However, eradication or total 
transmission interruption, set for 2030, seems to be a less achievable goal 
considering the current limitations in diagnosis and control of asymptomatic 
individuals or animal reservoirs, especially for T. b. rhodesiense HAT (Simarro et al., 
2015).     
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1.3 Trypanosoma brucei biology 
 
1.3.1 Cell biology 
 
 Trypanosoma brucei is a unicellular parasitic protozoa that belongs to the 
genus Trypanosoma and to the order kinetoplastida (Stevens, 2004). T. brucei is a 
diploid organism containing 11 chromosome pairs in the nucleus along with ~100 
intermediate and mini-chromosomes, which mostly contain arrays of vsg genes 
(Berriman et al., 2005). The megabase-chromosomal genome size is of 
approximately ~ 26 Mb containing 9068 predicted genes, most of them lacking introns, 
and it goes up to ~35 Mb including smaller chromosomes and mitochondrial DNA. T. 
brucei has been extensively studied not only as the causative agent of sleeping 
sickness, but also because of its unique biology as primitive eukaryotic organism. 
Although the human pathogenic subspecies are T. b. gambiense and T. b. 
rhodesiense, the related animal-infectious T. b. brucei has been the main T. brucei 
subspecies used in research due to safety reasons and because of the high 
conservation between their genomes. T. b. rhodesiense is known to have an identical 
genome than T. b. brucei (Sistrom et al., 2016), except for the presence of the serum 
resistance antigen gene (Gibson, 2005; Zoll et al., 2018), which confers resistance to 
killing by human apolipoprotein A1 (APOL1), which is part of the trypanolytic factor 
(TLF) complex (Thomson et al., 2014; Vanhamme and Pays, 2004). Interestingly, T. 
b. gambiense lacks the sra gene, but its resistance to human serum relies on a slower 
endocytosis rate of the TFL (Uzureau et al., 2013). T. brucei is a flagellated organism 
that presents a broad variety of cell sizes and morphologies throughout its life cycle. 
As all eukaryote cells (Figure 1.2), it has one nucleus containing the chromosomal 
DNA, a complex reticular system and a mitochondrion whose morphology varies 
depending on the nutritional conditions. As in all kinetoplastids, T.  brucei has a 
kinetoplast (kDNA) which contains the mitochondrial DNA formed by ~50 maxicircles 
and ~10,000 mini-circles, and it is part of the flagellum insertion complex at the 
flagellar pocket (Simpson and Simpson, 1980; Webster and Russell, 1993). 
Remarkably, the bloodstream form of T. brucei has modified peroxisomes called 
glycosomes in where glycolysis occurs in a compartmentalised manner (Opperdoes 
et al., 1984).  
 
  
25 
 
 
 
 
 
 
 
 
 
Figure 1.2. T. brucei cell architecture. Schematic of a T. brucei bloodstream form 
cell highlighting the major organelles. The DNA is contained in the nucleus and 
kinetoplast. The highly-developed endoplasmic reticulum (ER) and mitochondrion are 
found along the cell. The Golgi apparatus, lysosomes, endosomes and glycosomes 
(only in BSF cells) are usually found between the nucleus and the kinetoplast. The 
flagellar pocket is found at the flagellum insertion site in the cell body. The cell surface 
is usually coated by major surface glycoproteins (e.g. VSGs in BSF cells) and a 
complex grid of pellicular microtubules is found under the plasma membrane to 
control cell shape and motility (modified from Prof. Markus Engstler ®).     
 
 
1.3.2 Life cycle  
 
T. brucei is an obligate parasite that alternates its life cycle between a 
mammalian host and the tsetse fly vector (Figure 1.3). It continuously undergoes 
developmental changes to adapt and overcome the challenges found in the different 
environments in the hosts (Matthews, 2005). These include changes in cell 
morphology, motility, metabolism or glycocalyx composition among others, all 
ultimately a result of either induced or programmed changes in gene expression. 
 
When a tsetse takes a bloodmeal from a T. brucei-infected mammalian host, 
the trypomastigote pleomorphic bloodstream forms (BSFs) reach the midgut  of the 
tsetse. While the BSF ‘slender’ (SL) forms are not capable of surviving in the tsetse, 
the ‘stumpy’ (ST) forms are able to differentiate into the trypomastigote procyclic form 
(PF) (Matthews, 2005; Vickerman, 1985). Within the first week, PFs establish a 
chronic infection in the tsetse MG and reach the ectoperitrophic space (ES) by a 
mechanism that remains unclear but assumed to be due to crossing of the tsetse 
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peritrophic matrix (PM) (Roditi, 1989); see also Chapter 6). During the following week, 
PFs migrate to the tsetse cardia or proventriculus where the elongated mesocyclic 
trypomastigotes establish an infection and differentiate into long epimastigote forms 
(EMFs) (Sharma et al., 2009). These long EMFs undergo an asymmetric division to 
produce short EMFs (Sharma et al., 2008; Van Den Abbeele et al., 1999). It has been 
suggested that the long EMFs, still attached to the short ones, escape the PV via the 
oesophagus to migrate towards the salivary glands (SG). Once in the SGs, the long 
EMFs die whereas the short EMFs attach to the SG epithelium microvilli through the 
flagellipodia and establish a local SG infection after three weeks post-infection. 
Attached EMFs can either replicate or eventually differentiate into pre-metacyclic (P-
MCF) forms which detach from the epithelium (Rotureau et al., 2012; Tetley et al., 
1987; Van Den Abbeele et al., 1999). It has been reported that T. brucei may undergo 
sexual genetic exchange in SG stages only, particularly in rare promastigote-like 
forms with multiple nuclei and kDNA and expressing meiotic markers (Gibson and 
Stevens, 1999; Peacock et al., 2014). P-MCFs dwelling free in saliva finally 
differentiate into non-dividing mature metacyclic trypomastigote forms (MCF) which 
are the only mammalian-infectious stage in the tsetse (Rotureau et al., 2012). Highly 
infectious MCF will be injected along with saliva into the mammalian host when the 
tsetse takes a bloodmeal. 
 
Since tsetse flies are pool feeders (i.e. they break the capillaries to form pools 
of blood in the skin from where they feed) (Gibson et al., 2017), MCFs are normally 
injected into the host’s dermis and not into the bloodstream directly, from where they 
first migrate to the lymph nodes and posteriorly to the peripheral bloodstream. Recent 
studies have shown that MCFs may also reside and proliferate in the dermis at the 
bite site, and closely interact with adipocytes from the connective tissue (Caljon et al., 
2016). This local dermal infection leads to a slight increase in the skin surface 
temperature as a mechanism to improve transmission. It has been proved to 
significantly attract more tsetse at the bite site where there are infectious resident 
parasites.  
 
During the stage 1 of infection, the bloodstream forms populate the blood and 
lymph of the host. The SL forms replicate to increase parasitaemia and undergo 
antigenic variation to evade the host immune system (Horn, 2014; Mugnier et al., 
2016). When a certain SL density threshold is reached, they are thought to excrete 
the ‘stumpy’ induction factor (SIF) to induce the formation ST forms (Mony and 
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Matthews, 2015; Reuner et al., 1997), although a quorum sensing-independent 
mechanism for ST formation linked to antigenic variation has been recently described 
(Zimmermann et al., 2017). STs are known to be arrested quiescent cells that do not 
undergo antigenic variation and are pre-adapted to be infective to tsetse. STs can be 
molecularly distinguished from SLs as the former express large amounts of Protein 
Associated with Differentiation (PAD) transporters, whose surface expression 
increases as a response to the cold-shock suffered by STs inside the tsetse midgut 
(Dean et al., 2009). These proteins transport citrate/cis-aconitate, which are 
metabolites that trigger differentiation into PF. 
 
 
 
Figure 1.3. T. brucei life cycle. T. brucei alternates its life cycle between a 
mammalian host (top) and the tsetse vector. Black circles represent the host spaces 
T. brucei invades which are depicted with actin-stained reconstructed tissues (tsetse) 
or scanning electron microscopy (host blood). Parasite life stages are represented by 
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scanning electron microscopy modified images. In the tsetse cartoon, the relevant 
tissues for trypanosomes infection; i.e. midgut (MG), proventriculus (PV) and salivary 
glands (SG) are highlighted. The discontinued arrow represents the transmission of 
metacyclics to the host skin and the possible re-infection of tsetse from skin parasites. 
The human clinic phases 1 and 2 are represented in the host by the invasion of the 
central nervous system (CNS).   
 
 
For many years, it has been understood that BSF remain in the host’s 
bloodstream and lymph, and can eventually undergo extravasation to the liver, spleen 
and brain (Blum et al., 2008; Kennedy, 2004). It has been recently found that T. brucei 
has, at least, two mechanisms to escape from the hostile environment that are the 
blood and lymph. The parasites can migrate to the adipose tissue (where they are 
called adipose tissue forms (ATFs)) and reach high densities comparable to that in 
blood (Trindade et al., 2016). The ATFs can normally replicate and become STs. 
However, their overall gene expression is remarkably different from those in blood 
since they seem to rely on the catabolism of the host’s fatty acids through beta-
oxidation (Trindade et al., 2016). Alternatively, T. brucei can hide into the host skin in 
where it can replicate, differentiate into ST and be transmitted to the tsetse (Capewell 
et al., 2016). Importantly, the discovery of these novel human tissue reservoirs 
challenges the current epidemiological concept of T. b. gambiense HAT explained in 
section 1.2.6 (Casas-Sanchez and Acosta-Serrano, 2016).    
 
 
1.4 Glossina biology  
 
Tsetse flies (Glossina spp.) are insects from the order Diptera that populate 
most territories in sub-Saharan Africa. Their biology and life cycle are particularly 
unusual compared with most insects. Both male and female feed exclusively on 
animal blood at least twice a week. The feeding host range is broad including humans, 
wildlife and livestock. Behavioural studies have shown that they sense and require 
the host’s heat to guide landing (Chappuis et al., 2013). They are attracted to the 
carbon dioxide exhaled by animals, and some are attracted to blue and black colours 
(Lindh et al., 2012). After host seeking, the fly lands and penetrates the host skin with 
the proboscis. The bite breaks the dermis capillaries to form an intradermal pool of 
blood from where the fly drinks (Gibson et al., 2017). During bloodmeal acquisition, 
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the fly injects saliva rich in factors that inhibit the haemostatic response to the 
cutaneous trauma (Alves-Silva et al., 2010). The fly rapidly engorges by temporarily 
storing the blood into the crop, which then slowly empties into the PV en route to the 
midgut where digestion occurs. Once in the tsetse midgut, the bloodmeal gets 
compartmentalised by the acellular chitin-rich (Lehane et al., 1996) PM. The tsetse 
PM (type II) is constantly secreted by epithelial cells in the PV at an estimated rate of 
~ 1mm/h in young flies and ~0.44 mm/hour in adults (Lehane and Msangi, 1991), and 
its main function is to prevent the blood, digestion products and oral pathogens from 
direct contact with the midgut epithelial cells. The cavity formed between the PM and 
the gut epithelium is known as ectoperitrophic space (ES), which is assumed to be 
the preferred place where PF trypanosomes establish a MG infection (Gibson and 
Bailey, 2003).  
 
After a single mating, the female tsetse stores the sperm in the spermathecae. 
The sperm are released during each gonadotrophic cycle to fertilise the ovulated egg 
during the entire life of the female (Langley, 1993). Since tsetse are viviparous, a 
single larva develops in the uterus after fertilisation, which is nourished by milk 
produced by dedicated, intrauterine milk glands. The larva is birthed ~9 days after 
fertilisation and then buries itself into the soil (to avoid desiccation) where it rapidly 
transforms into a pupa to develop in the dark for 3-4 weeks depending on ambient 
temperatures. After hatching, the newly emerged fly crawls through the soil back to 
the surface and within hours can fly and engage in host-seeking (Jackson, 1946). The 
females reach sexual maturity and deposit the first progeny after 19-22 days under 
ideal climatic conditions. Ovulation cycles occur every 9-12 days, implying that a 
female can produce 8-12 larvae during her lifetime. 
  
Tsetse are naturally highly refractory to a trypanosome infection, but age is a 
critical factor and young, newly emerged flies show the highest susceptibility (Van 
Hoof, 1937).  This is called the teneral phenomenon (Haines, 2013).  While adult flies 
are rarely susceptible to parasite infection, teneral (unfed, recently-emerged flies) 
tsetse are very susceptible to trypanosome infection mainly due to three factors 
related with an underdeveloped immunity (Wijers, 1958). First, the PM is yet immature 
and discontinuous (Wigglesworth, 1929), which facilitates trypanosome invasion of 
the ES, critical for the establishment of a MG infection. Second, several immune 
molecules (e.g. tsetse-EP, antimicrobial peptides and ROS), which are known to 
prevent trypanosome infections, are less active in a teneral MG and PV compared to 
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adult flies (Haines et al., 2010; Weiss et al., 2013). Lastly, the type of microbiota 
present at the time of the infection also effects the susceptibility of teneral flies to 
trypanosome infections (Wang et al., 2013). There are three important tsetse bacterial 
symbionts which are known to modulate both tsetse and trypanosome physiology. 
The gram-negative bacterium, Wigglesworthia glossinidia, is an obligate symbiont 
mainly found in the tsetse bacteriome and milk glands, which provides nutritional, 
immunological and reproductive advantages to the tsetse (Chen et al., 1999). The 
gram-negative facultative bacterium, Sodalis glossinidius, exists intra- and 
extracellularly in a broad range of tsetse tissues (Cheng and Aksoy, 1999) and has 
been linked to increase susceptibility to a trypanosome infection by interfering with 
trypanocidal mechanisms (Dr. Lee Haines, unpublished). Lastly, the gram-negative 
facultative Wolbachia is only located intracellularly in germ line tissues and modulates 
tsetse fertility.  The presence of Wolbachia has been found to correlate with an 
increased resistance to trypanosomes (Cheng et al., 2000).  
 
 
1.5 Trypanosoma brucei major surface glycoproteins  
 
1.5.1 Variant Surface Glycoproteins and antigenic variation 
 
 During its life cycle, T. brucei expresses abundant surface 
glycosylphosphatidylinositol (GPI)-anchored glycoproteins, which are 
developmentally regulated and involved in parasite protection. The best studied of 
these molecules are the VSGs, which in the blood stages are primarily responsible 
for antigenic variation (Horn, 2014; Mugnier et al., 2016). Each BSF cell expresses 
on the surface ~5 x 106 VSG homodimers (Cross, 1975), which creates a 
macromolecular barrier that masks invariant surface proteins such as receptors or 
transporters. VSG monomers have an estimated molecular size of 50-60 kDa, they 
are formed by a large N-terminus domain and one or two small C-terminus domains 
interconnected by a linker domain (Figure 1.4-A) (Freymann et al., 1990). Recent 
studies have shown that these linkers provide great flexibility between domains, so 
VSGs can adopt two different spatial conformations to adapt the coat thickness in 
response to the protein density of invariant surface proteins (Bartossek et al., 2017). 
The GPI anchor of VSG molecules provides free diffusion of these molecules along 
the membrane (Ferguson et al., 1988). This is essential for the clearance of anti-VSG 
antibodies by endocytosis of the complex immunoglobulin-VSG and subsequent 
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recycling of the VSG (Engstler et al., 2007). Most VSGs are known to be N-
glycosylated with up to three N-glycans and, despite N-glycans seem not to be 
essential to create an effective coat, they have been suggested to play a role in filling 
the empty spaces between homodimers (Mehlert et al., 2002). Besides their role in 
antigenic variation in the vertebrate host, T. brucei VSGs have been recently 
suggested to promote the colonisation of the tsetse midgut by trypanosomes by 
downregulating the expression of genes involved in PM synthesis (Aksoy et al., 2016). 
  
 T. brucei has a wide repertoire (>1,000) of genes encoding for VSG proteins 
with variable sequences (Berriman et al., 2005; Cross et al., 2014), but conserved 
tertiary structures (Blum et al., 1993). Antigenic variation is based on the expression 
of clone-specific single VSG in combination with periodical switching of the expressed 
VSG (1 switch/105 cells per generation), which is controlled through a mechanism of 
monoallelic expression that remains poorly understood (Horn, 2014). Surface 
exposure of VSGs triggers the generation of trypanolytic anti-VSG antibodies by the 
host’s immune system as the major mechanism for parasite clearance (Mugnier et 
al., 2015). It takes ~1 week to generate the anti-VSG antibody response, time period 
in which the parasite population expands without control reaching high densities that 
leads to the formation of ST forms. Then, anti-VSG antibodies effectively clear most 
of the clonal population except for a minority of cells that switched to express another 
immunogenically-different VSG. These clones can freely expand within the next 
antibody-generation period until the new antibody response is launched (Figure 1.4-
B). 
 
In the blood stages, VSGs are expressed from one of the ~20 sub-telomeric 
expression sites (BES) (De Lange and Borst, 1982). The basic structure of a BES 
consists in an RNA polymerase I promoter (Gunzl et al., 2003) placed at ~ 60 kb 
upstream the vsg gene (Figure 1.4-C) (Zomerdijk et al., 1990). In between, there is a 
series of up to 12 expression site-associated genes (ESAGs), which are 
polycistronically co-transcribed with the vsg (Cully et al., 1985). ESAGs are known to 
be important in immune evasion (i.e. ESAG4 flagellar adenylate cyclase and T. b. 
rhodesiense SRA) or nutrient acquisition (i.e. ESAG6/7 transferrin receptor and 
ESAG10 folate transporter) (Gadelha et al., 2015). Most ESAGs have paralog genes 
in chromosomal regions called Genes Related to ESAGs (GRESAGs). A short 70-bp 
repeats sequence is found upstream the vsg gene to promote vsg recombination 
events (Liu et al., 1983). BSF can switch VSG expression by multiple mechanisms 
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(Horn, 2014). First, they can shut down the expression of the active BES and switch 
on the expression of a previously-silenced BES (Glover et al., 2016). Second, the vsg 
gene in the active BES can be replaced by homologous recombination through the 
70-bp repeats sequence either from a silent BES or from the sub-telomeric arrays of 
vsg genes usually found in minichromosomes (Cross et al., 2014; Williams et al., 
1982). Alternatively, vsg genes can recombine with each independently from the 70-
bp repeats through short conserved sequences in the open reading frame to generate 
mosaics (Marcello and Barry, 2007). 
 
 
 
Figure 1.4. VSGs and antigenic variation. (A) Crystal structure of a VSG 
homodimer (VSG221, PDB: 1VSG) GPI-anchored to the outer face of the BSF plasma 
membrane. Domains highlighted: N-terminus domain (NTD), C-terminus domain 
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(CTD), linker and both monomers. (B) Schematic of T. brucei antigenic variation 
representing the parasitaemia peaks in function of time in the mammalian 
bloodstream. (C) Structural representation of a BES (BES-1 as example) containing 
the vsg221 gene, ESAGs (numbered boxes, Y represents the pseudogenes), the 70-
bp repeats sequences (striped boxes) and the RNA pol I promoter. Below, a putative 
MES and a mini-chromosome are represented.   
 
 
1.5.2 Metacyclic Variant Surface Glycoproteins 
 
The expression of BSF VSGs is shut down right after trypanosomes are taken 
up by the tsetse vector and start to differentiate into the procyclic stage. Within 24h, 
the VSG coat gets completely replaced by a new one mainly composed of procyclins 
(Roditi et al., 1989). However, before the formation of mature MCFs in the SGs, a 
new coat of metacyclic VSGs (mVSG) is reexpressed by P-MCF parasites (Tetley et 
al., 1987). Although MCFs do not appear to undergo antigenic variation probably due 
to their short half-life in the mammalian host, it seems that acquisition of the mVSG 
coat may still be essential for parasite virulence and survival in the vertebrate host 
(Tetley et al., 1987). Based on monoclonal antibody recognition, it is estimated that a 
population of tsetse-derived MCFs expresses as many as 27 different mVSGs (also 
known as metacyclic variant antigen types (mVATs)) (Barry et al., 1983; Le Ray et 
al., 1978; Lenardo et al., 1984; Turner et al., 1988), although like in BSFs individual 
cells express only one mVSG at-a-time. Some studies, in an attempt to develop a 
vaccine against sleeping sickness, tried to perform immunisations with neutralised 
MCF to generate protection against all mVATs. Despite obtaining some level of 
protection against most mVATs, full protection was never achieved. mVSGs are 
expressed from the metacyclic expression sites (MES) placed in sub-telomeres of the 
largest chromosomes (Alarcon et al., 1994; Barry et al., 1983) (Figure 1.4-C). Unlike 
BES, MES lack functional ESAGs. There is no apparent recombination between 
mVSGs because they lack the 70-bp repeats sequences upstream the mvsg gene. 
Remarkably, Pol-I transcription of MES is monocistronic and life-stage regulated 
rather than post-transcriptionally as the vast majority of T. brucei genes (Graham and 
Barry, 1995; Lenardo et al., 1986) (see section 1.6). In general, MCFs have been 
under-investigated compared to BSFs due to the scarce yield of cells obtained from 
inefficient controlled tsetse infections, and to the lack of an in vitro production system. 
Thus, it has been assumed over decades that the surface glycocalyces of both MCFs 
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and BSFs are equivalent and that in both, their VSG molecules hide the low copy 
number invariant surface proteins from the immune system.    
 
 
1.5.3 Procyclins 
 
PFs are known to abundantly express GPI-anchored procyclins on the 
surface, a family of proteins that appears important for an efficient cyclical 
transmission in the tsetse, but whose biological function remains unknown (Vassella 
et al., 2009). Within the first days of MG infection, recently-differentiated or ‘early’ 
procyclic cells first express GPEET, a form of procyclins that contains 5-6 Glu-Pro-
Glu-Glu-Thr repeats at the C-terminus and in which all Thr residues can be 
phosphorylated (Mowatt and Clayton, 1987; Roditi and Clayton, 1999; Roditi et al., 
1989). After several days, GPEET gets then replaced by a family of EP procyclin 
isoforms, which contain 18-30 Glu-Pro repeats at C-terminus depending on the 
isoform, and whose expression is maintained in trypanosomes infecting either the 
tsetse MG or PV (Roditi et al., 1987; Sharma et al., 2008). There are several EP 
isoforms (EP-1, EP-2 and EP-3) that differ in the length of the repeats domain and the 
presence or absence of N-glycans (Acosta-Serrano et al., 1999; Acosta-Serrano et 
al., 2001)(see section 1.7.5). In culture, GPEET expression can be maintained in the 
presence of glycerol and absence of glucose, otherwise PCF preferentially express 
EP isoforms (Vassella et al., 2000). Procyclins transcription is carried out by the RNA 
polymerase I in the nucleolus (Schumann Burkard et al., 2013). Remarkably, both 
GPEET and EP procyclins undergo N-terminal proteolysis in the tsetse MG but not in 
culture, suggesting that cleavage is probably produced by vector proteases (Acosta-
Serrano et al., 2001).  
 
 
1.5.4 Brucei Alanine-Rich Proteins (BARPs) 
 
Further in development, mesocyclic trypomastigotes in the PV still conserve 
the EP procyclin coat and, although controversial, the asymmetrically dividing PV 
EMFs still display EP remains (Sharma et al., 2008). Parasites dwelling in SGs, 
however, despite transcribing procyclin genes, no longer translate them into proteins 
(Acosta-Serrano et al., 2001; Urwyler et al., 2005). The procyclin surface coat of 
attached epimastigotes in the SGs is replaced by a coat of BARPs (Urwyler et al., 
  
35 
2007). There are 14 BARP isoforms in the T. brucei genome (Berriman et al., 2005), 
and their expression is up to 20-fold upregulated in SG parasites compared to MG 
procyclics (Urwyler et al., 2007). The structure and biological role(s) of BARP remain 
unknown to date. T. brucei BARP haven been suggested to be analogue proteins to 
the T. congolense Glutamic Acid-Rich proteins (GARPs) (Bayne et al., 1993), which 
are also expressed in epimastigote forms infecting the tsetse mouthparts, and their 
function remains undetermined.    
  
 
1.6 Gene expression regulation in Trypanosoma brucei 
 
 In T. brucei, long arrays of genes are transcribed polycistronically by the RNA 
polymerase II (Berriman et al., 2005; Johnson et al., 1987), except for major surface 
glycoproteins such as VSGs or procyclins, which are transcribed by RNA polymerase 
I (Gunzl et al., 2003; Schumann Burkard et al., 2013). The polycistronic transcripts 
become then monocistronic after a trans-splicing event coupled to polyadenylation of 
the 3’ ends (Figure 1.5) (LeBowitz et al., 1993; Matthews et al., 1994). During trans-
splicing, a 39-nucleotide splice leader transcribed by the RNA pol II or III, containing 
the 5’ cap structure required for translation, is added at the 5’ end of each spliced 
monocistronic transcript, and individual transcripts are then separated by cleavage 
from upstream genes by RNAses (Patzelt et al., 1989; Perry et al., 1987). cis-splicing 
is virtually absent in T. brucei. Unlike higher organisms, gene expression in T. brucei 
is mainly regulated post-transcriptionally at the level of trans-splicing and 
polyadenylation, which determine RNA stability (Liang et al., 2003). However, mature 
mRNA levels may greatly vary between flanking genes or within the same gene during 
different developmental stages of the parasite (Archer et al., 2009; Vasquez et al., 
2014). This precise regulation, which shapes most of the morphological and metabolic 
changes, essential for parasite adaption to the different environments, is mainly 
carried out by RNA-binding proteins (RBPs) (Clayton, 2013; Glisovic et al., 2008). 
RBPs have been shown to be involved in life cycle development, differentiation, cell 
cycle, rRNA processing and heat shock response. The T. brucei genome contains 
~150 genes encoding for proteins with putative RNA-binding domains (Berriman et 
al., 2005). RBPs typically bind the untranslated regions (UTRs) of the transcripts to 
modulate their fate, including synthesis, localisation, turnover and decay among 
others (Clayton, 2013; Siegel et al., 2011). For instance, RBP10 is known to play a 
role in BSF differentiation as overexpression in PCF led to the reverse differentiation 
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to BSF (Mugo and Clayton, 2017; Mugo et al., 2017). On the other hand, RBP6 which 
is only expressed in PV trypanosomes, was found to be related with differentiation too 
when its overexpression forced PCF to differentiate into EMFs and MCFs in vitro 
(Kolev et al., 2012).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. Post-transcriptional regulation of gene expression in T. brucei. An 
array of chromosomal genes is transcribed by the RNA pol I or II to create a 
polycistronic pre-mRNA. Simultaneously, the splice leader (SL) 39 nt sequence is 
transcribed by the RNA pol III or II and modified by the addition of a 5’ cap and 
depletion of a 100 nt 3’ sequence. Trans-splicing of the polycistronic pre-mRNA 
couples the SL to single monocistronic mRNAs which are polyadenylated. The RNA-
binding proteins (RBPs) can then bind the 3’ UTR of the mRNA and determine its fate 
involving either translation to protein, storage or degradation.   
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1.7 N-glycosylation 
 
 Virtually, all eukaryote organisms are able to undergo protein glycosylation, 
even ancient organisms like Plasmodium spp. which have truncated glycosylation 
pathways (Cova et al., 2015). Protein glycosylation is a post-translation modification 
(PTM) consisting in the attachment of mono-, oligo- or polysaccharide to a newly 
synthesized protein (Parodi, 1998; Varki, 1993). To date, 5 different types of protein 
glycosylation have been described in eukaryote organisms, among which N-
glycosylation and O-glycosylation are the most common ones. N-glycosylation 
consists in the addition of an N-glycan chain to the sequon Asn-X-Ser/Thr (where X 
can be any residue except proline) (Marshall, 1972). Among other properties, N-
glycans are important for protein folding, stability and solubility (Helenius and Aebi, 
2004). However, the role of N-glycans may vary between proteins and glycosylation 
sites, and their depletion may not always critically affect the normal function of the 
protein (Kornfeld and Kornfeld, 1985). N-glycans are attached to proteins via the 
anomeric carbon of the innermost b-N-acetylglucosamine (GlcNAc) residue linked to 
the Asn amide nitrogen (Marshall, 1972). The sole presence of the Asn-X-Ser/Thr 
sequon does not always ensure the addition of the N-glycan as the residues 
surrounding the sequon have been shown to play a role in the processing (Izquierdo 
et al., 2009b). Addition of N-glycans to proteins is the main type of protein 
glycosylation present in African trypanosomes, including all T. brucei sub-species 
(Ferguson, 1997) .  
 
 
1.7.1 N-glycan structures 
 
There are three main types of N-glycans based on their structure and 
composition: oligomannose, complex and hybrid N-glycans (Figure 1.6) (Varki et al., 
2015). They all share a common core structure of Mana1-6(Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb, but differ in the extensions. The oligomannose type N-glycans 
typically contain two to six a-mannoses on top of the three mannose residues from 
the core (five to nine mannose residues in total) thus creating a tri-antennary glycan. 
In contrast, the complex type N-glycans have a more diverse composition typically 
including bisections from the core mannose residues of NeuAca2-3/6Galb1-
4GlcNAcb (where Neu is sialic acid and Gal is galactose). Other common variants 
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include tri- and tetra-antennary structures. Hybrid N-glycans present characteristic 
structures from both oligomannose and complex types. They usually contain 
mannose residues attached to the Mana1-6 arm and a bi- or tri-antennae containing 
a complex type structure attached to the Mana1-3 arm (Figure 1.6).    
 
 
 
Figure 1.6. N-glycan structural types. Schematic of the representative structures 
for the three major types of N-glycans: oligomannose, complex and hybrid. 
Monosaccharide code on the right, linkages annotated between residues.   
 
 
1.7.2 N-glycan biosynthesis and processing 
 
The biosynthesis and processing of N-glycans occur entirely in the ER and 
Golgi apparatus of the eukaryote cells, carried out by a series of enzymes associated 
to the membranes of these organelles (Figure 1.7) (Helenius and Aebi, 2004; 
Helenius et al., 2002; Kornfeld and Kornfeld, 1985). Briefly, a precursor lipid-linked 
oligosaccharide is first synthesised and posteriorly transferred to the glycoprotein in 
the ER. The resulting (immature) N-glycan is usually trimmed and modified in both 
the endoplasmic reticulum (ER) and Golgi apparatus to produce its final structure. 
 
The formation of the lipid-linked precursor oligosaccharide starts in the 
cytoplasmic face of the ER membrane. Two distinct transferases, UPD-
GlcNAc:dolichol-P (ALG7) and UDP-GlcNAc:GlcNAc-1-P (ALG13/14), add two 
GlcNAc residues to dolichol-phosphate (P-Dol) –from the nucleotide activated sugar 
donor uridine diphosphate (UDP)-GlcNAc– forming GlcNAc2-P-P-Dol. Posteriorly, a 
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series of mannosyltransferases (ALG1, ALG2 and ALG11) add 5 mannose residues 
–using Man-P-Dol as donor– forming Man5GlcNAc2-P-P-Dol. This precursor, still 
facing the cytosolic side of the ER membrane is then translocated into the luminal ER 
face by a flippase known as RFT1 (Helenius et al., 2002) thus becoming the substrate 
of the mannosyltransferases ALG3, ALG9 and ALG12 forming Man9GlcNAc2-P-P-
Dol. Unlike Man-transferases involved in the synthesis of Man5GlcNAc2-P-P-Dol, 
ALG3, ALG9 and ALG12 use GDP-Man as donor. Depending on the organism and 
cell type, the intermediate Man9GlcNAc2-P-P-Dol is further decorated with three a-
glucose (Glc) residues forming the final mature precursor Glc3Man9GlcNAc2-P-P-Dol. 
The glucosyltransferases, ALG6, ALG8 and ALG10, which use GDP-Glc as donor, 
are in responsible for transferring these three terminal Glc residues.  
 
The mature oligosaccharide is co-translationally transferred en bloc to the 
nascent glycoprotein by the oligosaccharyltransferase complex (OST). The 
mammalian OST complex is formed by up to nine transmembrane proteins, being 
STT3 the catalytic subunit. After transfer, the N-glycan is trimmed in the ER lumen to 
remove the three Glc residues and at least one Man residue by the exoglycosydase 
glucosidase I/II and the ER mannosidase I, respectively. The N-glycan is then 
monoglucosylated by a glucosyltransferase to enter into the calnexin/calreticulin 
(chaperones) cycle for proper protein folding and quality control (Helenius and Aebi, 
2004; Parodi, 2000). Incorrectly folded proteins can either lose the glycan, be re-
glucosylated and re-folded, or signalled for degradation through a process known as 
endoplasmic-reticulum-associated protein degradation (ERAD). Unlike lysosomal 
proteins, most glycoproteins leave the ER and enter the Golgi apparatus for further 
glycan processing. At the Golgi, mannosidase I removes up to four Man residues and 
the resulting glycan (oligomannose) can then remain unaltered or can be further 
modified by a broad range of enzymes to form complex and hybrid type N-glycans. 
The final structure of a particular N-glycan is not directly encoded in the DNA code of 
a gene but depends on multiple factors related with glycan processing in the Golgi, 
including availability and concentration of activated sugar donors, abundance and 
compartmentalisation of transferases, glycan accessibility, and differential speed of 
the reactions, among others.         
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Figure 1.7. N-glycosylation synthesis pathway. Assembling of the precursor 
oligosaccharide starts (1) at the ER cytosolic face where a series of enzymes (pink 
italics font) build up the Man5GlcNAc2-P-P-Dol which is then translocated into the 
luminal ER face (2) where the structure is modified until the final precursor 
Glc3Man9GlcNAc2-P-P-Dol is made. The precursor is then linked en bloc to an 
asparagine from the nascent glycoprotein by the oligosaccharyltransferase (OST). 
The N-glycoprotein enters the calnexin/calreticulin cycle for quality control of folding 
(4), the N-glycan structure is reduced to a Man9GlcNAc2 and the folded N-glycoprotein 
exported to the Golgi apparatus (5) for further trimming and modifications of the N-
glycan. Schematic modified from Essentials of Glycobiology, A. Varki.  
 
 
1.7.3 N-glycosylation in Trypanosoma brucei     
 
 T. brucei has a simpler N-glycosylation machinery compared to most of 
eukaryotes, but efficient processing (~96%) of all potential N-glycosylation sites 
(Parodi, 1993a, b). Trypanosomes cannot synthesize the activated sugar donor, Glc-
P-Dol, and also lack the glucosyltransferases ALG6, ALG8 and ALG10. 
Consequently, they are unable to undergo the glucosylation steps to form the mature 
precursor Glc3Man9GlcNAc2-P-P-Dol from Man9GlcNAc2-P-P-Dol. The lack of 
glucosylation of the N-glycan precursor is characteristic of all trypanosomatid 
parasites. T. brucei in particular can either transfer Man9GlcNAc2 or Man5GlcNAc2, 
depending on the parasite life stage; i.e. while BSFs transfer both glycans, procyclics 
only transfer Man9GlcNAc2. The quality control calnexin/calreticulin is present in 
trypanosomatids (despite having unglucosylated precursor oligosaccharides) thanks 
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to a glucosyltransferase dependent on uracil diphosphate(UDP)-Glc and a 
glucosidase II. In addition, the OST complex is much simpler compared to that from 
mammals and it is only composed by the catalytic subunit STT3.  
 
 
1.7.4 Glycosylphosphatidylinositol (GPI) anchors  
 
GPI anchors are PTMs that allow the attachment of proteins to the outer leaflet 
of the plasma membrane through a lipid-linked glycan, as an alternative to protein 
transmembrane domains (Ferguson, 1999). GPI anchors are ubiquitous among 
eukaryotes and especially abundant in protozoa such as kinetoplastids (Ferguson and 
Williams, 1988), being the only exception so far Trichomonas vaginalis, which lacks 
the whole GPI machinery (Hirt et al., 2011). The first GPI anchor structure was solved 
from a T. brucei VSG (Ferguson et al., 1988). GPI-anchored proteins may have very 
diverse functions such as adhesion, signalling, hydrolysis or cell protection. All known 
GPI anchors are attached through an ethanolamine phosphate (EtNP) group to the 
C-terminus of the protein, and they are formed by a common core structure (Varki et 
al., 2015). The oligosaccharide Mana1-2Mana1-6Mana1-4GlcNa1-6 (being GlcN 
glucosamine) links the EtNP to the phosphatidylinositol (PI) moiety containing a D-
myo-inositol-1-P and up to three fatty acids that anchor the molecule to the plasma 
membrane (McConville and Ferguson, 1993). GPI anchor structures are broadly 
variable since up to eight side chains of the oligosaccharide can be substituted by 
several chemical groups, and the glycerol-fatty acids may vary in length and 
chemistry, including the loss of one fatty acid forming a lyso-PI. GPI anchors are first 
synthesized in the ER, in where they are posteriorly attached to the newly-synthesized 
protein with simultaneous cleavage of the GPI anchor signal peptide. Lastly, both the 
fatty acids and the carbohydrate side chains can be modified in the ER and Golgi.    
Some protozoa and mycobacteria also express glycoinositol phospholipids (GIPLs) 
on the cell surface resembling protein-free GPI anchors (Ferguson, 1997). They have 
been reported in T. brucei, T. cruzi and L. major among others, and their biological 
function remains undetermined.  
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1.7.5 N-glycan and GPI anchor structures in Trypanosoma brucei 
 
 In T. brucei, N-glycosylation has been found to be the only type of protein 
glycosylation. N-glycan and GPI anchor structures have been extensively studied in 
major surface glycoproteins of biological relevance, mainly VSGs and procyclins 
(Figure 1.8) (Ferguson, 1997). In addition, in T. brucei BSFs, flagellar pocket 
glycoproteins can be modified with giant complex-type N-glycans that can contain 
more than 50 N-acetyl-lactosamine (Galb1-3GlcNAc) repeats (Atrih et al., 2005). 
These structures are the largest N-glycans ever reported from any organism. 
   
 GPEET procyclins lack N-glycosylation sites, and only EP-1 and EP-3 have 
been found to be N-glycosylated in a single N-terminal residue (Asn29) (Acosta-
Serrano et al., 1999; Hwa et al., 1999). The only N-glycan identified in these sites is 
the oligomannose Man5GlcNAc2. Procyclin GPI anchors (either from GPEET or EP) 
show more structural variability and complexity. The PI moiety is unusual in that it is 
composed of lyso-(acyl)PI species, containing mostly stearic acid (C18:0) in the sn-1 
position and a heterogeneous acyl chain (mainly C18:0, C18:1 and C18:2) linked to 
the inositol ring. Lastly, the core mannoses are decorated with branched 
polylactosamine repeats that may be sialylated, forming oligosaccharides of average 
composition NeuAc5Gal9GlcNAc9 (Izquierdo et al., 2009a; Mehlert et al., 1998). Since 
T. brucei cannot synthesise sialic acid, this one is added by trans-sialidases 
depending on the presence of the sugar donor in the environment (from either the 
mammalian host or tsetse vector) (Engstler et al., 1993; Engstler and Schauer, 1993). 
 
VSGs, in contrast, can present more complex N-glycans but simpler GPI 
anchor structures. The main types of N-glycan found linked to VSG polypeptides are 
the oligomannose Man9GlcNAc2 and variable complex-type glycans that may contain 
terminal aGal residues (i.e. Gala1-3)2(Galb1-4GlcNAc)2Man3GlcNAc2 (Ferguson, 
1997) and or several degrees of poly-acetyllactosamine repeats (Galb1-
4GlcNAc)nMan3GlcNAc2. As for the composition of the VSG GPI anchor, it contains a 
lipid moiety exclusively composed of di-myristoyl(C14:0)glycerol-PI, while the 
mannosylated glycan core is decorated with a variable number of aGal residues, 
depending on the VSG type (Ferguson, 1997; Izquierdo et al., 2009a; Mehlert et al., 
1998).  
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Figure 1.8. N-glycan and GPI glycan structures in T. brucei. Major 
structures identified in VSGs from BSF (left) and EP procyclins from PCF. 
Monosaccharide key at the bottom, linkages annotated between residues. The +/- 
symbols indicate the residues that can be sometimes absent. Sialic acid is added 
depending on the expression of trans-sialidases and the presence of the sugar donor 
in the environment.  
 
 
The N-glycan or GPI anchor structures from other major T. brucei surface 
glycoproteins, such as BARP or mVSGs (from SG EMFs and MCFs, respectively), 
remain unknown mainly because these life stages cannot be cultured in vitro, and 
tsetse-derived parasites cannot be obtained in sufficient number for standard 
structural analyses based on mass spectrometry approaches.    
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1.7.6 Functional studies on Trypanosoma brucei N-glycosylation  
 
A key enzyme in the N-glycosylation pathway, STT3, has been extensively 
used for the study of N-glycosylation (Castro et al., 2006; Hese et al., 2009; Izquierdo 
et al., 2009b; Nasab et al., 2008). The T. brucei genome contains three paralogs 
(stt3a, stt3b and stt3c) and one pseudogene (stt3h) encoding for at least three distinct 
STT3 catalytic subunits of the trypanosome OST, which have no homology with OST 
subunits found in higher organisms (Berriman et al., 2005). It has been determined 
that T. brucei differentially expresses the STT3 isoforms depending on the stage of 
development (Izquierdo et al., 2009b). Cultured BSF express STT3A and STT3B in a 
similar proportion, while PCF mainly express STT3B. The expression of STT3C was 
found to be undetectable in both parasite stages and therefore it has been suggested 
that it may play a role in the tsetse stages of the parasite (e.g. epimastigotes).  Unlike 
STT3A, both STT3B and STT3C were found to rescue Saccharomyces cerevisiae 
Dstt3 mutants. Interestingly, isoforms STT3A and STT3B have very different 
specificities regarding the type of oligosaccharide precursor they better transfer. For 
example, STT3A has a clear preference to transfer the intermediate biantennary 
precursor Man5GlcNAc2, which has been proved to be the only route for the formation 
of complex N-glycans in BSFs. In contrast, STT3B only transfers the full triantennary 
precursor Man9GlcNAc2 as the sole route for the creation of oligomannose N-glycans. 
Consequently, BSF can N-glycosylate proteins with complex and oligomannose 
glycans, as previously described in VSGs (Mehlert et al., 1998), because they express 
both STT3A and STT3B, while PCF mainly express STT3B and thus only 
oligomannose N-glycans are found in the procyclins (Hwa et al., 1999).  
 
In addition, the STT3 isoforms also differ in the specificity they present for the 
amino acid residues flanking the N-glycosylation sequon (Izquierdo et al., 2009b). 
While STT3A and STT3C were found to present similar patterns of specificity for 
acidic residues, STT3B has an increase tolerance for different flanking residues. 
Accordingly, the isoelectric point of the flanking residues of the glycosylation sequon 
can directly determine which isoform will preferentially glycosylate a specific site and 
with which oligosaccharide precursor, thus determining the N-glycan type. However, 
other factors like secondary and tertiary structure of the polypeptide, or the position 
that the N-glycosylation site occupies in the protein may slightly alter this dogma. As 
for the essentiality of STT3 in T. brucei, partial depletion of N-glycosylation after RNAi 
of stt3 genes led to severe growth defects in cultured BSF, and this effect was 
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magnified in vivo resulting in low parasitaemia levels in infected mice (Izquierdo et al., 
2009b). The essentiality of N-glycosylation for development and transmission in the 
tsetse remains unknown, although N-glycans do not seem to be essential for the in 
vitro growth of PCFs. Interestingly, BSF cells exposed to glycan-binding agents which 
normally induce cell lysis became resistant in vitro by either down-regulation of 
specific stt3 genes (Castillo-Acosta et al., 2016) or by undergoing recombination 
between stt3 genes to create chimera enzymes which produced glycan structures for 
which the glycan-binding agents had no affinity (Castillo-Acosta et al., 2013). 
However, mouse infectivity of these mutants was severely compromised, highlighting 
the importance of specific glycan structures for parasite virulence.  
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1.8 Aims of the thesis 
 
As reviewed above, vaccine development against sleeping sickness and African 
animal trypanosomiases has been hampered mainly because of antigenic variation 
and the masking of invariant surface proteins by the VSG coat in the parasite blood 
stages. In addition, the inability to culture in vitro metacyclic trypomastigotes, together 
with the difficulties in accessing a suitable tsetse facility for infection experiments, 
have prevented the development of a transmission-blocking vaccine against 
trypanosomiasis. Thus, this thesis aimed to identify and characterise novel targets in 
tsetse-derived metacyclic trypomastigotes for the potential development of 
transmission-blocking or preventive approaches against African trypanosomiases. 
The specific aims of this thesis were: 
 
1. To characterise a novel family of T. brucei invariant surface proteins herein 
named as Metacyclic Invariant Surface Proteins (MISP) 
2. To establish and characterise an in vitro production system of T. brucei 
metacyclic forms for the study of MISP. 
3. To identify and characterise T. brucei genes whose expression is essential for 
its development into the metacyclic transmissible stage. 
4. To characterise surface N-glycans from T. brucei metacyclics and the 
essentiality of N-glycosylation for parasite transmission. 
5. To develop new methods for imaging T. brucei in the tsetse with the aim to 
study parasite development within the vector.  
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CHAPTER 2 
Materials and Methods 
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2.1 Cell culture methods 
 
2.1.1 Trypanosoma brucei brucei bloodstream forms 
 
 T. b. brucei strain AnTat 1.1 90:13 (MacGregor et al., 2013) bloodstream forms 
were cultured in HMI-9 medium (Hirumi and Hirumi, 1989) (Gibco) supplemented with 
10% heat-inactivated faetal bovine serum (FBS), containing G418 (2.5 µg/mL, 
Invivogen) and Hygromycin B (4 µg/mL, Invivogen) in 25 cm2 or 75 cm2 plastic vented 
non-treated flasks (Corning) at 37°C and 5% CO2. Cells were typically maintained at 
exponential growth phase <106 cells/mL and passaged every 1-2 days by dilution with 
fresh medium, to prevent the formation of ‘stumpy’ non-proliferative forms.   
 
 
2.1.2 Trypanosoma brucei brucei procyclic cultured forms 
 
 T. b. brucei strain AnTat 1.1. 90:13 (MacGregor et al., 2013), strain Lister 427 
29:13 (Wirtz et al., 1999) and strain TSW-196 (Paindavoine et al., 1986) were cultured 
in SDM-79 medium (Gibco) supplemented with 10% heat-inactivated FBS, haemin 
7.5 mg/L, L-glutamine 320 mg/L and GlutaMax (Gibco) in 25 cm2 or 75 cm2 plastic 
vented non-treated flasks (Corning) at 27°C and 5% CO2. The parental marker 
selection drugs G418 (15 µg/mL) and Hygromycin B (50 µg/mL) were permanently 
added to the medium except for the strain TSW-196. Cells were typically maintained 
at exponential growth phase (i.e. between 106 cells/mL and 2x107 cells/mL) and 
passaged every 2-3 days by dilution in fresh medium. Alternatively, the strain AnTat 
1.1 90:13 was cultured in DTM medium (Ziegelbauer et al., 1990) supplemented with 
10% FBS, haemin 7.5 mg/L, L-glutamine 1,6 g/L and GlutaMax (Gibco).  
 
 
2.1.3 Trypanosoma brucei brucei stabilates 
  
 T. b. brucei cultures were preserved and stored in a cryostore with liquid 
nitrogen (-195.7°C). BSF cells (~106) or PCF cells (~107) were spun down at 1,000 x 
g for 5 minutes at room temperature (RT) to remove the culture media and 
resuspended in 0.5 mL of HMI-9 10% FBS or SDM-79 10% FBS, respectively, 
supplemented with 20% glycerol (as cryoprotectant) in a cryovial. Cells were first 
frozen at -80°C using a Mr. Frosty freezing container (Nalgene, 1°C/min cooling) 
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before being transferred to the cryostore. To set a new culture from frozen stabilates, 
cryovials were warmed up at ~37°C, and spun down at 1,000 x g for 5 minutes at RT 
to remove the cryoprotective media. Cells were then resuspended in pre-warmed 
HMI-9 10% FBS (37°C) or SMD-79 10% FBS (27°C) media according to the cell type 
and let recover in a flask overnight before passaging. 
 
 
2.1.4 Induction of the tetracycline-inducible genetic system in T. b. brucei 
 
 The T. b. brucei strains AnTat 1.1 90:13 and Lister 427 29:13 are mutant clonal 
lines created by the community for the expression of transgenes under the control of 
a tetracycline (Tet-ON) inducible system (Wirtz et al., 1999). Both strains contain the 
insertion of the construct pLEW13 (neo marker) in the a/b tubulin array for the 
constitutive expression of the T7 RNA polymerase and the tetracycline repressor (Tet 
R) (Figure 2.1). In addition, they either have the insertion of the pLEW90 (AnTat, in 
the tubulin array, hyg marker) or pLEW29 (Lister 427, in the RNA polymerase I locus, 
hyg marker) for the constitutive expression of a second Tet R gene under the control 
of a modified (10% of wildtype activity) T7 promoter.  
 
 
Figure 2.1. Transgene insertions required for the tetracycline-inducible system 
in the T. b. brucei parental lines AnTat 1.1. 90:13 and Lister 427 29:13. The 
pLEW13 insertion in the tubulin locus provides the T7 RNA polymerase (T7 RNA Pol), 
the tetracycline repressor (Tet R) and it is selected with the neomycin (NEO) marker 
gene. The pLEW90 insertion (tubulin locus) or pLEW29 insertion (RNA Pol I locus, 
striped box) provide and extra copy of Tet R driven by a modified T7 promoter (T7*) 
and they are selected with the hygromycin (HYG) marker gene. Coding sequences 
are flanked by 5’ and 3’ UTRs either from actin (dark grey), aldolase (pink), tubulin 
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(green) or procyclin (light grey) to provide stability to the transcripts. Adapted from 
Wirtz et al. 1998.  
 
These genetic backgrounds allow the transcription of genes under the strong 
viral promoter T7, and most importantly, the tight regulation of gene transcription by 
the addition or removal of tetracycline (Tet) or its analogue doxycycline (Dox). The 
gene under tetracycline induction needs to contain the tetracycline operator (Tet Op) 
DNA sequences (typically 2 to 3 in tandem) between the promoter and the 5’ 
regulatory UTR sequence. By default, the constitutively-expressed Tet R protein 
strongly binds to the Tet Op sequences and physically blocks transcription of the 
transgene (Figure 2.2). When Tet or Dox are added to the culture, the drugs enter 
the cell by diffusion and detach the Tet R from the Tet Op sequences because of the 
higher affinity between them, unblocking the path for the RNA polymerase to 
transcribe the transgene. The estimated half-life of Tet (2 days) and of Dox (4 days) 
is relatively short and therefore they need to be continuously added to the culture 
medium. Otherwise, the drugs can be removed from culture to eventually repress the 
transgene expression again.  
 
 
 
Figure 2.2. Schematic of the tetracycline-inducible system in T. brucei. When 
uninduced (Dox -), the RNA polymerase (RNA Pol, blue circle) binds to the promoter 
but is unable to transcribe the gene of interest because the tetracycline repressors 
(Tet Rep, yellow ovals) are bound to the tetracycline operator (Tet Op, orange 
squares) DNA sequences downstream the promoter. Only when doxycycline (Dox, 
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red circles) is added the system is induced (Dox +) as Dox binds to the Tet Rep 
detaching it from the Tet Op DNA sequence and thus allowing the RNA Pol to 
transcribe the GOI.  
 
For Tet-inducible transgene induction, both BSF and PCF cultures were 
supplemented with 1 µg/mL doxycycline (1 mg/mL stock in 70% ethanol). Uninduced 
controls were supplemented with equal volume of 70% ethanol only. Transgene 
induction can also be applied to trypanosomes infecting the tsetse by supplementing 
every bloodmeal with 2 µg/mL doxycycline or the same volume of 70% ethanol only 
as uninduced control. Doxycycline may increase tsetse mortality after 2 weeks of 
treatment as it may affect the bacterial symbionts which provide essential metabolites 
to the tsetse (unpublished observation).   
 
 
2.1.5 Escherichia coli culture 
  
E. coli strain DH5a (ThermoScientific), strain Rosetta-gami 2 (DE3) pLysS 
(Merk Millipore) or strain Rosetta 2 (DE3) pLysS (Merk Millipore) were grown for 
multiple purposes in autoclaved Lennox lysogenic broth (LB) medium 20 g/L 
supplemented with selection antibiotics (see Table 2.1 for antibiotic concentrations) 
at 37°C and 220 rpm shaking overnight. Alternatively, E. coli were grown on LB 
Lennox (20 g/L) agar (15 g/L) plates supplemented with antibiotics (Table 2.1) at 37°C 
overnight. Plates were kept at 4°C until further use.  
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Table 2.1 Antibiotics used for selection of transformant E. coli. 
Gene (a) Drugs (b) Class Mode of action (c) 
Bla/Amp Ampicillin 100 Beta-lactam  
Cell wall synthesis 
inhibition  
 Kan Kanamycin 50 Aminoglycoside 
Mis-translation by binding 
ribosomal 30S  
 Cam Chloramphenicol 25        - 
Peptidyl translocation 
inhibition by 50S binding 
 Tet Tetracycline 12.5 Tetracycline  
Protein synthesis inhibition 
by 30S binding  
 
(a) Selection gene in the transformed plasmid. 
(b) Available commercial antibiotics for selection. Concentrations in µg/mL. 
(c) Mode of action in prokaryotes 
 
 
 
2.1.8 Escherichia coli stocks 
  
 Transformant E. coli stocks were stored at -80°C. Single isolated colonies 
grown overnight on agar plates were used to inoculate LB Lennox and grown 
overnight at 37°C 220 rpm shaking. Cells were then transferred to LB 20% glycerol 
and frozen at -80°C in cryovials. To start a culture from an E. coli stock, the frozen 
stock was briefly scratched with a tip and plated on a pre-warmed LB agar plate and 
incubated at 37°C overnight.  
 
 
2.2 Molecular biology methods 
 
2.2.1. Extraction of Trypanosoma brucei genomic DNA (gDNA)  
  
Exponential growth phase BSF or PCF cells (~106 cells) were collected by 
centrifugation at 1,000 x g for 5 minutes at RT, washed in cold PBS and resuspended 
in 200 µL PBS for gDNA extraction using the QIAGEN DNeasy Blood and Tissue kit, 
following the manufacturer’s protocol for cultured cells. gDNA was eluted in nuclease-
free water (NFW) and stored at -20°C until further use. gDNA concentration measured 
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using a Nanodrop spectrophotometer ND1000 by 260 nm light absorbance (Abs) 
determination. DNA purity estimated by measuring the ratios Abs 260 nm/Abs 280 
nm (for protein contamination, optimal value of 2.0) and Abs 260nm/Abs 230 nm (for 
phenol contamination, optimal value of 2.0).   
 
 
2.2.2 Plasmid purification 
 
 Bacterial plasmids were extracted and purified from E. coli single colonies 
(clones) after overnight growth in liquid LB at 37°C using the QIAGEN Miniprep Kit 
(for culture volumes < 3mL) or the QIAGEN Midiprep Kit (for volumes <20 mL) 
following the manufacturer’s protocol. Plasmids eluted in NFW and stored at -20°C 
until further use. Plasmid concentration and purity were estimated as in section 2.2.1.  
 
 
2.2.3 DNA purification  
 
  Non-genomic DNA such as PCR or digestion products (>100 bp) were 
purified from liquid reactions using the QIAGEN PCR Purification Kit following the 
manufacturer’s protocol. Alternatively, DNA molecules were purified after agarose gel 
electrophoresis by excising the DNA gel bands of interest (>100 bp) using a scalpel 
on a UV-transilluminator and using the QIAGEN Gel Extraction Kit following the 
manufacturer’s protocol. DNA eluted in NFW and stored at -20°C until further use. 
DNA concentration and purity estimated as in section 2.2.1. 
 
 
2.2.4 RNA extraction and cDNA synthesis 
 
 To extract RNA, several T. brucei cell types (cultured and collected from 
tsetse) or tsetse tissues were collected, washed in cold PBS and immediately snap-
frozen in liquid nitrogen and stored at -80°C until purification. RNA extraction was then 
performed using the GeneJet RNA Purification Kit (Thermo Scientific) following the 
manufacturer’s protocol. 2-mercaptoethanol was used as denaturing agent. RNA was 
eluted in NFW and immediately processed for DNAse treatment using the TURBO 
DNA-free kit (Ambion) to remove DNA traces. The rigorous (1 hour at 37°C 
incubation) treatment was performed following the manufacturer’s indications. cDNA 
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synthesis was immediately run at 52°C for 10 minutes using the SuperScript IV 
reverse transcriptase (Invitrogen), oligo(dT)20 primers and <1µg DNA-free RNA. 
Whenever possible, the starting RNA amount was set equally to normalise equivalent 
samples. A negative control was set without reverse transcriptase to ensure specific 
amplification from cDNA only in further PCR reactions.  
 
 
2.2.5 Polymerase chain reaction (PCR) 
  
 PCR has been extensively used in this thesis to amplify DNA molecules from 
T. brucei gDNA and bacterial plasmids for cloning or genotyping purposes. As a 
general approach, the Taq DNA polymerase 2X Master Mix (New England Biolabs) 
was used in 20 µL reactions with 0.2 µM forward and reverse primers and <1 ng DNA 
template. Reaction volume and primer concentrations were eventually modified for 
convenience. Temperature conditions were set as follows: initial denaturation at 95°C 
for 30 seconds (1 cycle), denaturation at 95°C for 30 seconds followed by the 
annealing step (variable temperature) for 30 seconds, and the extension step at 68°C 
at variable times according to the Taq speed of 1 minute/kb (30 to 40 cycles), and a 
final extension step at 68°C for 4 minutes before storing the samples at 4°C or -20°C. 
Annealing temperatures set 4°C below the lowest primer Tm (calculations described 
in section 2.2.6). 
 
 To perform DNA amplifications for cloning, the high-fidelity Q5 DNA 
polymerase (New England Biolabs) was used instead in 25 µL reactions with 0.5 µM 
forward and reverse primers and < 1ng DNA template. Reaction volume and primer 
concentrations were eventually modified for convenience. Temperature conditions set 
as follows: initial denaturation at 98°C for 30 seconds (1 cycle), denaturation at 98°C 
for 10 seconds followed by annealing (variable temperature) for 30 seconds and 
extension at 72°C for variable time considering a polymerase speed of 30 seconds/kb 
(30 to 40 cycles), final elongation at 72°C for  2 minutes before storing the samples 
at 4°C or -20°C. Annealing temperatures set 3°C above the lowest primer Tm 
(calculations described in section 2.2.6). Primer sequences in Appendix I.   
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2.2.6 Primer design 
  
Primers for PCR, semi-quantitative and quantitative RT-PCR were manually 
designed and analysed using OligoAnalyzer 3.1 (Integrated DNA Technologies). 
Primer design aimed for Tm ~60°C calculated under standard buffer conditions (Na+ 
50 mM, Mg2+ 1.5 mM, dNTPs 0.2 mM, oligonucleotides 0.4 µM), a length of 18 to 22 
bp, GC content between 40% and 60% and to meet the 3’ GC clamp rule. Primers 
were thermodynamically checked to avoid the formation of hairpins and primer-primer 
interactions at the annealing temperature. To avoid unspecific annealings, primers 
were then BLASTed against the genome of T. b. brucei TREU972 reference strain 
(TriTrypDB.org) and the Glossina morsitans morsitans Yale strain transcriptome 
GmorY1.8 (VectorBase.org) only if trypanosomes were extracted from tsetse. 
 
For cloning, primers were analysed in the same way described above and 
restriction targets were manually added to the 5’ end preceded by the bases ‘CGC’ to 
allow the restriction enzyme to properly settle on the DNA strand. For example, the 
sequence 5’- CGCAAGCTT- 3’ was added upstream the annealing sequence to add 
the restriction target HindIII (underlined) to the resultant amplicon after PCR 
amplification. These sequences were not considered during Tm calculations. 
 
Primers for qRT-PCR (using the intercalant dye SYBR Green) were designed 
following the same procedure described above plus considering the length of the 
amplicon to be between 80 bp to 200 bp for optimal detection and quantification. The 
resultant Tm and melting curve of the amplicons were predicted using uMelt (Wittwer 
Lab, University of Utah). 
 
 
2.2.7 Agarose gel electrophoresis 
 
 Products from PCR, RT-PCR and restriction reactions were resolved by gel 
electrophoresis. Agarose (0.8% to 2%) Tris-Acetate EDTA (TAE) gels stained with 
the DNA-intercalant dye SYBR Safe (Invitrogen) or ethidium bromide were loaded 
with DNA samples mixed with loading buffer (contains glycerol, EDTA and colorant) 
were run in TAE buffer at 90V to 120V for variable times. Resolved gels were imaged 
using a GelDoc EZ system (Bio-Rad) under variable exposure conditions.  
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2.2.8 Semi-quantitative RT-PCR 
 
 Semi-quantitative RT-PCR was used to determine relative gene expression 
levels in samples with originally reduced content of RNA (i.e. RNA extracted from SG 
trypanosomes) or to determine the expression of genes with high sequence identity 
(i.e. misp homologs, Chapter 3), virtually impossible to differentiate by the more 
restrictive quantitative RT-PCR.  PCR reactions were setup using the Taq DNA 
polymerase as described in section 2.2.5 and using cDNA as template. Reactions 
were paused and sampled several times between PCR cycles 30 to 40 to analyse the 
products during the exponential phase of the reaction and not at plateau phase when 
products saturate. Samples were then resolved by gel electrophoresis as described 
in section 2.2.7 under identical conditions and band intensities determined using the 
ImageLab software (Bio-Rad) after imaging. T. brucei gene expression was 
normalized to the expression of tert (telomerase reverse transcriptase, 
Tb927.11.10190; Brenndorfer et al. 2010). Detection of tert was obtained using the 
primers TERT_RT-PCR_F and TERT_RT-PCR_R. Primer sequences in Appendix I.       
 
 
2.2.9 Real-time quantitative RT-PCR (qRT-PCR) 
 
 qRT-PCR was the standard method used to quantify gene expression in T. 
brucei. The Luna qPCR Universal 2X Mastermix (SYBR Green and ROX reference 
dye, New England Biolabs) was used in 20 µL reactions with 0.25 µM forward and 
reverse primers and 1µL cDNA as template. Samples were run in triplicates in 96-well 
plates in an Agilent Mx3005P qPCR machine. PCR temperature conditions were set 
as follows: initial denaturation at 95°C for 1 minute, followed by 40 cycles of 95°C for 
15 seconds and 60°C for 30 seconds before measuring fluorescence. Product melting 
curves were determined with a final dissociation curve from 55°C to 95°C (0.5°C 
fluorescence measurements). Gene expression was normalised to the expression of 
tert (Brenndorfer and Boshart, 2010) whose detection was made using the primers 
TERT_qPCR_F and TERT_qPCR_R. Amplification plots and melting curves were 
analyzed using the MxPro software (Agilent). The threshold was set automatically on 
the selected samples and the gene expression fold changes were calculated from the 
resultant cycle threshold values (Ct) applying the 2-DDCt method (Livak et al., 2001). 
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2.2.10. Restriction of DNA 
 
 DNA restriction using restriction enzymes was extensively used in molecular 
cloning. Restriction of plasmid DNA (<1 µg) was set in 20 µL reactions with FastDigest 
buffer (Thermo Scientific) and 1 µL of each FastDigest restriction enzyme. Reactions 
were incubated at 37°C for <30 minutes for restriction (variable time according to 
manufacturer’s protocol) and heat-inactivated. Alternatively, PCR products (<200 ng) 
were restricted in 30 µL reactions under similar conditions.  
 
 
2.2.11 Plasmid dephosphorylation 
 
 Restricted plasmids had to be eventually dephosphorylated in both 5’ and 3’ 
free ends to prevent self-ligation using a recombinant shrimp alkaline phosphatase 
(rSAP, New England Biolabs). A 20 µL reaction was set with 1 µg restricted plasmid, 
CutSmart buffer (New England Biolabs) and 1 unit rSAP, incubated at 37°C for 30 
minutes and heat-inactivated at 65°C for 5 minutes. The dephosphorylated plasmids 
were then used in further ligation reactions (section 2.2.12).  
 
 
2.2.12. DNA ligation 
 
 DNA ligation reactions were extensively used in molecular cloning. Typically, 
a restricted plasmid was ligated to a smaller dsDNA molecule called insert (e.g. PCR 
product) restricted with the same restriction enzymes or different ones yielding 
compatible ends. Ligation reactions were set in 20 µL containing 50 ng restricted 
plasmid, a variable amount of restricted insert (see Figure 2.3) and 400 units T4 DNA 
ligase with the appropriate buffer (New England Biolabs). Reactions were incubated 
either at RT for 2 hours or at 16°C overnight and posteriorly heat-inactivated at 65°C 
for 20 minutes. Ligation reactions were kept at 4°C until further use.   
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Figure 2.3. Equation for the calculation of the amount of insert to use in a typical 
ligation reaction. By default, 50 ng plasmid are used, and the 3:1 ratio 
(insert:plasmid) can be increased up to 8:1 in challenging ligation reactions.  
 
 
2.2.13. Escherichia coli transformation 
 
 Ligation reaction products were transformed into E. coli strain DH5a 
competent cells (CaCl2-acquired competency, Invitrogen). Cells were removed from -
80°C and thawed at 0°C before adding ~10 ng ligation reaction and incubated on ice 
for 30 minutes. Cells were then heat-shocked at 42°C for 20 seconds, incubated on 
ice for 2 minutes and SOC medium was added for recovery at 37°C for 1 hour, 220 
rpm shaking. Cells were concentrated by centrifugation at 6,000 x g for 3 minutes and 
plated on LB agar plates containing the selection antibiotic (see Table 2.1). Plates 
were incubated at 37°C overnight. Isolated bacteria colonies (clones) were then 
streaked on a new agar plate for further use. Transformation of E. coli Rosetta 2 (DE3) 
pLysS and Rosetta-gami 2 (DE3) pLysS strains was done as described above except 
for a first incubation on ice for 5 minutes and a heat-shock at 42°C for 30 seconds. 
Both strains were plated on LB agar plates supplemented with chloramphenicol and 
tetracycline (to maintain parental markers) besides the selection antibiotic.   
  
 
2.2.14. Plasmid linearisation 
 
 The plasmids containing the final DNA constructs (entire plasmid or section) 
for T. brucei transfection were linearised to increase the efficiency of homologous 
recombination. To linearise 20 µg of plasmid requiring restriction at the NotI site, 4 
reactions of 50 µL were setup containing each 5 µg plasmid, 1 unit NotI high-fidelity 
restriction enzyme (New England Biolabs) and the appropriate buffer (CutSmart) and 
incubated at 37°C for 16 hours before heat-inactivating the enzyme at 65°C for 20 
minutes. Plasmids requiring partial linearisation at HindIII and SacI sites were 
restricted using 1 unit of FastDigest HindIII and SacI (Thermo Scientific) in 50 µL 
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reactions with 5 µg plasmid and FastDigest buffer, incubated at 37°C for 4 hours and 
heat-inactivated at 80°C for 10 minutes. Linearised plasmids were kept at -20 °C until 
further use. 
 
 
2.2.15. DNA precipitation 
 
 Linearised plasmids were precipitated before transfection to purify, sterilise 
and concentrate the DNA. 20 µg plasmid was incubated in ice-cold 300 mM sodium 
acetate pH=5, 70% ethanol (-20°C) and 57 µg/mL glycogen for 10 minutes and spun 
down at 13,000 x g for 15 minutes at 4°C to pellet the DNA. The pellet was washed 
in 70% ethanol and air-dried before resuspension in ~12 µL NFW (for a concentration 
> 1 µg/µL). DNA was stored at -20°C until further use in parasite transfections 
(sections 2.2.19 and 2.2.20).     
 
 
2.2.16 General cloning procedure 
 
 To create DNA constructs to either express recombinant proteins in E. coli or 
to transfect into T. brucei for the generation of transgenic cell lines (sections 2.2.17 
and 2.2.18), a series of cycles of cloning procedures were performed as follows. DNA 
coding sequences were typically amplified by PCR (high-fidelity polymerase) (section 
2.2.5), resolved by gel electrophoresis (section 2.2.7) to identify the desired DNA 
band based on relative molecular size, and purified from the agarose gel (section 
2.2.3). Alternatively, DNA coding sequences contained in plasmids were obtained by 
restriction of the surrounding restriction targets and purified from resolved gels 
(section 2.2.10). DNA coding sequences were then ligated (section 2.2.12) into pre-
restricted plasmids with the same restriction targets or others yielding compatible 
ends. Ligation products were transformed into E. coli DH5a (section 2.2.13) for 
selection of clonal transformants. The resultant plasmids were purified from bacteria 
cultures (section 2.2.2) and either used in subsequent cloning rounds or in different 
downstream procedures. These cloning methods are described here as a general 
approach and they were eventually modified in particular cases. Specific cloning 
procedures for the creation of plasmids for the expression of recombinant proteins in 
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E. coli detailed in section 2.2.17, and for the generation of T. brucei transgenic cell 
lines described in section 2.2.18. 
  
 
2.2.17. Creation of plasmids for the expression of MISP recombinant proteins  
 
 For the expression of recombinant MISP380 in E. coli (Figure 3.12-A), the 
coding sequence of misp380 lacking the signal and GPI anchor peptide sequences 
was amplified by PCR from gDNA extracted from T. b. brucei PCF using the primers 
MISP_-SP_F_NcoI and MISP_-GPI_R_XhoI, containing the restriction sites NcoI and 
XhoI (Appendix I). Briefly, the plasmid pET28a (Novagen) and PCR product were 
digested with NcoI and XhoI and ligated for the insertion of the amplicon into the 
plasmid in frame fused to a poly-histidine tag (6xHis) at C-terminus. The ligation 
reaction was transformed into E. coli DH5a for selection and the sequence was 
corroborated by Sanger sequencing. The pET28-MISP380-6xHis plasmid was then 
transformed into E. coli Rosetta 2 (DE3) pLysS for protein expression.    
For the expression of recombinant MISP360 (Figure 3.14), the coding 
sequence of misp360 (lacking both the signal and GPI anchor peptide sequences) 
was obtained by PCR as described above using the primers MISP_-SP_F_NdeI and 
MISP_-GPI_XbaI, containing the restriction sites NdeI and XbaI (Appendix I), for 
cloning into the plasmid pCOLD II (Takara) in frame fused to a 6xHis-tag at N-
terminus. Alternatively, for the recombinant expression of either the N-terminus or C-
terminus domains of MISP360, the corresponding coding sequences were amplified 
by PCR using the primers MISP_-SP_F_NdeI and MISP_N_R_XbaI, and 
MISP_C_F_NdeI and MISP_-GPI_R_XbaI, respectively. Both sequences contained 
the restriction sites NdeI and XbaI (underlined) for cloning into the plasmid pCOLD II 
fused to a N-terminus 6xHis-tag. The resultant plasmids pCOLD-6xHis-MISP360N+C, 
pCOLD-6xHis-MISP360N and pCOLD-6xHis-MISP360C were checked by 
sequencing as described above and then transformed into E. coli Rosetta-gami 2 
(DE3) pLysS for protein expression.   
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2.2.18 Creation of plasmids for the generation of T. b. brucei mutant lines 
 
2.2.18.1 Generation of plasmid pDEX577-HA/eGFP-MISP360 
 
 The plasmid pDEX577-HA/eGFP-MISP360 was built for the tetracycline-
inducible overexpression of chimeric MISP360 (Tb927.7.360), which has an HA 
epitope and an enhanced GFP (eGFP) fused at N-terminus, downstream the MISP 
signal peptide (Figure 3.24-A). First, the HA coding sequence was obtained by 
annealing (95°C for 5 minutes and progressive cooling at RT) of the complementary 
oligonucleotides HA_F_HindIII and HA_R_SpeI and restriction of the resultant DNA 
sequence with HindIII and SpeI. This fragment was then ligated in frame into the 
plasmid pDEX577 (Kelly et al. 2007, Table 2.2) using the same restriction sites. 
Second, the coding sequence of the MISP360 signal peptide was obtained by 
annealing of the complementary oligonucleotides MISP360_SP_F_HindIII and 
MISP360_SP_R_HindIII as described above; the DNA fragment was then restricted 
with HindIII and ligated into the pDEX577-HA plasmid previously generated. Insertion 
of the signal peptide sequence in the correct direction was corroborated by 
sequencing. Lastly, the coding sequence for MISP360 without signal peptide was 
amplified by PCR from T. brucei gDNA using primers MISP360_CDS-SP_F_XbaI and 
MISP360_CDS_R_BglII, containing the restriction targets XbaI and BglII. Plasmid 
pDEX577, containing the signal peptide, HA and eGFP was restricted with the 
enzymes XbaI and BamHI and ligated with the PCR product previously digested with 
XbaI and BglII (BamHI and BglII yield compatible sticky ends).  The sequence of the 
resultant plasmid (pDEX577-HA/eGFP-MISP360) was checked by sequencing at the 
insertion site. 
 
 
2.2.18.2 Generation of pALC14 plasmids for the RNAi knockdown of T. b. brucei 
misp, rbp6 and stt3 genes 
 
 Three different plasmids were made for the tetracycline-inducible 
overexpression of a short-hairpin dsRNA to RNAi silence the expression of all misp 
(e.g. Tb927.7.360), rbp6 (Tb927.3.2930) and stt3 (e.g. Tb927.5.890) transcripts 
(Figures 3.33-A, 4.8-A and 5.4-A).  For the knockdown of misp, a unique short 491 
bp coding sequence of misp fully conserved between the five homologs was amplified 
by PCR in both sense and antisense directions using the primer pairs 
  
62 
MISP_RNAi_SENSE_F_XhoI and MISP_RNAi_SENSE_R_BamHI  (containing the 
targets XhoI and BamHI) and MISP_RNAi_ANTI_F_NdeI and 
MISP_RNAi_ANTI_R_HindIII (containing the targets NdeI and HindIII). Both sense 
and antisense fragments were inserted into the plasmid pALC14 (MacGregor et al., 
2013) (Table 2.2) using the restriction sites HindIII, NdeI, XhoI and BamHI 
surrounding the 460 bp stem loop sequence. The inserted sequences were checked 
by sequencing of the resultant plasmid pALC14-MISP-RNAi. 
  
For the knockdown of stt3, a conserved 537 bp coding sequence of stt3 in 
both sense and antisense directions was amplified by PCR using the primers 
STT3_RNAi_SENSE_F_XhoI and STT3_RNAi_SENSE_R_BamHI, and 
STT3_RNAi_ANTI_F_NdeI and STT3_RNAi_ANTI_R_HindIII , and inserted into the 
plasmid pALC14 under identical restriction sites and the resultant plasmid pALC14-
STT3-RNAi was checked by sequencing. 
 
For the knockdown of rbp6, a 516 bp coding sequence of rbp6 in sense and 
antisense directions was amplified by PCR using the primers 
RBP6_RNAi_SENSE_F_XhoI and RBP6_RNAi_SENSE_R_BamHI, and 
RBP6_RNAi_ANTI_F_NdeI and RBP6_RNAi_ANTI_R_HindIII, and was inserted into 
pALC14 using the same restriction sites as described above. The resultant plasmid 
pALC14-RBP6-RNAi was checked by sequencing.   
 
 
2.2.18.3 Generation of plasmids for the overexpression of RBP6  
 
 The plasmids pMS-3xHA/sfGFP-RBP6 and pDEX577-HA-RBP6 were made 
for the tetracycline-inducible overexpression of RBP6 (Tb927.3.2930) either fused to 
a tandem of three HA epitopes and superfolder GFP (sfGFP) or a single HA epitope 
only, respectively, both tagged at N-terminus (Figure 4.1).  For the first construct, the 
coding sequence of rbp6 was amplified by PCR from T. brucei gDNA using the 
primers RBP6_CDS_F_XhoI and RBP6_CDS_R_BamHI containing the restriction 
sites XhoI and BamHI and inserted into the pMS plasmid (Serricchio et al., 2013), 
Table 2.2) under the same restriction targets. The sequence coding for three tandem 
HA epitopes followed by the sfGFP was obtained by PCR from the plasmid pSIG 
(Gadelha et al., 2015) using the primers 3xHA_sfGFP_F_HindIII and 
3xHA_sfGFP_R_XhoI containing the restriction sites HindIII and XhoI and inserted 
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into the plasmid pMS-RBP6 into the same restriction sites. The resultant plasmid 
pMS-3xHA/sfGFP-RBP6 was checked by sequencing. 
  
 To create the second plasmid, the coding sequence of rbp6 was amplified by 
PCR from T. b. brucei gDNA using the primers RBP6_HA_CDS_F_HindIII (containing 
the HA coding sequence) and RBP6_CDS_BamHI with the restriction targets HindIII 
and BamHI and ligated into the plasmid pDEX577 using the same restriction targets. 
The resulting plasmid pDEX577-HA-RBP6 was corroborated by sequencing of the 
insert. 
 
 
2.2.18.4 Generation of plasmids for the overexpression of MYND, GDH and FT  
 
 The plasmid pMS (Table 2.2) (Serricchio and Butikofer, 2013) was used to 
overexpress (tetracycline-inducible) the hypothetical protein MYND (Tb927.4.4670), 
the glutamate dehydrogenase (GDH) (Tb927.9.5900) and one folate transporter (FT) 
homolog (Tb927.8.3630) (Figure 4.17). The coding sequences were obtained by 
PCR amplification from T. brucei gDNA. To amplify mynd, the primers 
MYND_CDS_F_HindIII and MYND_CDS_R_XbaI (HindIII and XbaI targets) were 
used, for gdh the primers GDH_CDS_F_XbaI and GDH_CDS_R_XbaI (XbaI only; 
insert direction corroborated by sequencing) were used, and for the folate transporter 
the primers FT_HA_CDS_F_HindIII (containing the HA coding sequence) and 
FT_CDS_R_BamHI (HindIII and BamHI targets) were used. The coding sequences 
of mynd and gdh were inserted under their corresponding restriction sites into the 
plasmid pMS containing a previously-inserted single HA epitope inserted under the 
restriction sites XbaI and BamHI at C-terminus. On the other hand, the coding 
sequence of the folate transporter was inserted into the pDEX577 (Kelly et al., 2007) 
under the restriction sites HindIII and BamHI as the amplicon contained the HA 
sequence at N-terminus. The resulting pMS-MYND-HA, pMS-GDH-HA and 
pDEX577-HA-FT plasmids were checked by sequencing of the inserts.   
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2.2.18.5 Generation of plasmids for the creation of stt3 and rft1 conditional-null 
mutants 
 
 For the creation of the stt3 and rft1 conditional-null mutants, several DNA 
constructs were built (Figure 5.2). For the knockout of the stt3 array (Tb927.5.880, 
Tb927.5.890, Tb927.5.900 and Tb927.5.910), flanking regions at 5’ and 3’ of the array 
(556 bp and 570 bp respectively) were obtained by PCR amplification from T. brucei 
gDNA using the primer pairs STT3_5_F_HindIII and STT3_5_R_EcoRI (HindIII and 
EcoRI), and STT3_3_F_XbaI and STT3_3_R_SacI (XbaI and SacI). These regions 
were inserted using the same restriction sites into pKO plasmids (modified 
pBlueScript, Agilent), either containing the resistance marker gene puro (puromycin) 
or blast (blasticidin), flanking the marker genes. For knocking out rft1 (Tb927.11670), 
the same procedure was applied with a 5’ flanking region of 397 bp and a 3’ region of 
427 bp using the primer pairs RFT1_5_F_HindIII and RFT1_5_R_EcoRI (HindIII and 
EcoRI), and RFT1_3_F_XbaI and RFT1_3_R_SacI (XbaI and SacI). 
  
 The rft1 addback construct was made by inserting the coding sequence of rft1 
obtained by PCR with the primers RFT1_CDS_F_HindIII and RFT1_CDS_R_XhoI 
(HindIII and XhoI) into the plasmid pMS with a single HA epitope sequence inserted 
at C-terminus under the targets XhoI and BamHI.    
 
 
2.2.18.6. Generation of plasmid pALC14-mNeonGreen 
 
 The plasmid pALC14-mNeonGreen was built for the tetracycline-inducible 
overexpression of the reporter mNeonGreen fluorescent protein in BSF. The coding 
sequence of mNeonGreen was obtained by PCR amplification using the primers 
mNG_CDS_F_HindIII and mNG_CDS_R_BamHI containing the restriction sites 
HindIII and BamHI. The DNA fragment was ligated into the plasmid pALC14 (Table 
2.2) (MacGregor et al., 2013) digested with the same restriction enzymes, resulting 
into the plasmid pALC14-mNeonGreen, which was sequenced before use. 
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Table 2.2. Plasmids used for the creation of T. b. brucei transgenics. 
   
(a) Promoter driving the expression of the transgene in T. brucei 
(b) Drug selection in E. coli 
(c) Drug selection in T. brucei  
(d) Recombination site in T. brucei 
 
 
 
2.2.19 Transfection of Trypanosoma brucei brucei BSFs   
 
 T. b. brucei strain AnTat 1.1 90:13 BSF cells were used for transfection at 
culture densities between 4 x 105 cells/mL and 9 x 105 cells/mL (exponential growth 
phase). Cells were spun down at 1,000 x g for 10 minutes at 4°C and washed in Tb-
BSF ice-cold buffer (90 mM NaPO4 buffer, 5 mM KCl, 0.15 mM CaCl2, 50 mM HEPES, 
pH=7.3). Per transfection, 4 x 107 cells were mixed with 10 µg linearised DNA 
construct in 100 µL Tb-BSF buffer and electroporated in a cuvette using the Amaxa 
4D Nucleofector X unit, program FI-115. Cells were then immediately transferred to a 
flask containing 10 mL of pre-warmed (37°C) HMI-9 medium, supplemented with 10% 
FBS, G418 (2.5 µg/mL) and hygromycin B (4 µg/mL) and let recover for 6 hours at 
37°C and 5% CO2. After recovery, the selection drug (see Table 2.3 for concentration 
details) was added and serial dilutions in 24-well non-treated plates were performed 
for further selection of clonal cell lines. The following controls were added: 1) 
transfection negative control (no DNA added) and 2) drug selection control (parental 
cell line with and without selection drug). After 5 days, transfectant cell lines were 
typically screened based on the corresponding phenotype and the transgene insertion 
was checked by PCR.  
 
 
Plasmid Promoter (a) E. coli (b)  T. brucei (c)  Insertion site (d) 
pDEX577 Procyclin (EP) Ampicillin 
Phleomycin/ 
Zeocin 
177 bp repeats 
pALC14 Procyclin (EP) Ampicillin Puromycin rDNA spacer 
pMS rDNA Ampicillin 
Phleomycin/ 
Zeocin 
rDNA spacer 
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2.2.20 Transfection of Trypanosoma brucei brucei PCF  
 
 T. b. brucei strain AnTat 1.1 90:13 or strain Lister 427 29:13 PCF cells were 
used for transfection at exponential growth phase at densities between 5 x 106 
cells/mL and 107 cells/mL. Cells were spun down at 1,000 x g for 5 minutes at RT and 
washed in Tb-BSF buffer. Per transfection, 4 x 107 cells were mixed with 10 µg 
linearised DNA construct in 100 µL Tb-BSF buffer and electroporated in a cuvette 
using the Amaxa 4D Nucleofector X- unit, program FI-115. Cells were then 
immediately transferred to a flask containing 10 mL of pre-warmed (27°C) SDM-79 
medium, supplemented with 15% FBS, G418 (15 µg/mL) and hygromycin B (50 
µg/mL) and let recover for 2 hours at 27°C and 5% CO2. After recovery, serial dilutions 
were done in SDM-79 15% FBS and 20% conditioned medium (0.22 µm-filtered 
supernatant from parental cell line at exponential phase of growth) in 96-well plates 
for further selection of clonal cell lines, and cells were incubated overnight at 27°C 
and 5% CO2. 24 hours post-transfection, the selection drugs were added (see Table 
2.3 for concentration details). The controls described in section 2.2.19 were also 
applied to PCF transfections. After 14 days, transfectant cell lines were typically 
screened based on the corresponding phenotype and the transgene insertion was 
checked by PCR. Alternatively, the entire procedure of PCF transfection was carried 
out using DTM medium instead of SDM-79 under identical conditions for the 
transfection of DTM-adapted PCF.    
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Table 2.3 Drugs used for the selection of transfectant T. b. brucei BSF and PCF. 
  
(a) Selection marker gene for the transgene insertion.  
*Neo and *Hyg not used for selection but for maintenance of the parental markers. 
(b) Available commercial drugs for selection. 
(c) Concentration in µg/mL.   
(d) Affects both eukaryotes and prokaryotes 
 
 
 
2.3 Methods for protein analysis 
 
2.3.1 Expression of recombinant proteins in E. coli 
 
 For the expression of MISP recombinant proteins, several plasmids were 
created and transformed into E. coli BL21 (DE3) strains (section 2.2.17) for the 
inducible overexpression of the proteins. The selected clones of E. coli Rosetta (DE3) 
pLysS or Rosetta-gami 2 (DE3) pLysS were set to exponential phase growth in ~50 
mL Lennox LB supplemented with kanamycin (pET28) or ampicillin (pCOLDII), 
chloramphenicol and tetracycline (Table 2.1), and 40 mg/L L-leucine at 37°C 220 rpm 
shaking for 2 hours until an optical density of OD600nm=1.2 was reached. These cells 
were then used to inoculate 4 litres LB with antibiotics and incubated at 37°C 220 rpm 
shaking until a OD600nm= 0.5 to 0.7 was reached. Protein overexpression was then 
induced with 0.5 mM isopropyl b-D-1-thiogalactopyranoside (IPTG) and cultures were 
incubated at 16°C overnight reaching OD600nm = ~1.2. Cultures were set at 4°C to stop 
growth before harvesting. 
Gene (a) Drugs (b) BSF selection (c) PCF selection (c) Mode of Action (d) 
 Ble 
Phleomycin/ 
Zeocin 
Phleomycin 2.5 
+ Zeocin 5  
Zeocin 10  
DNA binding and 
cleavage  
 Puro Puromycin Puromycin 1  Puromycin 10  
Inhibits peptidyl 
transfer  
 Blast Blasticidin Blasticidin  Blasticidin  
Blocks protein 
synthesis  
 Neo* 
Neomycin/ 
G418 
G418 2.5  G418 15  
Blocks protein 
synthesis  
 Hyg*  Hygromycin B Hygromycin B 4  Hygromycin B 50  
Blocks protein 
synthesis  
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2.3.2 Ni-NTA chromatography 
 
 E. coli cells from section 2.3.1 were harvested by centrifugation in 250 mL 
bottles at 3,500 x g for 30 minutes at 4°C. The supernatant was discarded, the 
bacteria pellet transferred to a smaller tube and spun down for 20 more minutes at 
4°C. Medium leftovers were removed and pellet was frozen and kept at -80°C at least 
24 hours before proceeding with protein purification. Pellets were dissolved in lysis 
buffer (50 mM imidazole, 20 mM HEPES pH=7.8, 100 mM NaCl) supplemented with 
EDTA-free protease inhibitors (Roche) and 10 mg/mL DNAse I (Sigma), and 
sonicated on ice at 70% amplitude for 15 pulses of 10 seconds each. The solution 
was centrifuged at 35,000 x g for 30 minutes at 4°C, the soluble fraction (containing 
the protein) was collected and filtered using a 0,22 µm filter. This was then incubated 
in batch with 2mL Ni-NTA HisPur Superflow (Thermo Scientific) agarose (equilibrated 
with 10 volumes of lysis buffer) for 3 hours at 4°C and posteriorly assembled in a PD-
10 column for several washes with washing buffer (20 mM HEPES, 100 mM NaCl). 
Lastly, two 0.5 mL elutions in elution buffer 1 (100 mM imidazole washing buffer) 
followed by other 13 elutions of 0.5 mL of elution buffer 2 (300 mM imidazole washing 
buffer) were collected. Protein concentrations were estimated using a Nanodrop 
ND1000 spectrophotometer from the absorbance at 280 nm corrected with the molar 
extinction coefficient of the corresponding recombinant protein. The resulting flow-
through, washes and elution samples were resolved in SDS-PAGE gels for purity 
assessment.  
 
 
2.3.3 Size exclusion chromatography (SEC) 
 
 The elutions with the apparent purest content of recombinant protein from 
section 2.3.2 were pooled and further purified by SEC in an AKTA Fast Protein Liquid 
Chromatography (FPLC) system (GE Healthcare) using a Superdex 200 10/30 GL 
analytical column (GE Healthcare). The column was first washed with degassed dH2O 
and then equilibrated with degassed buffer (20 mM HEPES, 100 mM NaCl) before 
running the standard molecular size markers (Sigma). After several washes with 
buffer, a Ni-NTA-purified MISP380 pooled sample of ~0.5 mL was run into the column 
at ~1.5 MPa pressure, and 35 fractions (of 0.5 mL each) were collected and analysed 
by SDS-PAGE.  
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2.3.4 Production of anti-MISP polyclonal antibodies 
 
 The polyclonal anti-MISP was obtained through immunisation of a single rabbit 
(Davids Biotechnologie GmbH) with 0.3 mg of SEC-purified MISP380 recombinantly 
expressed in E. coli Rosetta 2 (DE3) cells (sections 2.3.1, 2.3.2, 2.3.3). The rabbit 
was bled at 63 days post immunisation and the anti-sera was processed for IgG 
purification through a protein A column. Purified IgGs were run into a column 
containing recombinant MISP380 for affinity-purification of specific IgGs with affinity 
for MISP380. The anti-MISP380 IgGs were passed through a column containing E. 
coli Rosetta 2 (DE3) cell lysate to deplete IgGs with affinity for bacterial proteins. The 
resultant purified anti-MISP380 IgG sample was tested by immunoblotting and found 
to remain stable after two freeze-thaw cycles. Antibodies were kept at -20°C for long 
term storing or at 4°C for frequent use. Non-purified anti-sera and pre-immune sera 
were obtained and used in control reactions.  
 
 
2.3.5. SDS-PAGE 
 
 Variable amounts of different T. brucei stages or purified proteins were heat-
denatured at 98°C for 8 minutes in Laemmli sample buffer (Laemmli, 1970) containing 
DTT as reducing agent. Samples were resolved in 12.5% SDS-PAGE Bis-Tris gels at 
50V for 20 minutes followed by ~2 hours at 120V in running buffer (0.1% SDS, 25 mM 
Tris, 192 mM glycine, pH=8.3) using a Bio-Rad mini-Protean system. Gels were either 
stained with InstaBlue UltraFast (Expedeon) to reveal protein bands or further used 
for immunoblotting or lectin blotting. Stained gels were imaged using a GelDoc EZ 
system and ImageLab software (Bio-Rad).  
 
 
2.3.6 Western blotting  
 
 Proteins resolved in SDS-PAGE gels were transferred to a polyvinylidene 
fluoride (PVDF) membrane pre-activated in 100% methanol for 30 seconds and 
equilibrated in transfer buffer (20% methanol, 25 mM Tris, 192 mM glycine, pH=8.3) 
for 15 minutes. Wet transference was normally carried out at 90V for 1 hour in cold 
conditions. Membranes were briefly washed in washing buffer (PBS-Tween 0.1 % v/v) 
and Ponceaux S-stained for rapid visualisation of the transferred proteins. After 
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washing off the stain, membranes were blocked in blocking buffer (PBS-Tween 0.1 % 
v/v, 5 % w/v skim milk powder) for 1 hour at RT. Membranes were then probed with 
the primary antibody (Table 2.4) in blocking buffer overnight at 4°C or 1 hour at RT. 
Membranes were extensively washed in washing buffer and secondary antibodies 
(Table 2.4) conjugated to horse radish peroxidase (HRP) were incubated in blocking 
buffer for 1 hour at RT. After extensive washings in washing buffer, membranes were 
probed with Super Signal West Dura or Femto Dura luminol substrate (Thermo 
Scientific) for 5 minutes in the dark and exposed to X-ray Amersham Hyperfilm (GE 
Healthcare) at variable exposition times. After exposure, membranes were stained in 
0.2% nigrosin for 15 minutes for sample loading control visualisation.  
 
 
Table 2.4. Antibodies used in western blotting. 
Antibody Antigen Type Host Dilution 
a-Sodalis Sodalis Hsp60 
Monoclonal 
hybridoma sup. 
Mouse 1:10 
a-MISP T. brucei MISP (all) Polyclonal purified Rabbit 1:2,000 
a-BARP T. brucei BARP (all) Polyclonal purified Rabbit 1:2,000 
a-CRD T. brucei CRD epitope Polyclonal purified Rabbit 1:500 
a-HA HA epitope Polyclonal purified Mouse 1:10,000 
a-EP T. brucei EP procyclin Monoclonal purified Mouse 1:2,000 
a-rabbit-HRP Rabbit IgG (H+L) Polyclonal purified Goat 1:20,000 
a-mouse-HRP Mouse IgG (H+L) Polyclonal purified Goat 1:20,000 
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2.3.7 Lectin blotting 
 
 PCF procyclins resolved in SDS-PAGE were transferred at 90V for 1 hour to 
nitrocellulose membranes pre-equilibrated in transfer buffer for 15 minutes. Lectin 
specificity control samples were either digested (or mock treated) under denaturing 
conditions with 25 units/µL PNGase F (New England Biolabs) at 37°C overnight to 
deglycosylate N-glycoproteins. Membranes were briefly washed in washing buffer 
and blocked in PBS-Tween 0.05 % v/v, BSA 1% w/v overnight at 4°C. Biotinylated 
concanavalin A (Vector Laboratories) was incubated at 1 µg/mL for 30 minutes at RT 
and washed off extensively in washing buffer. Lectin control samples were instead 
incubated with pre-saturated biotinylated ConA (ConA pre-incubated with 200 mM a-
methyl-D-mannoside and 200 mM a-methyl-D-glucoside at 27°C for 30 minutes). 
Membranes were incubated with streptavidin-HRP (1:100,000 dilution) (Vector 
Laboratories) for 1 hour at RT. After washing, membranes were probed with Super 
Signal Pico Plus (Thermo Scientific) for 5 minutes in the dark and developed and 
stained with nigrosin as described in section 2.3.5.  
 
 
2.3.8 Procyclin extraction from T. brucei PCF cells 
 
 PCF cells were harvested, washed in PBS and pelleted by centrifugation at 
2,000 x g for 5 minutes. Cell pellets were snap-frozen in liquid nitrogen and 
lyophilised. Lyophilised cells were ground using a pestle and dissolved in 150 µL 
chloroform-methanol-water (10:10:3, v/v/v) solution for lipid extraction. After 
sonication in an ultrasonic bath, samples were spun down at 6,000 x g for 3 minutes 
at RT and the supernatant was discarded. This process was repeated 3 times before 
the pellets were dried in the SpeedVac concentrator. 100 µL 9% 1-butanol were 
added to the pellets, and the samples were sonicated and centrifuged at 10,000 x g 
for 3 minutes at RT. The supernatant, rich in procyclins, was collected. This processed 
was repeated 3 times, and the supernatants were pooled, dried in a SpeedVac and 
stored at -80°C until further use.  
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2.3.9 nLC-MS/MS Proteomics 
 
Samples from naïve and T. brucei-infected tsetse saliva were lyophilised and 
sent to the Dundee University Fingerprints Proteomics Facility for in-solution trypsin 
digests and mass spectrometry. Following trypsinisation, the resulting peptides were 
analyzed by nano-liquid chromatography tandem mass spectrometry (nLC-MS/MS) 
using the Ultimate 3000 RSLC nano coupled to LTQ-Orbitrap Velos Pro MS. Resulting 
spectra from HR-MS/MS analysis of T. b. brucei and G. m. morsitans samples were 
searched with Proteome Discoverer (PD) 2.1.1.21 (Thermo Scientific) and filtered with 
an estimated false-discovery rate (FDR) of 1%. The PD settings were as follows: HCD 
MS/MS; cysteine carboxyamidomethylation as fixed modification; methionine 
oxidation and acetylation on any amino acid as variable modifications; fully tryptic 
peptides only; up to 2 missed cleavages; parent ion mass tolerance of 10 ppm 
(monoisotopic); and fragment mass tolerance of 0.6 Da (in Sequest) and 0.02 Da (in 
PD 2.1.1.21) (monoisotopic). Tandem MS/MS spectra were searched against the 
following databases: a combined protein database of T. b. brucei, T. b. gambiense 
and T. b. rhodesiense (18,729 entries from TriTrypDB, October 2017) and (25,450 
entries from UniProtKB, October 2017); and G. m. morsitans (12,494 entries from 
VectorBase, May 2017). A database of common contaminant sequences (MaxQuant) 
was also added to the combined database. The resulting PD dataset was further 
processed through Scaffold Q+ 4.8.2 and perSPECtives (Proteome Software). A 
protein threshold of 95%, peptide threshold of 95%, and a minimum number of 1 
peptide were used for identification of proteins. Manual inspection of the MS/MS 
spectra was always performed for the identification of any protein based on a single 
peptide. Using BLAST2GO (BioBam), proteins were BLAST searched against the 
non-redundant NCBI protein database, mapped and categorised according to gene 
ontology (GO) terms. The Sodalis glossinidius proteins were identified using the 
Liverpool School of Tropical Medicine in house MASCOT MS/MS ion search using a 
protein database from UniProtKB generated from the latest re-annotated coding 
sequences in S. glossinidius (Belda et al., 2010), and the following settings: 2 missed 
trypsin cleavages, same peptide modifications described above, peptide tolerance of 
1.2 Da, MS/MS tolerance of 1.2 Da and peptide charges set to +1, +2 and +3. 
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2.3.10 Protein pulldown assay 
 
 Streptavidin magnetic beads were washed in TBST buffer and mixed with ~10 
µg of recombinant MISP400 or HpHbR (T. brucei haptoglobin haemoglobin receptor) 
(Dr. Olivia MacLeod) biotinylated at C-terminus in TBST, and incubated for 1 hour at 
RT. Tubes were then put on magnetic racks to trap the beads bound to the 
recombinant proteins and washed in TBST buffer. Saliva samples from 46 naïve or 
25 T. brucei-infected tsetse were incubated with the recombinant proteins for 1 hour 
at RT before using the magnetic rack to perform several washes. All flow-through, 
washes and bead samples were collected, mixed with Laemmli buffer (Laemmli, 
1970) and heated at 98°C for 5 minutes before loaded into 17.5% SDS-PAGE gels. 
Gels were run in duplicate for both Coomassie Blue and silver staining.  
 
 
2.4 Tsetse methods 
 
2.4.1 Tsetse fly infections and maintenance 
 
Glossina morsitans morsitans were obtained from the tsetse insectary at the 
Liverpool School of Tropical Medicine, where they are maintained at 26 ˚C (+/-1 ˚C) 
and 65-75 % relative humidity. They are fed for 10 minutes every two days on sterile, 
defibrinated horse blood (TCS Biosciences) through a silicone membrane system. 
Teneral (unfed, recently emerged) male flies, no older than 48 h, were fed with animal 
infected blood by combining ~0.5 ml of T. b. brucei-infected rat or mouse blood (stored 
at -195.79°C) with ~5 ml fresh, sterile, defibrinated horse blood for 10-20 minutes. 
BSF cells were counted and the percentage of ‘stumpy’ forms estimated based on 
cell morphology. If flies were infected with cultured BSF, cells were washed in drug-
free HMI-9 10% FBS medium three times and mixed with defibrinated horse blood at 
a standard density of 106 cells/mL (variable) before feeding. Alternatively, teneral flies 
were infected with T. b. brucei PCF cells which were washed 3 times in drug-free 
SDM-79 10% FBS medium by centrifugation at 1,000 x g for 5 minutes at RT.  Sterile 
defibrinated horse blood was washed 3 times with the same culture medium by 
centrifugation at 1,000 x g for 10 minutes at RT to remove the complement since PCF 
are susceptible to it. PCF were mixed with washed blood at a standard density of 
5x105 cells/ml and fed to the tsetse for 10-20 minutes. For tsetse infections intended 
for T. brucei MCF collection (section 5.2.3), the bloodmeal was supplemented with 10 
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mM glutathione to boost MG and PV infections. Uninfected control flies were fed on 
the same blood type without trypanosomes for the same amount of time. After <24 
hours, flies were briefly chilled at 4-8°C to remove the ones that did not engorge. 
Experimental flies were maintained for up to 4 weeks, feeding on normal defibrinated 
horse blood every 2-3 days. Alternatively, flies infected with mutant trypanosomes 
requiring tetracycline activation of the transgene, were fed with normal defibrinated 
horse blood supplemented with fresh 2 µg/mL doxycycline (dissolved in 70% ethanol). 
Bloodmeals for control flies were supplemented with the same volume of 70% ethanol 
only.  
 
 
2.4.2 Tsetse dissections and T. brucei collection 
 
Flies were dissected at variable time points after infection, as late as 30 days 
post infection and 72 hours after receiving the last bloodmeal. Typically, SGs were 
first dissected in sterile ice-cold PBS. SG infections were scored by visualising MCF 
exiting the glands right after dissection or attached EMF in the infected SG tissue. 
The PV was then dissected on ice-cold PBS with a sharp cut at the junction with the 
anterior midgut to prevent cross-contamination with MG trypanosomes. PV infections 
were scored either by squashing the tissue with a coverslip to make it visible or by 
tearing the organ apart to allow the mesocyclic trypomastigotes to come out. Lastly, 
MGs were dissected out the abdomen and shred on ice-cold PBS to score the 
infection. Parasites found in MG, PV and SG were eventually collected by pipetting in 
ice-cold PBS, washed in PBS by centrifugation at 2,000 x g for 5 minutes at 4°C and 
used alive, fixed or snap-frozen for downstream applications.  
 
 
2.5 Cell biology methods 
 
2.5.1 Immunofluorescence assay 
 
 Cultured or tsetse-extracted T. b. brucei cells were washed in PBS and fixed 
in fresh 4% paraformaldehyde (PFA) for 30 minutes at room temperature (RT). Cells 
were allowed to settle onto poly-L-lysine coated slides for 20 minutes in a humidity 
chamber. Alternatively, cells were first air-dried on a poly-L-lysine slide, fixed in 100% 
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methanol for 10 minutes at -20°C and rehydrated in PBS. PFA-fixed cells were then 
either permeabilised or not in 0.1% Triton X-100 for 10 minutes at RT. Methanol-fixed 
cells did not need permeabilisation. Cells were then blocked in 20% FBS vPBS 
(Voorheis’s modified PBS: 138.9 mM NaCl, 2.68 mM KCl, 16 mM Na2PO4, 3 mM 
KH2PO4, 45.9 mM sucrose and 10 mM glucose, pH=7.4) for 1 hour, washed in PBS 
and incubated for 1 hour at RT with the primary antibody in blocking solution (see 
Table 2.5 for antibody dilutions). After washing, cells were incubated for 1 hour at RT 
with the secondary antibody in blocking solution (Table 2.5). Cells were then 
incubated in 300 ng/mL 4',6-diamidino-2-phenylindole (DAPI) (ThermoFisher) for 10 
minutes, washed and mounted in Slowfade Diamond mounting oil (ThermoFisher).  
For co-localisation analyses, cells were eventually incubated in culture with 25 
nM MitoTracker (Molecular Probes) for 25 minutes before being fixed and processed 
for immunostaining. Alternatively, to label the cell surface, PCF were incubated with 
10 µg/mL ConA-FITC for 1 hour at RT along with the secondary antibody solution 
during the immunostaining procedure.  
 
 
Table 2.5. Antibodies used in immunofluorescence assays. 
Antibody Antigen Type Host Dilution 
a-MISP T. brucei MISP (all) Polyclonal purified Rabbit 1:200 
a-BARP T. brucei BARP (all) Polyclonal purified Rabbit 1:200 
a-CRD T. brucei CRD  Polyclonal purified Rabbit 1:50 
a-HA HA epitope Polyclonal purified Mouse 1:200 
a-EP T. brucei EP procyclin Monoclonal purified Mouse 1:800 
a-PFR T. brucei PFR Polyclonal purified Rabbit 1:100 
a-rabbit-AF555 Rabbit IgG (H+L) Polyclonal purified Goat 1:500 
a-mouse-AF488 Mouse IgG (H+L) Polyclonal purified Goat 1:500 
a-mouse-AF555 Mouse IgG (H+L) Polyclonal purified Goat 1:500 
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2.5.2 Live immunostaining 
 
 Live cells were washed in ice-cold PBS and incubated in 20% FBS vPBS for 
30 minutes on ice. The primary anti-MISP antibody was added (1:200 dilution) and 
incubated for 1 hour on ice. Cells were washed and incubated with the secondary 
goat anti-rabbit-Alexa Fluor-555 (1:500 dilution) for 1 hour on ice. Cells were then 
fixed in fresh 4% PFA for 15 minutes at RT, stained with DAPI 300 ng/mL for 10 
minutes and mounted on a slide with Slowfade Diamond mounting oil for imaging.  
 
 
2.5.3 Laser Scanning Confocal Microscopy (LSCM) 
 
Specimens were imaged using the confocal laser scanning microscope Zeiss 
LSM-880 (located at the LSTM Cat 3 facility) with a Zeiss Apochromat 63X/1.4 
objective and analysed with the Zen software (Zeiss). Imaging was carried out with 
lasers exciting at 405 nm, 488 nm, 514 nm, 561 and 633 nm according to the 
fluorochrome under excitation. The pinhole aperture was set by default at 1 unit, laser 
power and digital gain were adjusted to prevent saturation and scanning times were 
set for optimal results. For z-stack acquisition, the outer limits were set outside the 
specimen’s surface and the number of stacks set to optimal. To measure mean 
intensity fluorescence in Zen, images were taken conserving identical laser power, 
pinhole aperture and digital gain settings. Cell length measurements were obtained 
using Fiji (ImageJ) from microscopy images. 
 
 
2.5.3 Fluorescence-Activated Cell Sorting (FACS) 
 
 T. b. brucei PCF cells were washed in PBS and incubated with or without 
ConA-FITC 1 µg/mL in PBS for 1 hour on ice. Lectin control samples were incubated 
with pre-saturated ConA-FITC (pre-incubated with 200 mM a-methyl-D-mannoside 
and 200 mM a-methyl-D-glucoside at 27°C for 30 minutes). Tunicamycin-treated PCF 
controls had been previously cultured for 5 days in SDM-79 10% FBS supplemented 
with 1 µg/mL tunicamycin, a known N-glycosylation inhibitor (Takatsuki et al., 1971). 
After washing, cells were set at 106 cells/mL in PBS and acquired in a BD LSR II 
FACS system using the 488 nm laser and the FITC 530/30 detector. 20,000 cells were 
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acquired per sample at medium speed. Data were analysed using the FlowJo (FlowJo 
LLC) software.    
 
 
2.6 Ion-exchange chromatography 
 
 For its activation, 8 g D-52 cellulose matrix (Whatman, GE) were incubated in 
0.5M HCl for 30 minutes and washed in dH2O until a pH=4 was reached. The matrix 
was then incubated in 0.5 M NaOH for 30 minutes and washed to reach a pH=8. The 
matrix was then washed in separation buffer (44 mM NaCl, 57 mM Na2HPO4, 3mM 
KH2PO4, pH=8) and pH was adjusted to 8 with orthophosphoric acid. Ion-exchange 
columns were prepared with ~0.5 mL matrix and equilibrated in separation buffer. T. 
b. brucei cells were washed with separation buffer supplemented with 55 mM D-
glucose before being passed through the column.  
 
 
2.7 Bioinformatics 
 
Trypanosome sequences were obtained from TritrypDB (www.tritrypdb.org) 
(Aslett et al., 2010) or UniProt (www.uniprot.org) (Apweiler et al., 2004). G. m. 
morsitans sequences were obtained from VectorBase (www.vectorbase.org) (Lawson 
et al., 2007). Sequence analyses and multiple alignments were done using Clustal 
Omega (Sievers et al., 2011) and Geneious R9 (Biomatters Ltd). Alignment figures 
were made in Jalview (Waterhouse et al., 2009) and Geneious.  Phylogenetic trees 
were generated using PyML 3.1 (Guindon and Gascuel, 2003) under default 
conditions with a set bootstrap of 500. Signal peptide, GPI-anchor signal, and 
transmembrane domain predictions were determined under default conditions using 
the servers SignalIP 4.1 (Petersen et al., 2011), PredGPI (Pierleoni et al., 2008) and 
TMHMM 2.0 (Krogh et al., 2001), respectively. N-glycosylation site predictions were 
run using the NetNGlyc 1.0 server (http://www.cbs.dtu.dk/services/NetNGlyc). 
Domain searches were done in InterPro (Apweiler et al., 2001). Protein structure 
modelling was performed using I-TASSER (when possible, providing a template 
crystal structure and sequence alignment) (Roy et al., 2010; Yang et al., 2015; Zhang, 
2008) and IntFOLD (McGuffin et al., 2015). Available protein structures were obtained 
from Protein Data Bank (PDB, www.rcsb.org) (Bernstein et al., 1977). Structural 
homology searches were performed using DALI (Holm and Rosenstrom, 2010) and 
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conservation models using ConSurf (Ashkenazy et al., 2016; Ashkenazy et al., 2010). 
Protein structures were visualised and prepared for publication using PyMOL 
(Molecular Graphics System, Version 2.0 Schrödinger, LLC).  
 
 
2.8 Statistics 
 
 Statistical analyses were applied whenever possible to data involving at least 
two technical or biological replicates. The analysis of variance (ANOVA) t-test was 
performed to analyse the significance between means of independent (unpaired) 
groups. Results with p-values <0.05 were considered significant. Typically, the means 
were plotted, and the standard deviations were shown as error bars using Prism 
(GraphPad). 
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CHAPTER 3 
Metacyclic Invariant Surface Proteins (MISPs),  
a novel family of trypanosome surface proteins 
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3.1 Introduction 
 
 All blood stages of T. brucei (i.e. the metacyclic and bloodstream 
trypomastigotes) are coated with a dense layer of VSGs which, in BSFs, are known 
to be responsible for antigenic variation  (Horn, 2014) and clearance of VSG-bound 
host antibodies (Engstler et al., 2007). The VSG coat is also important because it 
masks other invariant surface proteins, hiding them from the host immune system. 
Thus, VSGs and antigenic variation are the main reason that has prevented the 
development of a vaccine against T. brucei and other African trypanosomes. 
Consequently, there is the need to identify, if any, new invariant proteins exposed 
over the VSG coat of either parasite stage which could lead to the development of a 
preventive (neutralising MCFs) or therapeutic vaccine (assisting the immune system 
to clear BSFs).  As it is suggested in multiple studies searching for invariant surface 
proteins, it is unlikely that BSFs expose any conserved epitopes above the VSG coat 
as this would compromise the efficacy of antigenic variation (Schwede et al., 2011; 
Schwede et al., 2015). Metacyclics, however, may not need to fully protect invariant 
surface proteins since they are pre-adapted to survive in the host for a few days after 
transmission, and rapidly differentiate into BSFs once they get transmitted by the 
tsetse. They may not be under pressure to mask conserved surface proteins because 
this short period of time is not long enough for the host to effectively develop a specific 
immune response. In addition, MCF are transmitted to the skin of the host through the 
bite of the tsetse (Caljon et al., 2016). These are inoculated along with saliva, whose 
main function is to inhibit the host’s haemostatic response to the cutaneous trauma, 
and it may also contain parasite factors important for transmission and early stages 
of infection in the host (Alves-Silva et al., 2010; Van Den Abbeele et al., 2010).  
Altogether, studying the MCF surface and searching for parasite soluble 
factors in saliva seem to be reasonable approaches to follow in pursuit of the 
identification of new vaccine candidates against trypanosomiasis. This chapter 
describes a proteomics approach on T. brucei-infected tsetse saliva, that led to the 
identification of a novel family of T. brucei proteins I hereby characterised and named 
Metacyclic Invariant Surface Proteins (MISP). MISP is a small family of highly 
conserved glycoproteins from T. brucei (including T. b. gambiense and T. b. 
rhodesiense), T. evansi and T. congolense. Due to their unique characteristics, MISP 
are proposed to be molecular markers for metacyclogenesis, to have potential uses 
in xenodiagnosis in the field, and to be potential vaccine candidates against several 
African trypanosomiases. 
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3.2 Results 
 
3.2.1 Mass spectrometry of trypanosome-infected tsetse saliva  
 
3.2.1.1 Obtaining naïve and T. brucei-infected tsetse saliva samples1  
 
 Groups of tsetse flies infected with T. b. brucei BSF strain TSW-196, and 
control flies (naïve) of the same age were dissected at 30 days post infection (dpi) 
and saliva was collected, in three biological replicates. The rate of SG infections is 
usually ~10-20% under these experimental conditions. SG infections were assessed 
by microscopy (attached EMFs and MCF can be seen moving through the SG). The 
collected SGs were pooled and centrifuged to collect the supernatant enriched with 
saliva (pellet contained SG tissue and trypanosomes). Infected and naïve saliva 
samples were lyophilised, submitted to in-solution trypsin digestion, and analyzed by 
nano-liquid chromatography tandem mass spectrometry (nLC-MS/MS) (Dundee 
University Fingerprints Proteomics Facility).  
 
 
3.2.1.2 MS/MS spectra analyses 
 
 The resulting MS/MS were searched with Proteome Discoverer against 
combined databases of T. brucei and G. morsitans proteins, and the resultant dataset 
was analysed using Scaffold Q+ and perSPECtives. After removing all Glossina hits 
and having manually inspected and curated all trypanosome hits and spectra, the 
resulting proteins were BLAST searched using BLAST2GO and mapped according to 
gene ontology (GO) terms. The complete workflow of sample processing is 
summarised in Figure 3.1. 
 
                                            
 
1 All the sample collection and initial proteomics data was obtained by Dr. Samïrah Perally. In 
collaboration with Prof. Igor Almeida (UTEP, USA), I then searched for significant hits, 
including manual curation of selected mass spectra, as shown below. 
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Figure 3.1. Workflow for the analysis of T. brucei-infected tsetse saliva. For each 
biological replicate, saliva samples from naïve flies were also collected and processed 
in parallel.  
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3.2.1.3 T. brucei proteins in infected tsetse saliva 
 
We identified 45 unique peptides that derived from a total of 27 T. b. brucei 
proteins in infected saliva datasets, with high confidence identification (>95%). 17 of 
those proteins (62.9%) (Figure 3.2, Table 3.1) are intracellular mainly linked to 
functions such as protein folding (14.8%), cytoskeleton (11.1%) and metabolic 
processes (7.4%). The remaining 10 proteins (37.1%), were predicted to be GPI-
anchored surface proteins from three major families: BARP, VSG and MISP (Figure 
3.2, Table 3.2). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Pie chart of T. brucei proteins identified in tsetse saliva. Surface 
proteins (blue shades) and intracellular proteins (red to yellow shades) grouped based 
on functional GO terms.  
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Table 3.1. Intracellular T. brucei proteins identified by nLC-MS/MS in infected 
tsetse saliva. All proteins and peptides identified have >95% confidence and were 
manually curated. Accession code (Protein ID), protein description (Annotation), 
number of identified unique peptides (Peptides) and number of unique spectra 
(Spectra).  
 
 
 
(1): Accession code of coding gene in strain TREU927, TriTrypDB. 
 *: Representative ID of multiple homologs sharing the detected peptide. 
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Table 3.2. Summary of T. brucei GPI-anchored surface proteins detected in 
infected tsetse saliva by nLC-MS/MS. All proteins and peptides identified with >95% 
confidence and manually curated. Protein accession code (Protein ID), protein 
description (Annotation), number of identified unique peptides (Peptides), and 
number of spectra (Spectra).  
 
 
(a) Accession code for T. b. brucei in TriTrypDB (MISP and BARP) or UniProt (VSG).  
(1) Representative ID. Peptide conserved in Tb927.9.15520, Tb927.9.15530, 
Tb927.9.15550, Tb927.9.15590, Tb927.9.15600, Tb927.9.15620 and 
Tb927.9.15660. 
(2) Representative ID. Peptide also conserved in T. b. brucei VSGs 646, 769, 3613, 
1125.408,   1125.474, 1125.1142, 1125.4207 and 1125.4707.   
(3) Representative ID. Peptide conserved across all 5 T. brucei MISP isoforms. 
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3.2.1.4 T. brucei surface proteins: BARPs 
 
One family of surface proteins identified is BARP, which are known to be 
expressed by EMFs in tsetse SG (Urwyler et al., 2007). According to the genome of 
T. b. brucei strain TREU927 (TriTrypDB), there are 14 barp homolog genes arranged 
in tandem (Berriman et al., 2005) (Figure 3.3). Out of 4 unique peptides detected, we 
identified 8 putative BARP isoforms (Table 3.2). For example, the peptide 
VQAEEAVELAESK (Figure 3.4) is conserved across 7 of the 14 BARP proteins 
(Figure 3.3). The peptide GLSQTVTSAVETSAAASSK is conserved in two isoforms 
(Tb927.9.15530 and Tb927.9.15630) and peptides QNTGWEVLTK and 
SAAEVVTAESISAALNDLGK are both unique for the isoform Tb927.9.15530.  
 
 
3.2.1.5 T. brucei surface proteins: VSGs 
 
We detected 7 unique VSG peptides (Table 3.2) that originated from the 
mammalian-infective MCFs and allowed the putative identification of VSG-221 
(QADAANNFHDNDAECR, DSEASEIQTELK, LQLSPIQPK), mVAT4 
(EAADVPCVNNGGGLNK), VSG 1125.4959 (LQQQLALYR), VSG 1125.3088 
(STEELCNAK) and the peptide KTDAADKTEEK, which is found in 8 different VSGs 
(e.g.  VSG 1125.408) (Figure 3.5). A multiple protein alignment revealed that these 
VSGs only share 10.5% identity. Since 6 out of 7 peptides did not correspond to 
metacyclic VSGs but to BSF VSGs, an extensive search over published similar works 
was done for comparison (Table 3.3).  
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Figure 3.4. Example of mass spectrum of a T. brucei BARP peptide (A) and VSG 
mVAT4 (B) detected by nLC-MS/MS in tsetse infected saliva. Scaffold Q+ captures 
of identified protein, peptide coverage, biological sample source, spectra and ions 
table. 
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Although no study specifically reported finding BSF VSGs originating from 
MCF, it was found in the raw data that many of them identified BSF VSGs in either 
RNA or protein forms (Christiano et al., 2017; Kariithi et al., 2016; Savage et al., 2016; 
Telleria et al., 2014) (see Discussion).  
 
 
Table 3.3. Summary of T. brucei VSG species found in either cultured or fly-
derived metacyclics (Literature). 
 
Metacyclic VSGs in bold font 
(a) In vivo samples isolated from infected G. m. morsitans flies 
(b) T. brucei strain in parentheses 
(c) VSG species; TritrypDB gene accession code; UniProt protein accession code 
(d) Genes with higher differential expression (MCF compared to PCF) than canonical 
mVSGs (>1100 fold) 
(e) There are 11 more VSG genes with differential expression MCF/PCF within the 
canonical mVSG range (250 to 730-fold) 
(f) Also upregulated in RNA-seq data 
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3.2.1.6 T. brucei surface proteins: MISP 
 
Lastly, we identified a unique peptide (SVAEDNSAASTAR) with 100% 
confidence (supported by two separate spectra; Figure 3.5), which belongs to a family 
of hypothetical GPI-anchored surface proteins (Table 3.2) that I further named 
Metacyclic Invariant Surface Proteins (MISP). The peptide SVAEDNSAASTAR is fully 
conserved across all MISP isoforms (see below; Figure 3.9). 
 
 
 
Figure 3.5. Example of mass spectrum of a T. brucei MISP peptide detected by nLC-
MS/MS in tsetse infected saliva. Scaffold Q+ captures of identified protein, peptide 
coverage, biological sample source, spectra and ions table. 
 
 
 
3.2.1.7 Sodalis glossinidius proteins in tsetse saliva 
 
In addition to proteins from T. brucei and G. morsitans, it was also detected in 
both naïve and trypanosome-infected saliva a few peptides from the symbiont Sodalis 
glossinidius (Cheng and Aksoy, 1999) (not shown). The presence of Sodalis proteins 
was corroborated by western blotting using 1H1 monoclonal antibody, which 
specifically recognises Sodalis Hsp60 (Haines, 2002) (Figure 3.6). Taking together, 
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T. brucei-infected tsetse saliva contains a complex mixture of soluble factors from 
trypanosomes and Sodalis bacteria, in addition to a diminished proportion of Glossina 
salivary proteins compared to saliva from naïve flies (Van Den Abbeele et al., 2010).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Immunoblotting of G. m. morsitans naïve and T. b. brucei-infected 
saliva probing with the mouse anti-Sodalis mAb 1H1. (1) Naïve (N) saliva and (2) 
infected (I) saliva probed with the antibody; film exposure: 10 seconds. (3) same naïve 
saliva and (4) infected saliva in PVDF membrane stained with nigrosin. Performed by 
Dr. Lee Haines (LSTM).  
 
 
3.2.2 In silico analyses on MISP 
 
3.2.2.1 Phylogenetic analyses 
 
 MISP were previously included in the cell-surface phylome (Jackson et al., 
2013), within the large family Fam50 of trypanosome surface proteins which includes 
proteins such as the BARPs (Urwyler et al., 2007), and the T. congolense Glutamic 
Acid-Rich Protein (GARP) (Bayne et al., 1993; Beecroft et al., 1993) and Congolense 
Epimastigote Surface Protein (CESP) (Sakurai et al., 2008). The T. b. brucei genome 
contains five misp homolog genes (Tb927.7.360, Tb927.7.380, Tb927.7.400, 
Tb927.7.420, Tb927.7.440 in strain TREU927, TriTrypDB) (Berriman et al., 2005), 
which encode for proteins that are unique in sequence and have no predictable 
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function. All five T. b. brucei homologs are found in an ‘array-like’ disposition in 
chromosome 7 (Figure 3.7), although the array contains unrelated genes between 
each pair of misp genes (i.e. Tb927.7.370, Tb927.7.390, Tb927.7.410 and 
Tb927.7.430; all predicted to be homologs encoding the Golgi complex component 
7). The same homologs are found in the human pathogenic subspecies T. b. 
rhodesiense and T. b. gambiense (Tbg972.7.270, Tbg972.7.290). Furthermore, 
slightly divergent versions of misp genes can also be found in the animal trypanosome 
species T. evansi (TevSTIB805.7.300, TevSTIB805.7.320 and TevSTIB805.7.380) 
and T. congolense (TcIL3000.0.02370). A phylogenetic analysis using PhyML 3.1 
(Guindon and Gascuel, 2003) on all MISP proteins determined that the family is 
divided in two sub-families, MISP-A and MISP-B, that originate from a common 
ancestor (Figure 3.8-A). The MISP-A sub-family, characterised by containing the N-
terminal sequences Asp18-Ser-Ile-Ile-Glu22 and Ala127-Gly-Lys-Thr130, and 1-3 repeats 
at the C-terminal (see below; Figure 3.8-B), is comprised by T. b. brucei Tb927.7.360, 
Tb927.7.380, Tb927.7.440, T b. gambiense Tbg972.7.290 and T. evansi 
TevSTIB805.7.300, TevSTIB805.7.320 and TevSTIB805.7.380 isoforms. MISP-B 
proteins, on the other hand, contain a conserved Gly18-Pro-Lys-Gly-Gly22 and Asn127-
Asn-Asn-Val130 at the N-terminus and no C-terminal repeats, and is represented by 
Tb927.7.400 and Tb927.7.420 (T. b. brucei), and T. b. gambiense Tbg972.7.270. 
Other N-terminus residues (e.g. Ser25, Ans27, Phe38, Arg121, and Pro123-Leu124 (for 
MISP-A), and Phe25, Asp27, Met38, Asn121, and Ser123-Ala124 (for MISP-B)) are 
characteristic in each protein sub-family (see Figure 3.8-B). As for T. congolense 
TcIL3000.0.02370, it cannot be included within either group as it does not share the 
common ancestor and it only conserves a 34.2% of identity with other MISP isoforms. 
A comparison of the five T. b. brucei misp homologs yielded an overall sequence 
identity of 82.9% and 80.5%, at the nucleotide and amino acid level (Figure 3.8-B), 
respectively. In addition, the amino acid sequence alignment showed that the N-
termini domains (Met1–Glu237) are more conserved (88.7%) than the C-termini (Glu–
Lys238) where the main divergence is found (49.0%). However, divergence is not 
random, but based on repetitions of negatively charged and acidic sequences of 26 
residues (EVEEVPKKDPEGNVEVPEDKEKTERT or DVQEISREEFEGNVEVPEDK 
EKTERT). Alignment of all MISP proteins across species (excluding 
TcIL3000.0.02370) shows an overall 79.1% identity conservation (Figure 3.8-B).  
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Figure 3.8. Sequence analysis of MISP protein family. (A) Unrooted phylogenetic 
tree estimated from a multiple alignment of all MISP proteins found across 
trypanosome species, pointing out the two sub-families MISP-A (green) and MISP-B 
(blue), and the T. congolense MISP (grey). The T. b. brucei MISPs are highlighted. 
Tree created using PhyML 3.1 and the WAG substitution model of maximum 
likelihood; bootstrap of 500; numbers show branch support values (%); scale bar = 
0.1 substitutions/site. (B) Multiple protein alignment of the T. b. brucei MISP isoforms 
(MISP360, MISP380, MISP440, MISP400 and MISP420). Residues coloured from 
grey (full conservation) to bright red (highest divergence). Protein domains 
highlighted: signal peptide (green), putative N-glycosylation sites (yellow asparagine 
residues), C-terminus motifs of 26 residues (blue) and GPI-anchor signal peptide. The 
conserved peptide ’SVAEDNSAASTAR’ identified by nLC-MS/MS is highlighted in 
orange. The top bar numbers indicate residue position starting from Met1. Top bar 
colours indicate the main protein domains N- (purple) and C- termini (grey).  
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3.2.2.2 Predictions on signal peptide, GPI-anchor and N-glycosylation 
 
The presence of signal peptides in all T. b. brucei MISP isoforms (Met1–
Ala/Thr17) was confirmed using the SignalP 4.1 server (Petersen et al., 2011), 
although, MISP-B Tb927.7.400 may also contain an alternative cleavage site at Gly24 
(Table 3.4). MISP proteins from other trypanosome species have equivalent signal 
peptide predictions (Table 3.4). According to the TMHMM 2.0 server, none of the 
MISP sub-families appear to contain a transmembrane domain (Table 3.4). However, 
all T. brucei isoforms have a strong prediction (99.9% specificity) for GPI-anchoring 
(Pierleoni et al., 2008), with a putative w site at Ser within the C-terminal sequences 
SYAESIGGYTLLILLAALSHSAAAHF or SYAESIGGYTLLILLAALFHSAAAHF (Figure 
3.9-A, Table 3.4). Furthermore, the NetNGlyc 1.0 server predicted that all T. b. brucei 
and T. b. gambiense MISP isoforms contain one N-glycosylation sequon (Asn59-Val-
Ser; except for Tb927.7.420), and members of the MISP-B sub-family may also 
contain a putative secondary N-glycosylation sequon (Asn121-Ala-Ser). In addition, 
two T. evansi MISPs (TevSTIB805.7.320 and TevSTIB805.7.380) contain one N-
glycosylation site (Asn58-Val-Ser) and, interestingly, the T. congolense MISP is 
potentially N-glycosylated at 6 different sites (Asn126-Ala-Thr, Asn163-Asp-Thr, Asn166-
Ser-Ser, Asn195-Ile-Thr, Asn198-Ala-Thr, Asn245-Thr-Ser) (Table 3.4). 
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Table 3.4. In silico predictions based on MISP protein sequences. Accession 
code (Protein ID), trypanosome species having the coding gene (Species), MISP sub-
family (Sub-family), predicted signal peptide (SP), predicted GPI anchor peptide 
(GPI), number of predicted N-glycosylation sites (N-glycan) and number of C-terminus 
26-residues motives (C- mot.) 
 
(a): Accession code of coding genes in TriTrypDB. 
(b): Starting-ending residues. Peptide cleaved after ending residue. 
(c): All GPI anchor peptides are formed by the last 26 residues of the protein. 
(d): 26 residues motifs described in Figure 3.8-A. 
 
 
 
 
3.2.2.3 Prediction on protease target sequences 
 
 Using the mature MISP360 and MISP400 protein sequences (representatives 
for MISP-A and MISP-B), potential sites of cleavage by proteases were predicted 
using the PROSPER server (Song et al., 2012) (Figure 3.10). This identifies target 
sites for 24 different protease families from the major types aspartic (A), cysteine (C), 
metallo- (M) and serine (S) proteases. The predictions show a similar profile of 
multiple potential cleavage sites in both TbMISP360 and TbMISP400. Considering 
the crystal structure of the MISP360 N-terminus (see section 3.2.6.1) it seems unlikely 
that these sites are accessible to proteases. However, sites at the C-terminus may be 
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actually susceptible to protease cleavage because of the lack of secondary structure 
(see section 3.2.6.3). The release of these surface proteins by C-termini cleavage, 
which maintains the protein attached to the plasmatic membrane, may explain the 
detection of MISP in the saliva proteomics, although the exact mechanism of MISPs 
released from the parasite surface remains to be investigated.  
 
 
 
Figure 3.10. PROSPER protease cleavage sites predictions. MISP360 (top) and 
MISP400 sequences with predicted protease cleavage sites highlighted. Only one 
member of each family is represented. Key, the top right.  
 
 
 
3.2.2.4 First insights into the 3D structures of MISP  
 
To get a first idea into the possible protein 3D structure of MISP, the amino 
acid sequences of MISP360 (representing the MISP-A sub-family and having the 
longest C-termini) and MISP400 (representing MISP-B and the shortest C-termini), 
both lacking the signal and GPI-anchor peptides, were used in both I-TASSER (Roy 
et al., 2010; Yang et al., 2015; Zhang, 2008) and IntFOLD (McGuffin et al., 2015) 
servers for in silico protein structure modelling. Both servers found the MISP N-
terminus to be structurally similar to the T. congolense GARP (PDB: 2y44) (Loveless 
et al., 2011). No structural hits were found for the C-termini, and MISP protein function 
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could not be predicted due to the lack of structural or sequence domain similarity. 
Final models of MISP360 and MISP400 were built in PyMOL 2.0 by assembling 
separate models of N- and C-termini (Figure 3.11). The generation and curation of 
these models was important to solve the crystal structure of MISP360 N-terminus by 
molecular replacement (see section 3.2.6.1) and for the design of recombinant 
versions of MISP360 for NMR studies (see section 3.2.3.2)  
 
  
 
 
Figure 3.11. 3D structural models of T. brucei MISP360 and MISP400 proteins. 
Models generated with I-TASSER (left) and IntFOLD (right) servers. Cartoon 
representation with molecular surface of N-termini domains (blue) and C-termini 
domains (red). Insets show a close up of the N-termini domains. 
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3.2.3 Production of MISP recombinant proteins 
 
3.2.3.1 Production of recombinant MISP for rabbit immunisation 
 
In order to create an antibody against MISP (see section 3.2.4), a recombinant 
MISP (rMISP380) was produced for immunization2. The misp380 gene was amplified 
by PCR from the T. b. brucei genome and cloned into the bacterial expression plasmid 
pET28. The complete coding sequence was depleted from the signal peptide and 
GPI-anchor signal peptide (both predicted to be absent in the mature protein) and 
fused to a poly-histidine tag (6xHis) at the C-terminus (Figure 3.12-A). The 
expression of the transgene is driven by a T7 promoter, and tightly regulated by a Lac 
operator sequence. The recombinant protein expression was induced with IPTG in E. 
coli and purified by nickel-agarose affinity (Figure 3.12-B-C-D). Several protein 
fractions of rMISP380 were collected and analysed by SDS-PAGE to select the 
elution fractions with the purest MISP content (Figure 3.12-D). All eluates were 
pooled together and further purified by size exclusion chromatography (SEC) using a 
FPLC system in a Superdex 200 column (Figure 3.13). Fractions were collected and 
analysed by Coomassie blue SDS-PAGE (Figure 3.13-A). The elution pattern 
showed that most of rMISP380 (predicted to be ~35 kDa in a monomeric state) comes 
out from the column with a molecular mass bigger than 650 kDa, suggesting that it 
may form non-specific aggregates that dissociate into monomers after processing for 
SDS-PAGE (e.g. fractions 5, 6, 7). A smaller peak at ~35 kDa suggests that rMISP380 
also elutes as a monomer, but in a much-reduced proportion (fraction 19). Fractions 
5 to 9 were pooled, yielding ~0.4 mg of purified rMISP380. This sample was used for 
the immunisation and antibody purification as described in Section 3.2.4. 
                                            
 
2 All attempts to express rMISP360 in bacteria, using the exact same procedure described for 
the expression of rMIPS380, were unsuccessful. However, due to the high degree of 
conservation among MISP isoforms, it is expected that antibodies anti-MISP380 cross-react 
with all MISP variants. 
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Figure 3.12. Expression and Ni-NTA purification of rMISP380. (A) DNA construct 
engineered for the expression of the protein. misp380 gene (lacking signal and GPI 
peptides) cloned using NcoI (containing the start codon, underlined) and XhoI 
restriction targets. T7 promoter (T7), Lac operator and ribosome binding site found 
upstream the transgene. (B) SDS-PAGE of E. coli BL21(DE3) Rosetta 2 cell lysates 
of 3 different cultures induced (+) or not induced (-) with IPTG for the production of 
rMISP380, compared with the purified rMISP380. (C) Protein concentration (mg/mL) 
graph of the different fractions acquired during Ni-NTA purification: bacteria lysate 
(Lys), column flow-through (FT), washes 1-3 (W) and elutions 1-11 (E). (D) SDS-
PAGE of Ni-NTA purification fractions.  
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Figure 3.13. (A) SEC elution pattern of Ni-NTA-purified rMISP380 and fractions 
collected (red numbers). Estimated molecular weights shown above the major peaks. 
SDS-PAGE (inset) of the pre-SEC sample and selected fractions (highlighted in red). 
(B) SEC elution pattern of standards used in calibration and molecular size 
estimation. 
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3.2.3.2 Production of recombinant truncated variants of MISP360. 
 
 As shown in section 3.2.2.4, 3D modelling of MISP360 and MISP400 
suggested that the C-terminus domain of MISP is likely to acquire an unstructured 
random coiled conformation, while the N-terminus domains seem to adopt a helical 
folding similar to the T. congolense GARP crystal structure (Loveless et al., 2011). 
The crystal structure of MISP360 N-terminus has been solved by X-ray 
crystallography (see section 3.2.6.1). However, the C-terminus could not be 
crystallised, probably due to this predicted disorganised nature, which makes this part 
of the protein very mobile. Accordingly, nuclear magnetic resonance (NMR) would be 
a more suitable method to solve the structure of the MISPs C-termini and/or the 
complete structures of MISP. Furthermore, it will also help to obtain more information 
about the motion dynamics of the different protein domains. Although due to time-
constraints no NMR studies were conducted in this thesis, I produced a series MISP 
recombinant proteins that could be used for these purposes in the future. 
  
 The coding sequence of misp360 was obtained by PCR from the T. b. brucei 
genome and cloned into a standard bacterial plasmid. From there, by using different 
primer pairs, the coding sequences for either the N- terminus, the C- terminus or the 
complete MISP360 proteins were cloned into the bacterial expression plasmid pCOLD 
II for production of recombinant protein under cold conditions to achieve an optimal 
protein folding (Figure 3.14). This is done by exploiting the cspA cold-shock protein 
promoter and UTRs. Coding sequences lacked the signal peptide and GPI-anchor 
signal peptide (removed in the mature protein) and were fused to a 6xHis tag at N-
terminus.  
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Figure 3.14. Engineered DNA constructs for the expression of MISP360 
recombinant proteins in E. coli. (Left) 3D model of the resultant recombinant 
protein. (Right) DNA constructs coding for the recombinant protein. The 3 variations 
use the pCOLD II plasmid backbone for the inducible (IPTG) expression of the 
transgene under the cold-shock cspA promoter and UTRs. All proteins are 6xHis 
tagged at N-terminus and contain the translation enhancer element (TEE) upstream 
the tag.   
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The resultant proteins (NMISP360, CMISP360 and N+CMISP360) were purified 
by nickel-agarose affinity (Figure 3.15) and the eluted fractions that showed the 
highest purity by SDS-PAGE were pooled together and stored for further use (see 
reactivity with anti-MISP polyclonal in section 3.2.4). As seen in Figure 3.15, all 3 
proteins were produced and had affinity for the purification column. NMISP360 
production had the highest yield (measured by UV-Vis spectroscopy), followed by 
NCMISP360. Protein content of CMISP360 elutions could not be measured using UV-
Vis spectroscopy since the protein lacks aromatic amino acids (Trp, Tyr and Phe) 
which absorb 280 nm light. NMISP360 is displayed as a major single band at ~25 kDa 
as its expected molecular weight. However, CMISP360 is shown in two bands with 
different molecular weights (~30 kDa and ~24 kDa) which do not correspond to the 
protein expected size (~15.6 kDa). Although proteins ran under denaturing conditions, 
this may indicate that the C-termini domains form several forms of dimeric 
aggregates. The complete NCMISP360 protein, similar to rMISP380 from section 
3.2.3.1, is displayed as a major single band with a relative molecular size of ~50 kDa, 
much bigger than its expected weight (~38.6 kDa). 
  
The presence of the unstructured C-terminus domain composed of low 
complexity regions seems to affect the yield of protein production and to alter the 
apparent molecular size on SDS-PAGE of both CMISP360 and NCMISP360 proteins. 
Interestingly, the two bands that appear to correspond to the MISP360 C-terminus 
are also shown in NCrMISP360 and rMISP380 purifications, but not in NMISP360 which 
does not contain a C-terminus domain. This suggests that the C-terminus may be 
very susceptible to cleavage or degradation, as predicted in Section 3.2.2.3.    
 
 
3.2.4 Creation of a polyclonal antibody against MISP 
 
 A polyclonal antibody was raised against MISP as a valuable tool to study 
many aspects of these proteins. Since the T. brucei MISP family is highly conserved 
(shown above), it was hypothesised that raising a polyclonal antibody by 
immunisation with a complete MISP protein would lead to a highly cross-reactive 
antibody for all isoforms. This antibody was widely used to detect expression of MISP 
proteins by immunoblotting and for cell localisation studies by immunofluorescence. 
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The immunisation and antibody purifications were carried out by the company 
Davids Biotechnologie GmbH (Germany) on a single rabbit using 0,3 mg of purified 
recombinant rMISP-380 (described in section 3.2.3.1), and anti-serum was obtained 
after bleeding the animal at 63 days post-immunisation (Figure 3.16). The anti-serum 
was then processed to purify IgGs using a protein A column. These IgGs were then 
affinity-purified using a column containing a matrix covalently bound to rMISP380. 
Lastly, anti-MISP IgGs were further passed through a column containing protein 
lysate from the same E. coli cells used to produce the recombinant protein, so IgGs 
with unspecific binding to bacterial proteins were excluded. A pre-immunisation rabbit 
serum was also acquired. All anti-sera and purified antibodies were tested for 
reactivity with the recombinant protein by immunoblotting (Figure 3.17). Reactivity 
was also tested after sample freezing, before aliquots were made and kept frozen at 
-20°C until further use. 
 
 
 
Figure 3.16. Schematic representation depicting the steps involved in the 
production of polyclonal antibodies a-MISP. Detailed procedure described in 
section 3.2.4 
 
 
 
 
 
  
108 
  Several western blottings were performed to evaluate the reactivity and 
specificity of the polyclonal anti-MISP. The antibody was tested against the rMISP380 
protein (used for the immunisation) as a positive control, bovine serum albumin  as 
negative control, and the recombinant protein NMISP360 (see section 3.2.3.2) as test 
subject. As shown in Figure 3.17, the antibody positively reacted with several 
rMISP380 (from independent batches) and NMISP360, partly confirming cross-
reactivity with at least one more isoform. Neither purified anti-MISP nor anti-serum 
reacted with a T. brucei PCF lysate, proving to have null unspecific binding to 
trypanosomal proteins and suggesting that MISP may not be expressed in PCFs. In 
addition, pre-immune serum did not react with any of the recombinant MISP variants, 
proving to be a good negative control in further assays.   
 
 
 
Figure 3.17. anti-MISP polyclonal reactivity tests. (A) Tests using purified 
rMISP380 and AnTat 1.1. 90:13 wildtype PCF lysate, probed with purified anti-MISP, 
anti-MISP anti-serum and pre-immune rabbit serum. For each blotting, PVDF 
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membranes stained with nigrosin and SDS-PAGE stained with InstaBlue are shown 
as loading control. (B) Immunoblotting probing with the purified anti-MISP on PCF 
lysate, E. coli lysate, 3 independently-produced rMISP380 and MISP360 N-terminus 
recombinant protein.   
 
 
3.2.5 Gene and protein expression analyses on MISP and BARP 
 
3.2.5.1 Developmental expression of MISP and BARP 
 
The nLC-MS/MS analysis identified MISP peptides in tsetse infected saliva, 
which originate from parasite stages dwelling in infected SG. To better understand 
the expression of misp during parasite development in the fly, we used semi-
quantitative and real time RT-PCR, alongside barp detection as a marker for SG 
EMFs (Urwyler et al., 2007). Total RNA samples were isolated from all T. b. brucei 
life stages obtained from both in vitro cultures (cultured bloodstream forms (cBSF) 
and procyclic cultured forms (PCF)) and fly-derived parasites at 30 d.p.i: i.e. midgut 
procyclics, proventricular parasites (95% mesocyclics, 5% epimastigotes), whole 
infected salivary glands (SG) and isolated metacyclic forms (MCF). Samples from 
naïve flies (30 days old) were used as negative control. Total RNA was reverse-
transcribed into cDNA using oligo dT20 primers for a faithful representation of mature 
mRNA. Due to the high sequence identity among the five misp homolog genes, 
assessing the expression of individual isoforms by real-time RT-PCR was not 
possible. I therefore approached this issue by using the more permissive semi-
quantitative RT-PCR method and exploited the differential lengths of the C-termini 
repeats region, which are unique for 4 of the 5 homologs, and show differences of 78 
bp (Figure 3.18).  
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Figure 3.18. Exploiting the misp C-termini repeats to determine homolog 
expression. (A) Schematic of the C-terminus coding region of the 5 T. brucei 
homologs, depicting the 78 bp repeats and the annealing sites of the forward and 
reverse primers (F, R, red arrows). (B) Representative 2% agarose gel displaying the 
4 expected bands from RT-PCR reaction products from PCF overexpressing (Dox +) 
or not (Dox -) misp360 (left); representative graph for band relative intensity 
quantification (arbitrary units).  
 
 
While control samples from naïve flies are all negative for misp expression, 
there is a great up-regulation of misp genes in SG stages compared to MG (11.8-fold) 
or cBSF (25.1-fold), with p-values <0.001 (Figure 3.19). Furthermore, although 
isolated MCF also presented similar expression levels compared to SG (1.5-fold less, 
p=0.003), we could not rule out that ~5% ‘contaminating’ EMFs in saliva also 
contributed to these high expression levels. PV trypanosomes, despite having a 2.1-
fold (p<0.001) lower expression compared to SG stages, showed significantly higher 
expression than MG procyclics, cBSF, and PCF (>5.5-fold, p=0.002) all showing 
negligible levels of misp. Interestingly, although there seems to be an overall 
preferential expression for misp homologs with short C-termini (misp400/420), the 
longer homologs misp380 and misp360 are only expressed in SG and MCF. In MCF, 
the expression of misp360 represents ca. 25% of the total expression of misp genes, 
  
111 
increase that appears to be compensated by the down-regulation of the shortest misp-
400/420. To further validate the specificity and sensitivity of the detection method, two 
control cDNA samples were added from a mutant PCF cell line overexpressing an 
ectopic copy of misp360 under a tetracycline-inducible system (Figure 3.20). The 
uninduced (Dox-) control cells showed low misp expression levels similar to wildtype 
PCF, while the induced (Dox+) cells showed a specific 2.8-fold increase in misp360 
expression only, thus proving a good sensitivity and specificity of our detection 
method (Figure 3.20). The expression levels of barp (all 14 homologs which share 
>60% identity at protein level) were also determined using the same samples for 
comparison (Figure 3.19). barp transcripts were found to be highly upregulated in 
infected PV compared to MG forms (10.6-fold), PCF (24-fold) or cBSF (26.6-fold), 
with p-values <0.01. This high expression levels of barp transcripts (-1.2-fold; with p-
values of <0.01) is maintained in total SGs (-1.6-fold) and MCF. cBSF, PCF and MG 
procyclics showed no significant barp expression levels. Uninfected tsetse controls 
were all negative (not shown). To validate these results, a similar expression analysis 
was performed using real time RT-PCR targeting universal sequences in misp and 
barp (Figure 3.20). Results showed the same trend in high expression of both misp 
(40-fold) and barp (95.6-fold) in SG compared to MG parasites, although with a 
greater fold change.  
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Figure 3.19. Expression levels of misp and barp throughout the T. b. brucei life 
cycle. (A) Relative mRNA expression levels (arbitrary units) of the T. b. brucei misp 
paralogs, detected by RT-PCR targeting the C-termini motifs in T. b. brucei AnTat 1.1 
90:13 cultured bloodstream forms (BSF), procyclic cultured forms (PCF), midgut 
procyclics, proventricular forms, salivary gland forms (SG) and isolated metacyclic 
forms (MCF). (B) Relative mRNA expression levels of T. b. brucei barps, targeting a 
universal region in all homologs. Error bars represent standard deviation, asterisks 
show statistical significance (* for p-value <0.05, ** <0.01, *** < 0.001). 
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Figure 3.20. Controls of detection method. (A) Controls for the semi-quantitative 
RT-PCR method used to determine the relative RNA expression levels of MISP. BSF, 
PCF and SG samples shown as in Figure 3.19. The introduced control is the MISP-
360 PCF mutant line either uninduced (360 -) or induced (360 +). The inset is a 
representative image of a DNA agarose gel displaying 4 bands corresponding to the 
amplification of the different misp homologs. (B) misp and barp relative RNA 
expression levels using quantitative RT-PCR on the samples in Figure 2. Control, 
same as in panel A.  
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3.2.5.2 Detecting MISP and BARP proteins in SG parasite stages 
 
Having identified trypanosome SG stages as the major contributors of misp 
and barp gene expression, I then determined their expression by 
immunofluorescence using polyclonal antibodies against MISP and BARP. Neither 
cBSF or PCF, nor parasites derived from MG or PV were recognised by either 
antibody (not shown). Recognition only occurred in infected SGs (Figure 3.21). Both 
anti-MISP and anti-BARP antibodies recognised all parasite stages in infected glands, 
staining clustered cells (EMF and P-MCF) that appeared attached to the epithelium, 
but also free-swimming MCF. Thus, both MISP and BARP proteins appear specifically 
expressed in trypanosome forms infecting SGs, and are absent in all other 
developmental stages, including those in the PV despite the high transcript levels 
(Figure 3.19). 
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Figure 3.21. T. b. brucei salivary gland life stages express MISP and BARP 
proteins during an infection in the tsetse salivary glands. Immunostaining of 
MISP and BARP proteins in trypanosomes infecting a tsetse salivary gland (‘d’ points 
towards the distal end of the glands). Representative images of uninfected (A) and T. 
b. brucei-infected salivary glands (B-E). Bright field (BF), DAPI (blue), ⍺-MISP (red) 
and ⍺-BARP (green). Scale bars = 20 µm. 
 
A 
B 
C 
D 
E 
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3.2.5.3. Cellular localisation of MISP and BARP 
 
In order to determine the precise cellular localisation of these proteins, I then 
probed individual PFA-fixed cells extracted from infected SG as well as cBSF, PCF, 
MG and PV forms (as negative controls). Only EMFs, P-MCFs and MCFs (Figure 
3.22-A) extracted from SG reacted with anti-MISP antibodies. Relative mean 
fluorescence intensities showed evidence of a higher recognition in MCFs compared 
to P-MCF (1.5-fold) and EMFs (2.3-fold) (Figure 3.22-B) (p-values 0.01 and <0.001, 
respectively). This suggests that MISP protein expression begins in EMFs and 
progresses along with parasite’s development within the SG, achieving its maximum 
level of expression in mature MCFs. MISP appeared to localise evenly throughout the 
cell surface in non-permeabilised cells (Figure 3.22-A). To confirm surface exposure 
of MISP epitopes (as predicted by molecular modelling analysis, see section 3.2.6.3), 
immunostaining with anti-MISP was performed on live (instead of PFA-fixed) MCF 
cells (Figure 3.23). In this case, all cells also stained positive and uniformly when 
incubated with anti-MISP antibody thus suggesting that at least part of MISP N-
terminal epitopes are accessible to antibodies. Remarkably, live MCF incubated with 
anti-MISP at RT showed reduced motility and expansion of the flagellar pocket 
compared with control cells, although cells recovered when incubated at 37°C (not 
shown), suggesting they may undergo antibody-mVSG endocytosis like BSFs 
(Engstler et al., 2007).  
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Figure 3.22. Expression and localisation of MISP and BARP proteins in T. b. 
brucei salivary gland stages. (A) Localisation of MISP. Immunostaining of non-
permeabilised parasites extracted from infected salivary glands: epimastigote (EMF), 
pre-metacyclic form (P-MCF) and metacyclic form (MCF). Bright field (BF), antibody ⍺-MISP (red), and DAPI (blue). Kinetoplasts (K) and nuclei (N) are highlighted in the 
DAPI channel. (B) Mean fluorescence intensity (arbitrary units) of anti-MISP stained 
cells. (C) Localisation of BARP. Immunostaining of non-permeabilised salivary gland 
parasites. Bright field (BF), antibody ⍺-BARP (green) and DAPI. Representative 
MCFs for BARP flagellar (1) and surface (2) localization. (D) Mean fluorescence 
intensity (arbitrary units) of anti-BARP. Scale bars = 5 µm. Error bars show standard 
deviation, asterisks represent significance (* for p-value < 0.05; *** for p-value < 
0.001). 
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Figure 3.23. Live staining of MCF with anti-MISP. Representative images of 
immunostaining on live SG parasites using anti-MISP. Epimastigote and metacyclic 
form stained with anti-MISP (red) and DAPI (blue). Nuclei (N) and kinetoplasts (K) 
noted in the blue channel. Scale bars = 5 µm. 
 
 
Interestingly, when an eGFP and HA-epitope tagged MISP360 was ectopically 
expressed in an induced (Dox+) PCF cell line (Figure 3.24), the protein was 
exclusively seen in the flagellum as suggested by its co-localisation with the flagellar 
marker (paraflagellar rod, PFR) (Figure 3.24-C). However, when the same MISP360 
overexpressor cell line progressed through the fly and infected the SGs, the ectopic 
protein re-localised evenly on the MCF surface (Figure 3.24-C), resembling that of 
wildtype MCF. All non-induced (Dox-) PCF were negative for both anti-HA and anti-
MISP antibodies (not shown). I then compared MISP protein expression and 
localisation in relation to BARP.  
Using the same method, BARP was detected on the surface of non-
permeabilised EMF, P-MCF and MCF cells (Figure 3.22-C). Relative mean 
fluorescence intensities in EMF were significantly higher compared to P-MCF (1.3-
fold) and MCF (3.3-fold) (Figure 3.22-D), with p-values of 0.04 and <0.001, 
respectively. BARP localises evenly throughout the cell surface in EMF and P-MCF 
cells. However, in MCFs BARP only conserved this localisation in 10.4% of cells 
(n=481) while the 89.6% of cells showed exclusive flagellar localisation (Figure 3.22-
C). The expression of BARP in MCF was corroborated using a second anti-BARP 
polyclonal anti-serum (not shown). 
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Figure 3.24. Ectopic localisation of tagged MISP360. (A) DNA construct encoding 
for the ectopic tagged MISP360. (B) Immunoblotting to detect ectopic (HA-tagged) 
MISP360 expressed by the mutant PCF cell line, either with the transgene uninduced 
(-) or induced (+), probed with anti-HA (top). PVDF membrane stained with nigrosin 
after film exposure for sample loading control. (C) Cellular localisation of the HA-
tagged ectopic MISP-360 in AnTat 1.1 90:13 procyclic (PCF) and metacyclic form 
(MCF), detected using immunostaining on fixed non-permeabilised PCF cells with 
either anti-HA plus anti-MISP (co-localisation of ectopic tag with MISP), or with anti-
HA plus anti-PFR (flagellar localisation) in methanol-fixed cells. Scale bars = 5 µm. 
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3.2.5.4 Indirect detection of mVSGs in SG parasites 
 
 To confirm identity of MCFs from infected SGs, cells were probed with anti-
CRD antibodies (Zamze et al., 1988), which recognise the cross-reacting determinant 
epitope. In the absence of specific anti-VSG antibodies expressed by MCFs, anti-
CRD antibodies have been successfully used by others to identify this parasite stage 
(Rotureau et al., 2012). The CRD epitope is formed when GPI-anchored surface 
proteins, lacking an acyl fatty acid chain on the inositol ring, are exposed to GPI-
specific PLC (GPI-PLC), which cleaves the phosphodiester bond between the inositol 
ring and the lipid moiety, forming a 1,2 cyclic phosphate ring on the inositol residue 
(i.e. CRD epitope) (Zamze et al., 1988). This enzyme cleaves the GPI detaching the 
protein from the membrane. For example, the di-myristoyl-PI anchor of the T. brucei 
“membrane-bound” mVSG is completely susceptible to the parasite GPI-PLC forming 
“soluble” sVSGs (Cardoso de Almeida and Turner, 1983; Zamze et al., 1988). 
Monomeric proteins with a single GPI anchor become soluble after cleavage, while 
dimeric proteins, such as VSG, may be only cleaved at one lipid anchor (thus 
exposing the CRD epitope in only one GPI glycan) and remain attached to the 
membrane by the second one. Because of the presence of VSGs on the surface but 
also due to the developmental expression of the GPI-PLC (Christiano et al., 2017), 
the BSF and MCF stages are the only forms of T. brucei reactive to anti-CRD. As 
shown in Figure 3.25, neither attached EMF nor P-MCF react to the antibody, and 
only MCF display positive signal on the surface as expected. This confirms the SG 
stages identified for the expression and localisation of MISP and BARP based on 
morphology, size and relative position of the kDNA. Technical reasons prevented 
unfortunately the co-localisation of CRD epitopes and MISP or BARP because all 
three antibodies were made in the same animal host.   
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Figure 3.25. Indirect detection of mVSG in T. brucei SG stages. Immunostaining 
of EMF (AE), pre-metacyclic (P-MCF) and metacyclic (MCF) stages from tsetse 
infected SG with anti-CRD antibodies. Differential interference contrast (DIC), DAPI 
(magenta) and anti-CRD (blue). Scale bars = 5 µm.   
 
 
3.2.6 Structural studies on MISP and BARP 
 
3.2.6.1 The crystal structure of MISP N-terminus 
 
The conserved N-terminal domain of MISP360 (Tb427.07.360, Gly24–Ala234) 
was recombinantly produced in E. coli (rN-MISP360) and purified to homogeneity 
using nickel affinity and size exclusion chromatography (SEC) (Figure 3.26-A). 
Comparison of the SEC elution profile against a series of globular protein standards 
showed that rN-MISP360 eluted as a monomer of approximately 22 kDa (Figure 3.26-
B). Crystals of purified rN-MISP360 were obtained using the hanging drop method 
and the structure of rN-MISP360 was determined by molecular replacement using a 
truncated form from T. congolense GARP (PDB: 2y44) as the search model. The 
identification of TcGARP as a suitable model was based on secondary structure 
predictions as the aminoacidic sequence identity of the N-terminal ectodomain is only 
15% (see section 3.2.2.4). The overall structure of rN-MISP360 was refined to a 
resolution of 1.82 Å (structure obtained by Prof. Martin Boulanger, University of 
Victoria). The core of the N-terminal ectodomain adopts an elongated structure 
  
122 
measuring approximately 83 Å in height and spanning approximately 25 Å in width 
(Figure 3.26-C). The ectodomain is well ordered with low B-factors throughout the 
protein (Figure 3.26-D). Similar to TcGARP, rN-MISP-360 adopts an overall triple 
helical bundle structure composed of a core of extended twisted helices capped by a 
smaller helical bundle at the N-terminal.  
 
 
Figure 3.26. The crystal structure of the MISP360 N-terminus. (A) Construct 
encoding the MISP360 N-terminus that was recombinantly expressed in E. coli and 
crystallized (N24-E235). (B)  Superdex 75 column size exclusion chromatogram of 
recombinant MISP360 and SDS-PAGE analysis of the column fraction (inset) with the 
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protein migrating at ~22 kDa. (C) MISP360 N-terminus crystal structure with surface 
representation. The structure was found to be 83.3 Å tall, 25.5 Å in width with a 30° 
helix bend at the top. (D) Secondary structure depiction highlighting the organization 
of the helices. The bend-forming residues are in parentheses: helix I (G44), helix II 
(A127) and helix VI (L194). Coiled structures are represented in white (left); B-factor 
putty model with ordered regions displayed in blue and thin tubes and flexible regions 
in red and thicker tubes (right). 
 
 
The helical bundle that dominates the structure consists principally of three 
helices (Figure 3.26-D), which adopt a bend of approximately 30° and, collectively, 
give rise to the helical bundle cap. In addition to the ends of the 3 major helices, this 
bundle includes 3 shorter helices. Moreover, the head structure of rN-MISP-360 is 
anchored by two disulphide bonds: one between Cys36 and Cys157, and the other 
between Cys177 and Cys185. 
 
 
3.2.6.2 BARP adopts a triple helical bundle structure  
 
 Attempts were also made to determine the crystal structure of BARP. A 
recombinant protein of BARP (Tb927.9.15630) was produced and crystallized, but the 
resultant structure had too low resolution (3.9 Å). However, using this structure and 
the crystal structures of MISP360 and TcGARP (PDB: 2Y44), a high confidence 
model of BARP was built (Figure 3.27) using Modeller 9v18 (Webb, 2016) (Prof. 
Martin Boulanger, University of Victoria). BARP adopts an almost identical triple 
helical bundle structure that of MISP. Unlike MISP, BARP does not have a C-terminal 
domain to include in the model (Figure 3.28-B). 
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Figure 3.27. High confidence model of TbBARP (Tb927.9.15630). (A) Cartoon 
representation of the model, in three different angle views. The structure is overall 
82.7 Å tall, 25.0 in width and a 34° helix bend. (B) Cartoon representation depicting 
the helices organisation.   
 
 
3.2.6.3 Modelling the MISP C-termini 
 
The C-terminus domain of MISP360 (Lys238–Ser357) was not included in the 
crystallised rN-MISP360 as it is less conserved across isoforms and it is predicted to 
lack defined secondary structures and to adopt random coiled dispositions (see 
section 3.2.2.4). As shown in Figure 3.28-A, the N-terminal domains of MISP, BARP 
and VSG (PDB: 1VSG, (Freymann et al., 1990) are very similar in height (MISP 6.9 
Å and BARP 10.7 Å shorter than VSG). However, their respective C-terminal domains 
are variable and could result in very different spatial arrangements on the MCF 
surface. To understand how these proteins are displayed and exposed on the MCF 
surface, a sequence length comparison was done between the T. brucei MISP C-
termini, two VSG C-termini whose structure has been solved and 2 BARPs (Figure 
3.28). All BARP isoforms have no C-terminal domain except for Tb927.9.15590 that 
has a C- domain slightly shorter than VSGs. Both VSGs (VSG MiTat 1.1 and MiTat 
1.2) have equivalent C-terminal lengths, comparable to that of MISP440. While 
MISP400 and MISP420 have shorter domains compared to VSGs, MISP360 and 
MISP380 have a ~71% and ~35% longer C-termini than VSGs respectively. Using the 
I-TASSER and IntFOLD severs, the C-termini of all T. brucei MISP isoforms were 
modelled and attached to their corresponding N-termini domains (Figure 3.29). These 
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were then modelled in the MCF surface context attached to the plasma membrane 
via GPI-anchor and surrounded by mVSGs. As predicted from the sequence length 
comparison, the MISP isoforms seem to adopt variable levels of exposure depending 
on the C-terminal domain length, which is a result of the number of repeats (see 
Figure 3.8-B). Thus, MISP360 is potentially the most exposed isoform, followed by 
MISP380, MISP440 and MISP400/420 (in that order). However, these C-termini 
structural models are of low confidence and it is unlikely they adopt these dispositions 
rather than folding and contracting in unpredictable ways. Thus, based on length, 
MISP400/420 are likely to be masked by the mVSGs, whereas MISP440 would be 
partly protected. In contrast, both MISP380 and MISP360 are likely to be exposed 
over the VSG coat. As shown in Figure 3.23, at least one MISP isoform is indeed 
exposed and available for antibody binding, supporting this model. However, it may 
be possible that when co-expressed with BARP in EMFs, MISP are exposed to the 
exterior regardless of the isoform expressed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.28. Comparison between MISP and VSG C-termini. (A) Structural 
comparison of MISP and VSG N-termini with their respective height. (B) Schematic 
length comparison between the five T. brucei MISP isoforms and two VSGs 
structurally characterised.  
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Figure 3.29. Proposed surface display of all MISP isoforms when expressed by 
T. brucei MCFs. The model of this metacyclic plasma membrane contains m-VSGs 
and displays the MISP isoforms modelled from the MISP360 N-terminus crystal 
structure using I-TASSER.  
 
 
3.2.6.4 Structural homologs of MISP and BARP 
 
The lack of significant sequence identity between MISP-360 and any protein 
with  known function led us to perform a DALI (Holm and Rosenstrom, 2010) search 
to identify structural homologs. TcGARP was identified as the top hit with a Z-score 
of 21.4. The DALI also revealed structural homology to the previously characterised 
haptoglobin-haemoglobin receptor (HpHbR) from T. brucei (PDB: 4x0j) (Lane-Serff et 
al., 2014)and T. congolense (PDB: 4e40) (Higgins et al., 2013; Lane-Serff et al., 2016; 
Stodkilde et al., 2014), and to a T. brucei variant surface glycoprotein monomer (VSG) 
(PDB: 1VSG) (Freymann et al., 1990) with Z-scores of 18.1, 17.7 and 6.5, 
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respectively. All these proteins exhibit a complementary core of twisted three helical 
bundles (Figure 3.30). Structural comparison, however, indicates a closer 
architectural similarity with HpHbR compared to VSG. This is due, in part, to the 
breakdown of third helix into loops and extensions enabling substantial 
conformational diversity (Freymann et al.). Moreover, rN-MISP-360 is monomeric in 
contrast to dimeric VSGs (Freymann et al.). Despite the general structural similarity 
with TcGARP, Tb/TcHpHbR and the VSG monomer, the overall low sequence identity 
and the lack of key conserved residues across them indicates a likely different 
biological role for MISP, as happens with GARP (unknown), Tb/TcHpHb (haeme 
binding) and VSG (antigenic variation).   
 
  
Figure 3.30. MISP structural homologs. (A) Structural comparison of the top-scored 
structural homologs of MISP in DALI search, coloured from blue (N-termini) to red (C-
termini). (B) Structural superimposition of MISP, BARP (high confidence model), and 
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GARP. (C) Residue conservation between MISP, BARP and GARP on the crystal 
structure of MISP. Colour code from blue (most variable) to purple (most conserved).  
 
 
3.2.6.5 MISP and BARP display a surface molecular pocket  
 
 A close analysis to rN-MISP360 and BARP structures revealed a similar 
distribution of acidic and basic patches along the entire length of the structure and no 
clear localised charge densities that would indicate a molecular recognition site. 
However, both structures present a surface pocket at the membrane distal end near 
the region where the core helices bend in both the proteins (Figure 3.31). In 
rMISP360, the pocket is formed by the N-terminal portion of helix I, the loop 
connecting helix II to III, helix V and N-terminal region of helix VI. The secondary 
structures contributing to pocket formation in TcGARP were similar with the N-
terminal portion of helix I, C-terminal region of helix II, the loop connecting helix III to 
IV, and N-terminal region of helix V forming the pocket. Intriguingly, the overall 
dimensions of the pockets are quite different. For instance, the measure of the 
rMISP360 pocket is approximately 12.2 Å in depth and 5.9 Å in diameter (Figure 
3.31), and is lined by ten hydrophobic residues (Ala35, Leu37, Phe38, Leu42, Ile133, 
Leu169 Ala172, Gly176, Ile184, and Leu188). In contrast, the pocket of BARP is significantly 
smaller measuring approximately 5.7 Å in depth and 6.4 Å in diameter and formed by 
predominantly polar residues (Thr46, Asp49, Val50, Gln53, Thr137, Glu168, Thr170, Ser171, 
Ala177, Leu181 and Asp190). Analysis of the solvent networks in these pockets revealed 
that the waters occupied the periphery of the pocket in both TcGARP and rMISP360 
with 5 and 3 water molecules, respectively. Importantly, both structures of BARP and 
rMISP360 lack a short peptide at the N-terminus (QAGDGEDCGGQSVPPK and 
DSIIEEGS respectively), which are not predicted to fold on the protein but may 
potentially alter the pocket structures and accessibility to ligands or solvent. Mapping 
of conserved residues on rMISP360 using ConSurf (Figure 3.31) (Ashkenazy et al., 
2016; Ashkenazy et al., 2010), revealed that most of the conserved domains are 
found forming the core helices and the pocket core. However, a striking 51% of the 
non-conserved residues (which represent a 22.3% of the total sequence) localized 
right around the pocket, suggesting these residues may mediate affinity or recognition 
of the pocket’s putative ligand. 
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Figure 3.31. MISP surface pocket and residue conservation. (A) Top view (left) 
and side view (right) of the surface molecular pockets of TbMISP360 (crystal 
structure), TbBARP (high confidence model) and TcGARP (PDB: 2y44). Residues 
coloured from red (negatively charged) to white (neutral) and blue (positively 
charged). Side views show the depth, width and forming residues of the pockets. (B) 
Residue conservation between pocket forming residues of TbMISP, TbBARP and 
TcGARP on the MISP pocket structure. (C) Residue conservation between the five 
MISP isoforms on the MISP360 crystal structure.  
 
 
3.2.6.6 Surface exposure of MISP suggests that MCFs express a more 
permissive VSG coat  
 
 From the crystal structure of rMISP360 and the C-termini sequences, 
structural models for all MISP isoforms were built using I-TASSER and IntFOLD 
(Figure 3.32). Considering MISP as an outer surface glycoprotein attached to the 
membrane via a GPI anchor, MISP are likely to point their C-termini towards the cell 
membrane and to project the N-termini towards the exterior. Similar to TcHpHb or a 
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VSG monomer, it was predicted that the MISP monomeric triple helical bundle is 
vertically oriented and, within the metacyclic surface context, in close contact with 
neighbour mVSG homodimers. However, since MISP have longer C-terminal 
sequences than any known C-terminus VSG type, and despite their lack of secondary 
structure, we predict that MISP N-termini are likely to reach higher levels of exposure 
than the mVSG coat (Figure 3.32). This is partly supported by the results obtained in 
MCF immunostaining, where the anti-MISP polyclonal antibody was able to 
specifically bind to MISP on live metacyclic cells (Figure 3.25). Together with the 
results of immunostaining experiments with anti-BARP, these data suggest that the 
surface of MCF is not only composed by a dense coat of mVSG homodimers, but 
instead allows the co-expression of invariant GPI-anchored glycoproteins, like BARP 
and MISP, the latter more abundant and completely accessible to antibodies (Figure 
3.32).  
 
 
Figure 3.32. Structural model of the metacyclic surface coat.  Model of the T. 
brucei metacyclic surface glycocalyx displaying the GPI-anchored VSG homodimers 
(light and deep blue), MISP (red) and remains of BARP. The mVSG structure is 
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represented with a low confidence model of mVAT4 based on the crystal structure of 
VSG 221 N- (PDB: 1VSG) and C-terminus (PDB: 1XU6); MISP is represented with 
the crystal structure of MISP360 N-terminus (PDB: 5VTL) and a model of its C-
terminus; BARP represented with a high confidence model.  
 
 
3.2.6.7 Re-defining the T. brucei life stage-specific glycocalyx 
 
 During its life cycle, T. brucei constantly keeps differentiating into multiple life 
stages to overcome external challenges (Matthews, 2005). During many of these 
changes, the parasite replaces its surface coat primarily composed by GPI-anchored 
glycoproteins (Ferguson, 1997). The discovery of BARP (previously known as the 
major surface glycoprotein on SG EMFs, (Urwyler et al., 2007) and MISP on the MCF 
surface will re-define our understanding of the changes in composition of the T. brucei 
surface glycocalyces during differentiation (Figure 3.32).  
 
 
Figure 3.33. The Trypanosoma brucei sequential expression of major surface 
GPI-anchored glycoproteins during its life cycle. Bloodstream forms (BSF), 
procyclic forms (PF), mesocyclic forms (MSC), short (SE) and long (LE) epimastigotes 
infecting the proventriculus (EMF PV), attached epimastigotes infecting the salivary 
glands (EMF SG), pre-metacyclic forms (P-MCF), metacyclic forms (MCF). 
Representative immunostaining images of the parasite stages highlighting the nuclei 
and kinetoplasts (magenta), and the cell surface coloured according to the major 
surface glycoprotein expressed (top). Bottom bars define the duration of the 
expression of the surface proteins in relation to parasite developmental stage.  
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3.2.7 Functional studies on MISP 
 
3.2.7.1 Determining the essentiality of MISP during a tsetse infection 
 
To gain more insight into the function of MISP, I created a PCF mutant cell 
line (mispRNAi) to knockdown all misp through a tetracycline-inducible RNAi stem loop 
system (Figure 3.34-A) (MacGregor et al., 2013). As expected, based on the low 
transcript levels, silencing of misp in PCF did not show any growth or morphology 
phenotype in vitro (Figure 3.34-B).  The essentiality of MISP in the tsetse was then 
analysed with the mispRNAi mutant. Trypanosomes were isolated (30 d.p.i) from MG, 
PV and SG to determine misp knockdown levels (Figure 3.34-C). In both PCF and 
MG procyclics, which express negligible levels of misp, the transcript levels in induced 
(Dox+) cells were slightly upregulated (19%; p=0.04) and downregulated (5.9%; 
p=0.56), respectively, compared to the control. In contrast, when misp expression is 
switched on, we observed a transcript reduction of 58.2% in PV (p-value=0.05) and 
31.5% in SG trypanosomes (pooled samples from three replicates). Representative 
samples of MG, PV and SG were also processed for immunostaining to indirectly 
quantify the reduction in MISP expression using the polyclonal anti-MISP antibody. 
As in the wildtype, either induced and non-induced MG and PV forms were negative 
for staining. However, as shown above, SG EMF and MCF reacted with the antibody 
(Figure 3.34-D) and Dox+ MCFs showed a significant 63.1% reduction in mean 
fluorescence intensity (p-value <0.001) (Figure 3.34-E). No defects in cell shape or 
motility were observed. Importantly, despite the reduction of misp in Dox+ cells, no 
significant alterations in the infection rates of MG, PV and SGs were observed 
compared to the non-induced (Dox-) control group (Figure 3.34-F).  
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Figure 3.34. T. b. brucei misp do not appear to be essential during parasite 
development in the tsetse. (A) DNA construct engineered for the tetracycline-
inducible expression of a shRNA targeting all misp transcripts. (B) In vitro growth 
curve of mispRNAi PCF cells, either induced (Dox+) or uninduced (Dox-). (C) Relative 
misp RNA expression in mispRNAi PCF cells, midgut procyclics, proventricular 
parasites and salivary gland forms (SG). Expression levels of Dox- cells are 
normalized to 100%. (D) Representative immunostaining images of non-
permeabilized mispRNAi MCF (Dox-/+) with anti-MISP (red), DAPI (blue) and phase. 
(E) MISP mean fluorescence intensities (arbitrary units) on mispRNAi MCF (Dox -/+). 
(F) Percentage of flies with mispRNAi cells infecting the midgut, proventriculus and 
salivary glands (SG). Error bars show standard deviation, asterisks represent 
significance (* for p-value < 0.05; *** for p-value < 0.001). Scale bars = 5 µm. 
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3.2.7.2 Determining putative binding partners of MISP 
 
 Having found that MISP seem not to be essential for T. brucei development in 
the tsetse and considering that MISP function cannot be inferred from homology 
searches, I next tried to identify potential MISP binding ligands. A recombinant 
MISP400 was produced in E. coli lacking the signal peptide and fused at C-terminus 
to a biotinylation target sequence. The recombinant biotinylated protein was used in 
Biacore resonance and pulldown assays by incubating the protein with either 
mammalian serum or tsetse saliva, the two environments where MCF cells can be in. 
In both assays, a recombinant T. brucei HpHbR, known to have a similar structure to 
MISP and to bind to haemoglobin (Lane-Serff et al., 2014), was used as negative 
control. Biacore results showed that MISP400 seems not to bind to any component 
from neither tsetse saliva (uninfected and infected) or human or bovine serum, while 
the HpHbR control only showed strong binding to both human and animal sera (not 
shown). In pulldown experiments, after samples were run in silver-stained SDS-PAGE 
gels, ~7 unique protein bands were revealed resulting from the interaction of MISP 
with proteins from both infected and naïve saliva (Figure 3.35). Although further 
identification by mass spectrometry needs to be carried out, these results suggest 
that MISP400 may interact with tsetse salivary proteins.    
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Figure 3.35. Pulldowns assays on MISP400. Silver-stained SDS-PAGE gels with 
pulled-down samples from two replicates (A, B). Biotinylated recombinant HpHbR (R) 
and MIS400 (MISP) incubated with PBS, uninfected tsetse saliva (uninf.), infected 
saliva (inf.) and whole infected tsetse salivary glands (SG). Direct samples, flow-
through (FT) and elution. Dots are placed at the right of the band to point out: rHbHpR 
(blue), rMISP400 (red), unique pulled-down bands (black).   
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3.3 Discussion 
 
3.3.1 T. brucei-infected tsetse saliva is enriched with trypanosome GPI-
anchored surface glycoproteins. 
 
 Transmission of vector-borne pathogens usually requires insect saliva as a 
“vehicle”, but it is also accompanied by a series of soluble components from both the 
parasite and the insect. For instance, Leishmania spp. secrete within sand flies 
abundant promastigote secretory gel and exosomes, which are important virulence 
factors for the transmission and establishment of the parasite infection in the 
vertebrate host (Atayde et al., 2015; Giraud et al., 2018; Rogers, 2012). Here, a semi-
quantitative proteomics approach was used to analyse the composition of T. brucei-
infected tsetse saliva with the aim of identifying potential soluble factors involved in 
parasite transmission. Besides hits from Glossina and T. brucei, proteins from the 
bacterial symbiont, S. glossinidius (Cheng and Aksoy, 1999), were also detected. 
Compared to naïve flies, Sodalis proteins seem to be more abundant in saliva during 
a trypanosome infection, as shown by western blotting (Figure 3.6). This could be 
explained in part by a higher cell permeabilisation led by the trypanosome infection, 
as Sodalis is normally found within epithelial cells (Cheng and Aksoy, 1999; Wang et 
al., 2013).  
 
The proteomics analysis identified 27 different T. brucei proteins in infected 
saliva, of which 62.9% are likely cytosolic and cytoskeletal. The reasons behind the 
presence of trypanosome proteins in saliva are unknown; they could simply originate 
from dying parasites or their release could be controlled by specific mechanisms. 
Interestingly, 7 of these proteins (41.2% of intracellular hits) have been described as 
part of the T. brucei exosome (Szempruch et al., 2016), but I did not investigate 
whether trypanosomes release exosomes during development in the tsetse SG. 
Notably, T. brucei-infected saliva is particularly enriched in trypanosome GPI-
anchored surface proteins (37.1%); i.e. BARPs (Tb927.9.15520, Tb927.9.15530, and 
Tb927.9.15570, similar to a previous report (Kariithi et al., 2016), several VSGs 
(discussed below) and MISP, which this thesis describes as the first family of invariant 
surface proteins in T. brucei MCFs. 
  
 In summary, the T. brucei-infected infected tsetse saliva is not only composed 
of infective MCFs (and EMFs in a low proportion), but it is rather a cocktail of G. 
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morsitans salivary, S. glossinidius and T. brucei proteins. How this complex 
composition modulates parasite transmission has yet to be investigated.  
 
 
3.3.2 Do metacyclic VSGs recombine? 
 
 The proteomics analysis identified peptides from several VSG species, which 
are considered as expressed only in the blood stages. Although the parasite re-
expresses VSGs only in the metacyclic stage (Tetley et al., 1987), their role during 
development within the tsetse or during transmission remains unclear. The 
identification of mVSG peptides in infected saliva is not surprising given that infected 
SGs contain thousands of quiescent metacyclic cells, which may release VSGs into 
the SG lumen or die before they get transmitted. The release of mVSG may occur 
partly by the action of the parasite GPI-PLC (Grandgenett et al., 2007; Gruszynski et 
al., 2003), which was found to be expressed in MCF in previous studies (Christiano 
et al., 2017; Rotureau et al., 2012). Interestingly, among the VSG species detected, 
only one corresponds to a canonical mVSG (mVAT4), which has not been previously 
found as protein, but its expression site has been well characterized by others 
(Pedram and Donelson, 1999). Only a similar study detected mVAT5 in tsetse saliva 
infected with a different T. brucei strain (Kariithi et al., 2016). Although a few studies 
reported BSF expressing mVSGs from BES at low levels (Alarcon et al., 1994), no 
study has described the expression of BSF VSG proteins in MCFs. This supports the 
assumption that, though recombination may occur from MES to BES, it does not 
appear to occur in the opposite direction since MES lack the 70-bp repeats upstream 
the mVSG gene (Alarcon et al., 1994; Pedram and Donelson, 1999). Surprisingly, 
however, we identified at least 4 VSG species that have been reported as expressed 
in BSFs, including MiTat 1.2 VSG 221 (identified by 3 unique peptides) (Cross et al., 
2014). This suggests that either 1) MCFs could activate BES in low levels (unlikely 
since MCFs do not appear to express ESAGs strongly associated with BSFs (i.e. 
ESAG6/7) (Christiano et al., 2017)), or 2) there is recombination at the MES to replace 
the mvsg with BSF vsg, or 3) there is recombination between mvsg and BSF vsg 
genes leading to the formation of mosaics. In addition, we cannot rule out that the 
undetermined VSG repertoire of the TSW196 strain (Paindavoine et al., 1986) (used 
in this study) could be different to that in other strains (e.g. Lister 427;(Cross et al., 
2014)) and lead to a misinterpretation of these results. Importantly, previous studies 
have found similar results although they have been overlooked (Christiano et al., 
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2017; Kariithi et al., 2016; Savage et al., 2016; Telleria et al., 2014) (summarised in 
Table 3.3). For example, at least 2 BSF VSGs were identified in a T. b. brucei EATRO 
1125-infected saliva proteomics (Kariithi et al., 2016); one BSF vsg was found to be 
highly transcribed in a T. b. brucei RUMP503 SG infection (Telleria et al., 2014); and 
15 BSF vsgs had similar transcription levels than mvsgs (and a few were translated 
into protein) in T. b. brucei Lister 427 MCF overexpressing rbp6 (Christiano et al., 
2017). 
 
 
3.3.3 The Metacyclic Invariant Surface Proteins (MISP) 
 
 We characterised the MISP family studying, among others, gene and protein 
expression during the parasite life cycle, cellular localisation, essentiality for parasite 
development in the tsetse and determined the crystal structure of the MISP360 
homolog. The majority of these studies were conducted alongside with BARP as a 
known family of surface proteins expressed by EMFs in SGs (Urwyler et al., 2007). 
MISPs were previously included in the trypanosome surface phylome (Jackson et al., 
2013), within the clade ‘iv’ of the Fam50 family, which also includes BARP, the T. 
congolense GARP (Bayne et al., 1993; Beecroft et al., 1993) and CESP (Sakurai et 
al., 2008). With the exception of T. vivax, most of the disease-relevant species of 
African trypanosomes such as T. brucei (including T. b. gambiense and T. b. 
rhodesiense), T. congolense and T. evansi encode misp genes. The conservation of 
MISPs across the family suggests an important role in the parasite’s life cycle within 
the tsetse or during transmission and may reflect a conserved function.  
 
Importantly, phylogenetic analyses have shown that MISP have evolved in two 
subfamilies (MISP-A and MISP-B) which, despite sharing high sequence 
conservation, diverge in many of the predicted characteristics. First, we have shown 
that they diverge in a few domains which mostly localise around the molecular pocket 
on the apical face of the protein, suggested to be involved in molecular recognition. 
This would imply minor differences in function between subfamilies. Second, MISP-B 
members vary in N-glycosylation sites having either 2 or none, compared to the 
conserved 1 site in MISP-A. In addition, although both subfamilies have a strong 
prediction for signal peptide, MISP-B seems to have a very distinct sequence that 
may be potentially cleaved at a different site compared to that of MISP-A. Lastly, a 
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distinct characteristic between subfamilies is the presence of C-terminal repeats of 26 
residues found in MISP-A and absent in MISP-B, which have been shown here to be 
important for the display and exposure of MISP above the mVSG coat. Despite minor 
differences between subfamilies, however, there are also many conserved features 
predicted such as GPI-anchor peptides, protease cleavage sites, and overall 3D 
structures of the N-termini.  
 
 
3.3.4 Production of MISP recombinant proteins for the study of MISP 
 
To study MISP, it was fundamental to raise an antibody specific against the 
proteins, so it could be used in immunodetection. The approach of choice was 
immunisation of a rabbit with a complete MISP recombinant protein. It was 
hypothesised that, due to the high sequence conservation between isoforms, the 
polyclonal antibody would cross-react with them all. For technical reasons, the isoform 
of choice was MISP380 as its expression levels turned out to be higher than the other 
MISP isoforms. This was recombinantly produced in E. coli, purified and used for 
immunisation. Immune anti-serum was further processed to isolate IgGs with specific 
binding with MISP and depleted from E. coli interactions. The polyclonal anti-
MISP380, broadly used in this thesis, proved to be specific for MISP and to cross-
react with, at least, the isoforms MISP360 and MISP400. The antibody did not react 
with E. coli proteins or T. brucei PCF lysates as expected.  
 
The use of recombinant proteins was not only useful for the production of a 
polyclonal antibody, but also for structural studies. The crystal structure of MISP360 
N-terminus was solved from crystals of a recombinant protein produced in E. coli. In 
addition, the production of trimmed versions of MISP360 (N-terminus, C-terminus and 
complete protein) will allow future NMR studies to determine the structure of MISP C-
terminus and the motion dynamics between the N- and C- terminal domains, even 
within the context of a plasma membrane (by using nanodiscs, (Munoz-Garcia et al., 
2018)).  
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3.3.5. Expression studies on MISP and BARP 
 
We have confirmed that misp and barp gene expression is upregulated in T. 
b. brucei SG stages as previously described (Savage et al., 2012; Savage et al., 2016; 
Telleria et al., 2014). However, semi-quantitative RT-PCR analysis has allowed, for 
the first time, a detailed study of the individual expression of misp homologs by 
exploiting the different number of repetitive motives at the C-termini. It was found that 
the upregulation of misp is not homogeneous across homologs but biased towards a 
preferential expression for misp-B paralogs (the shortest misp400 and misp420), at 
least at the transcript level. With the exception of misp440 that seems to have a low 
but stable expression, misp-A genes are only transcribed during the late stages of 
development in the SGs. It is unknown how the expression of these genes is regulated 
despite being part of a gene array that is likely polycistronically-transcribed and with 
>99.7% conservation in both UTRs and intergenic sequences. Differences in homolog 
transcript levels, however, may not reflect changes in protein isoform abundances, 
which remain unknown as the anti-MISP polyclonal antibody is expected to cross-
react with all isoforms due to high sequence conservation among them. In fact, this 
polyclonal antibody can detect, at least, MISP360 and MISP380 by western blotting, 
and MISP360 and MISP400 (not shown) by cell immunostaining. Interestingly, 
although PV-dwelling trypanosomes produce large amounts of misp and barp 
transcripts (this work and Urwyler et al., 2007), the proteins are only translated in SG 
forms and localise evenly over the cell surface, as shown by immunostaining of 
individual SG forms. Instead, immunostaining shows that all PV trypanosomes 
express EP-procyclins, even in EMFs, which is a surprising finding (Figure 3.33) 
(Sharma et al., 2008). While BARP protein expression peaks in EMFs and is lost 
during metacyclogenesis, MISP proteins start being expressed in EMFs but reach 
their highest expression in MCF, which suggests MISP is a major surface protein 
expressed by MCF. However, the copy numbers of MISP in relation to VSG remains 
to be determined. Strikingly, anti-MISP staining also occurs in live MCF cells (free of 
potential fixation artefacts), suggesting that MISP display immunogenic epitopes 
above the mVSG protective coat. Interestingly, despite the previous observation that 
BARP is absent in MCFs (Rotureau et al., 2012; Sharma et al., 2008), we detected 
low levels of BARP in MCFs with variable localisation, a phenomenon that could be 
explained by differences in parasite strain and/or infection timing. While a minority of 
cells showed a surface localisation of BARP, most had re-distributed the protein to 
the flagellum. An alternative explanation is that most metacyclic cells express low 
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(undetectable) amounts of BARP on the parasite surface, while its high concentration 
in the flagellum makes it easier to detect by fluorescent microscopy. Nevertheless, a 
similar flagellar localisation was observed in BSF (Jackson et al., 2013) and PCF 
(Figure 3.24) expressing ectopic MISPs, although, in the latter, it regained surface 
location once the cells differentiated into MCFs within the tsetse.  
 
 
3.3.6 Insights into the protein structures of MISP and BARP  
 
In order to gain more insight in to the function of MISP, the crystal structure of 
the N-terminal domain of the MISP-360 isoform (Tb427.07.360) was solved. It 
revealed to have a triple helical bundle structure resembling that of other trypanosome 
surface proteins such as the Tb/TcHpHbR (Higgins et al., 2013; Lane-Serff et al., 
2014), TcGARP (Loveless et al., 2011) or a VSG monomer (Bartossek et al., 2017; 
Freymann et al., 1990). The mature MISP, however, contains an additional, 127 
residue C-terminal tail predicted to be highly disordered. In the absence of definitive 
structural data, I modelled the C-terminus, which indicated that it might serve as a 
long tether effectively elevating the N-terminal head group from the surface of the 
parasite membrane. This explains in part the recognition of MISP by antibodies shown 
in live immunostainings. It is tempting to speculate that this extension facilitates a 
biologically relevant interaction between the parasite and its environment such as 
promoting the acquisition of nutrients, serving as an adhesion or decoy, or modulating 
a response in the host. The previously characterised TbHpHbR has been shown to 
lie partially within the VSG layer of the BSF and allows the trypanosome to acquire 
nutrients from the blood of the mammalian host. The mechanism by which it acquires 
nutrients is facilitated by a C-terminal extension that increases its height making the 
ligand-binding site accessible by protruding above the VSG layer (Higgins et al., 
2013). Since MCF express mVSGs (Tetley et al., 1987) along with MISP, its C-
terminal extension could support a similar role though the substantial length of the 
extension would likely render cellular uptake of a nutrient payload difficult. However, 
the unstructured extension is likely ideally suited to support an adhesion role for MISP, 
similar to the function described for bacterial adhesins like the Haemophilus Cha 
proteins (McCann et al., 2014). Interestingly, the only study showing evidence of a 
trypanosome surface protein with an adhesin function is on TcCESP, which is also 
part of the Fam50 family of trypanosome surface proteins (Sakurai et al., 2008). The 
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structural analyses of MISP360 revealed the existence of a predominantly 
hydrophobic pocket in the apical end. It is possible that the pocket may allow MISP360 
to coordinate a partner molecule, consistent with the putative role as an adhesin. 
Despite the high sequence identity, the residues forming and surrounding the pocket 
lacked sequence conservation and resulted in a distorted cavity between the homolog 
models that may reflect the capacity to coordinate a structurally diverse set of ligands. 
Furthermore, the homologs differ in the length of the C-terminal region, originated 
from the variable number of 26-residues motifs. This region could offer the parasite a 
robust mechanism to engage a variety of cell types or provide a sequential binding 
effect to enable tighter adhesion. It is noteworthy that these putative unstructured C-
terminal regions contain lysines and arginines indicating an inherent susceptibility to 
proteolysis consistent with predictions using the PROSPER software (Song et al., 
2012). This putative proteolytic susceptibility may be exploited by the parasite to 
release the molecular interactions anchoring it to the epithelial cells of the salivary 
glands of the tsetse and thereby facilitating transmission.  
 
 
3.3.7 The metacyclic surface glycocalyx 
 
 It has been assumed that the MCF surface is structurally and functionally 
equivalent to that of BSFs as they show the same thick VSG (electron-dense) layer 
in TEM sections (Kolev et al., 2012; Ooi et al., 2018). A few BSF VSG structures have 
been determined by X-ray crystallography (Bartossek et al., 2017; Blum et al., 1993; 
Freymann et al., 1990), but no mVSG structures have been reported so far. Based on 
protein sequence, however, it is likely that mVSGs should fold in a similar way and 
form the same homodimer structures. This implies mVSGs also form a dense 
macromolecular barrier that protects the parasite and masks most invariant surface 
proteins from the host’s immune system. Most of the characterised BSF invariant 
surface proteins are attached via transmembrane domains and localize in the flagellar 
pocket, with the exception of the GPI-anchored transferrin and haptoglobin-
haemoglobin receptors (Lane-Serff et al., 2014; Tiengwe et al., 2017). However, our 
crystallographic and in vivo labelling evidence shows that MISP appear to be 
displayed above the mVSG coat, suggesting that, unlike the blood stages, MCFs 
allow the homogeneous expression of other GPI-anchored invariant proteins on the 
surface. Thus, I hypothesise that MISP could be targeted by the host’s immune 
system, although it remains to be investigated if the brief exposure of MISP in skin 
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(Caljon et al., 2016), right after transmission by an infected fly, is able to trigger a 
protective and sustained immune response.  
 
 
3.3.8 Function of MISP 
 
 MCF are known to be cells with arrested cell cycle and low transcription activity 
and therefore, detecting high levels of misp and barp transcripts suggests that these 
proteins may play an important role in parasite development in the SG, or during the 
early stages of infection of the mammalian host. To gain insight into the possible 
role(s) of MISP, I partially depleted misp expression in a mutant cell line. A clonal 
mutant procyclic line with induced knockdown did not experience a misp down-
regulation and did not suffer growth defects. However, when these cells progressed 
through the life cycle in the tsetse, misp levels were significantly down-regulated in 
PV and SG parasites, as also shown by indirect immunostaining (Figure 3.34).  The 
reduction of MISP, however, did not seem to have an effect in parasite viability or 
infectivity in the tsetse, suggesting that MISPs may not be essential in development 
and perhaps play a role later in transmission or early infection of the mammalian host 
when MCF are found in the skin (Caljon et al., 2016). However, it cannot be ruled out 
that MISP knockdown was insufficient or that it has a limited role in tsetse infectivity. 
Remarkably, this is the first successful knockdown carried out in T. brucei SG forms. 
  
A conditional-null mutant for the 5 misp genes would be the ultimate tool to 
study MISP function. However, the complete knockout is technically unfeasible using 
the classic genetic approaches, since the complete removal of the misp array would 
also remove the unrelated genes in between. These could be potentially added back 
(along with misp) but achieving a proper regulation of their expression would be 
challenging too. Fortunately, the recently arisen CRIPSR/Cas9 gene editing 
technology will likely allow the complete knockout of misps without affecting the 
expression of unrelated genes in the same array. Although the technology has been 
optimised for several systems such as T. cruzi and Leishmania (Peng et al., 2014; 
Sollelis et al., 2015) in the last years, it has been more challenging to implement in T. 
brucei (Beneke et al., 2017; Rico et al., 2018; Vasquez et al., 2018). 
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I also investigated putative MISP binding partners. For technical reasons, a 
recombinant biotinylated MISP400 was used as a model. Biacore resonance studies 
showed that there seems to be no binding of MISP400 to any component from the 
two main environments metacyclic cells can be in: tsetse saliva and mammalian 
serum. However, pulldown assays suggested that MISP400 may interact with a few 
protein components from tsetse saliva (both uninfected and T. brucei-infected). These 
unique bands shown in the pulldown SDS-PAGE have been isolated and are currently 
under analysis by mass spectrometry. The identification and further validation of these 
pulled-down proteins may be key in the path towards the identification of the function 
of MISPs.  
 
Up to now, the function(s) of MISP remains unknown and can only be 
hypothesised. Due to the uniqueness of the protein sequences, no functions or 
domains can be found by sequence homology. The solved crystal structure showed 
that, despite MISP are structurally similar to other surface trypanosome proteins (e.g. 
BARP and GARP, both with unknown functions), the lack of conserved residues and 
low identity conservation suggests that these proteins may not have similar biological 
roles. From the MCF surface model generated, it can only be hypothesised that MISP 
may have a potential role in adhesion, ligand recognition or decoy for the host’s 
immune system.    
 
 
3.3.9 Uses of MISP and future work  
 
MISP and BARP have the potential to be used as molecular markers for 
metacyclogenesis. There is the need for the development of molecular tools to identify 
transmissible tsetse (i.e. carrying MCFs in SGs) in disease-endemic areas. Only a 
limited number (~0.1%) of flies trapped in the field carry infectious parasites (Auty et 
al., 2012; Jamonneau et al., 2004). Unlike current technologies based on manual and 
rather laborious dissection or PCR-based methods from pools of flies (Ngomtcho et 
al., 2017), exploiting immune-detection of MISP proteins could help to identify disease 
transmission areas requiring vector control intervention(s). Thus, immunodetection of 
MISP and BARP proteins would greatly facilitate identification of disease-
transmissible tsetse flies.   
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On the other hand, based on the results of this thesis, MISP can be proposed 
to be a candidate for the potential development of a transmission-blocking vaccine 
against HAT or AAT produced by either T. brucei brucei, T. congolense or T. evansi. 
As shown in this chapter, MISP are the first invariable proteins reported to be 
expressed on the surface of MCF, immunogenic and exposed to antibodies. 
Immunisations with MISP could potentially provide the mammalian host with 
antibodies capable of neutralising tsetse-injected MCF before they differentiate into 
BSF and start replicating. Although HAT is heading towards elimination in 5-10 years 
and a vaccine against sleeping sickness is probably no longer needed, this proof-of-
concept vaccine would open the door for these methodologies to explore metacyclic 
invariant surface proteins as vaccine candidates against animal trypanosomiasis. 
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CHAPTER 4 
Generation of T. brucei metacyclic forms 
in vitro for the study of MISP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
147 
4.1 Introduction 
 
 In Chapter 3, MISPs were presented as a novel family of invariant surface 
proteins expressed by the metacyclic trypomastigotes of T. b. brucei. Although many 
aspects of MISP have been characterised, more studies are required to understand 
the biological function(s) of these proteins. Most of these studies would require large 
amounts of MCF cells, which are difficult to obtain from infected tsetse. Thus, there is 
the need to explore alternative ways to obtain MCF cells. In 2012, a serendipitous 
discovery occurred while studying T. brucei RNA-binding proteins. It was found that 
the overexpression of the RNA-binding protein 6 (RBP6) in PCF triggered cells to 
differentiate into EMFs and MCFs, fact which does not normally occur in vitro (Kolev 
et al., 2012). RBP6 overexpressor cells experienced a progressive decrease in the 
proportion of PCF because some became EMFs as short as 2 days post-induction of 
the transgene, resembling those parasite stages found in the tsetse PV, and a peak 
of MCFs at 10 days post induction. MCFs were validated based on morphology, 
relative positions of nuclei and kDNA, mitochondria morphology, endocytosis rate and 
visualisation of the VSG coat by TEM, among others. In addition, MCF infectivity was 
proven when purified MCF were injected into mice, leading to high levels of 
parasitaemia in infected animals. Remarkably, since the Kolev et al. 2012 publication, 
no other works have been reported by other groups using this system to generate T. 
brucei EMFs and MCFs in vitro, presumably due to difficulties in reproducing the same 
protocol by different groups. 
  
 In this chapter, I first describe the reproduction and characterisation of this 
system to generate T. brucei MCF in vitro, with special focus on the expression of 
developmentally regulated major surface glycoproteins, including MISP and BARP. 
Remarkably, the generation of a BSF-like form (not reported by Kolev et al. 2012) was 
also observed, presumably originated from MCFs. I also show the purification of MCF 
by ion-exchange chromatography from large volumes of culture, which could be 
further used in downstream applications. Nothing is known about the biological role 
of RBP6 in T. brucei development in the tsetse. Several published and unpublished 
(this thesis) transcriptomics works (Christiano et al., 2017; Savage et al., 2016) have 
described that rbp6 is up-regulated in parasites residing in PV and SG compared with 
MG and blood stages, suggesting that it is important for completion of T. brucei 
developmental cycle in the fly. In this chapter I studied the role of RBP6 in vivo and 
also identified other T. brucei genes (besides rbp6) important for the establishment of 
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a SG infection and differentiation into MCF. These include several folate transporters, 
a glutamate dehydrogenase and a hypothetical protein of unknown function.    
 
 
 
4.2 Results 
 
4.2.1 Creation of novel T. brucei cell lines overexpressing RBP6 
 
 To reproduce the system for the generation of MCFs in vitro, several mutant 
T. brucei cell lines overexpressing rbp6 were created. Since it is unknown if the 
expression level of the ectopic rbp6 has an influence on the differentiation process, 
two plasmids with different promoters driving the expression of the transgene 
(tetracycline inducible) were used to ensure variable expression levels of the 
transgene: pDEX577 (Kelly et al., 2007) using a T7 promoter for medium-high 
expression, and pMS (derivate of pLEW100v5, (Serricchio et al., 2013) using a rDNA 
promoter for high expression (Figure 4.1). The ectopic rbp6 gene was either tagged 
with an HA epitope to allow immunodetection or with 3 consecutive HA epitopes 
followed by a superfolder GFP (sfGFP) to facilitate in vivo imaging as well as 
immunodetection. Both tags were fused to the RBP6 N-terminus (upstream the rbp6 
gene) as it was shown to be less involved in the overall protein structure in a model 
generated using I-TASSER (Roy et al., 2010; Yang et al., 2015; Zhang, 2008), 
compared with the C-terminus (Figure 4.1). No signal peptides were predicted in 
RBP6. In addition, I created RBP6 overexpressors in two different T. brucei PCF 
strains, Lister 427 29:13 (non-fly-transmissible; used in (Kolev et al., 2012) and AnTat 
1.1 90:13 (fly transmissible, (MacGregor et al., 2013); used for the characterisation of 
MISP in Chapter 3. After transfection and drug selection, clonal transfectant cell lines 
were screened and selected for homogeneous and high expression of ectopic RBP6. 
Cells were shown to express ectopic RBP6 upon Dox induction using a polyclonal 
anti-HA antibody, which showed it localised in the cytoplasm in small and diffuse 
microgranules (Figure 4.2). 
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Figure 4.1 Overexpression of ectopic RBP6 in T. brucei PCF. DNA constructs 
(left) used for the overexpression of RBP6 fused to an HA epitope at N-terminus (top) 
or 3xHA epitopes and superfolder GFP. Protein cartoon models (right) of the expected 
3D structure of tagged RBP6 (molecular surface in grey) bound to a putative RNA 
molecule (to predicted binding site). Domains highlighted: HA epitopes (HA, 3xHA), 
superfolder GFP (sfGFP), N- and C- termini of RBP6 (N, C).  
 
 
Alternatively, cells expressing RBP6 fused to sfGFP were selected by imaging 
the fluorescent protein, which co-localised with the HA label (Figure 4.2). This goes 
in agreement with the localisation results in TrypTag (www.tryptag.org, (Dean et al., 
2017) (high-throughput endogenous mNeonGreen fluorescent protein N-tag). Fused 
tags may sometimes make proteins mislocalise by affecting folding or transportation, 
so a correct localisation is an essential requirement to ensure functionality. 
Importantly, induced PCF cells from the 3 generated cell lines showed differentiation 
into EMF and MCFs, proving the ectopic tagged RBP6 to be functional (Figure 4.2). 
It is worth mentioning that EMF cells generated in vitro are equivalent to those found 
in infected tsetse and described in detail in Chapter 3, as they are mainly identified 
for having the kDNA in the anterior end of the parasite (Figure 3.22 and 4.2). 
However, because the differentiation rate in vitro (i.e. PCF-EMF-MCF) occurs too 
quickly, biochemical and cellular differences may exist between these in vitro forms 
and the ones found in infected flies.  
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Figure 4.2. Cellular localisation of ectopic RBP6. (A) Western blotting of RBP6 
overexpressor cells either uninduced (Dox -) or induced (Dox +). (B) Immunostaining 
of previous cells stained with DAPI (blue), probed with anti-HA antibodies (red), sfGFP 
in green and merged image. Representative images of cultured procyclics (PCF), in 
vitro-generated epimastigotes (EMF) and metacyclics (MCF) after 3 days post-
induction. Scale bars= 5 µm.  
 
 
4.2.2 Differentiation dynamics of RBP6 overexpressor cells 
 
 A time-course experiment was set to determine the timing of differentiation of 
PCF to EMF and MCF. Since induction, samples were taken each day to estimate the 
proportion of PCF-EMF-MCF and the cell cycle phase of PCF and EMF cells in culture 
(Figure 4.3-A), in relation to changes in growth rate (Figure 4.3-B-C-D). After 24 
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hours post-induction, ~23% of PCF (characterised by a “torpedo”-shaped body and a 
kDNA posterior to the nucleus and far from the posterior end) triggered differentiation 
into EMF since they started migrating the kDNA to an anterior position relative to the 
nucleus. This proportion of EMF remained more or less stable during the time course 
analyses. Also, no significant changes in the proportion of dividing PCF and EMF cells 
were detected (Figure 4.3-A). As soon as 3 dpi, the first P-MCF and MCF cells, short 
with a rounded posterior end and with the kDNA at the tip of the posterior end, 
appeared in culture in a proportion of ~37%. MCF are known to be quiescent cells 
that cannot divide but differentiate into BSF or die within a few days. This may explain 
why in the days following the peak of MCF production, the culture becomes ~90% 
PCF again as the dividing PCF overcome the terminally-differentiated MCF (as 
reported in (Kolev et al., 2012). However, it was also observed that some MCF were 
significantly longer than usual (Figure 4.4 and 4.5) and some were even in the 
process of division; i.e. having 2 nuclei and kDNA. Thus, I considered these as MCF 
that potentially differentiated into BSF (BSF-like) as a result of the RBP6 
overexpression or as an adaptation to the culture conditions. Although difficult to 
prove, these BSF-like could have differentiated into PCF and thus account for the re-
emergence of PCF towards the end of experiment (Figure 4.3-A). In parallel, cell 
growth was recorded at each day post RBP6 induction. Compared to uninduced 
control cells, induced cells experienced a severe decrease in growth rates since 
induction started (Figure 4.3-B-C). Cell differentiation seems to be the most likely 
cause, as cells do not divide while undergoing this process. Despite the overall 
reduction, big changes in the growth rate can be matched with the differentiation event 
peaks (Figure 4.3-D). The slowest cell growth rates were found at day 0-1 and day 
3-4 post-induction, corresponding with the main differentiation to EMFs (1 dpi) and 
MCF (3 dpi) events.   
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Figure 4.3 Overexpression of RBP6 triggers the differentiation of T. brucei cells 
in vitro. (A) Distribution of parasite stages during a time course (10 days) 
differentiation process of RBP6 overexpressor PCF cells (3xHA-sfGFP-RBP6 in strain 
Lister 427 29:13). ~99% control cells remained in the procyclic stage. Key: PCF 
(procyclic), EMF (epimastigote), MCF (metacyclic), BSF-like (bloodstream form like); 
KN refers to the number of kDNA and nuclei. The ‘pre-’ (P-) forms are intermediate 
stages characterised by the partial rotation of the kDNA and similar cell size than the 
preceding stage. (B) Growth curve of induced (Dox +) RBP6 overexpressor cells 
compared to uninduced (Dox -). Cultures split by 1/10 dilution at day 2, 4, 6, 8 and 10 
post-induction. (C) Cumulative cell growth and (D) culture growth rate (fold change).  
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Figure 4.4. T. brucei life stages generated in vitro during RBP6 overexpression.  
(A) Representative images of procyclic cultured forms (PCF), pre-epimastigotes (P-
EMF), epimastigotes (EMF), pre-metacyclics (P-MCF), metacyclics (MCF) and 
bloodstream form-like (BSF-like) stages. (B) Box plot of the measurements of total 
cell length of the previous stages. The boxes limit quartiles, the inner lines represent 
the medians and the whiskers represent variability. Scale bars = 5 µm.      
 
 
4.2.3 Ion-exchange purification of in vitro MCF and BSF-like cells 
 
 The in vitro-generated MCF and BSF-like can be purified from the rest of 
parasite forms (i.e. PCFs and EMFs) by ion-exchange chromatography using a 
cellulose DE52 column based on the diethylaminoethyl (DEAE) tertiary amine 
functional group (Fox et al., 1986). Although not well understood, separation appears 
to occur thanks to the different surface net charges of the cells, mainly provided by 
the surface glycoprotein coats. MCF and BSF-like (mainly coated by VSGs) passed 
through, while PCF and EMF got trapped in the column. Induced RBP6 cultures at 3 
dpi (found to have the highest percentage of MCF and BSF-like, Figure 4.3-A) could 
be scaled up in volume and purified using this method, yielding an average of ~100 
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MCF cells/mL. Remarkably, this purification method was applied to control uninduced 
cells, which yielded a 100% retention of cells under the same conditions. This 
supports the strong reliability of the purification method and provides one more 
evidence of parasite differentiation in induced cells.  
  
 
4.2.4 Developmental expression of major surface glycoproteins 
 
 Morphology and relative position of nuclei and kDNA are not fully reliable 
parameters to characterise cell differentiation, especially in cultured parasites forced 
to differentiate in vitro, as morphologies within a life stage may greatly vary. Thus, 
there is the need to use molecular markers to track differentiation events more 
precisely and with higher confidence. It is well understood that T. brucei expresses 
stage-specific major surface glycoproteins to adapt to the different environments it 
encounters during its life cycle. Briefly, as discussed in Chapter 3, BSF express VSGs 
for antigenic variation (Horn, 2014) which are then replaced by procyclins (GPEET 
and EP) when it differentiates to PF in the tsetse MG (Roditi et al., 1987). EP-procyclin 
expression is maintained in PV mesocyclics and EMFs, although these may start 
expressing BARP to prepare for migration to the SGs (Sharma et al., 2008). Attached 
EMFs in the SG are known to be free of EP but to express a BARP coat instead 
(Urwyler et al., 2007) and this thesis) alongside MISP (Chapter 3). P-MCFs switch on 
the expression of mVSGs which will fully coat the mature MCF cells (Rotureau et al., 
2012; Tetley et al., 1987) along with MISP and some BARP remains (Chapter 3). 
Accordingly, the detection of these molecules in the RBP6-differentiated cells could 
be a valuable tool to better understand the differentiation dynamics, assuming that 
these in vitro cells follow the same expression patterns as in the tsetse. Induced cells 
at 3 dpi were searched for the molecular markers BARP, MISP and CRD (Cardoso 
de Almeida and Turner, 1983; Zamze et al., 1988) by both immunofluorescence using 
fixed cells and western blotting in cell lysates.  
 
The blottings were only found positive for anti-MISP in induced cells compared 
to uninduced (Figure 4.5-A). However, the apparent molecular mass of the 
components recognised by the antibodies is ~100 kDa, which is higher than the 
expected molecular mass of MISP (<40 kDa) on SDS-PAGE. This is not surprising, 
since all the recombinant versions of a complete MISP have always shown several 
bands in western blottings, being the 100 kDa band one of the major ones besides 
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the 40 kDa and suggesting a possible physical association (Figure 3.17). As 
explained in section 3.2.3.2, it is possible that MISP form aggregates through the C-
termini which are not totally denatured when heated in sample buffer. Both anti-BARP 
and anti-CRD failed to detect the proteins in cell lysates despite the recombinant 
proteins positive controls reacted as expected. It is likely that the amount of protein is 
below the levels of detection, since the proportion of cells that could express these 
proteins is significantly small compared to the amount of undifferentiated PCFs.  
 
 The second approach consisted in immunostaining of individual fixed cells, 
which overcomes the problem of having small amounts of expressor cells. Induced 
and uninduced cultures at 3 dpi were fixed and probed with anti-MISP, anti-BARP and 
anti-CRD, the latter in combination with anti-EP procyclin. Both anti-MISP and anti-
BARP failed to reveal any positive signal in either culture. Since at least MISP was 
found by western blotting, it might be possible that these molecules or epitopes are 
not accessible to antibodies on the surface compared to “real” fly forms. The anti-
CRD, however, did clearly react with a few induced cells only. These cells were found 
to have the same size, morphology and DNA relative position considered in section 
4.2.2 for the identification of MCF and BSF-like stages. Remarkably, all positive cells 
for anti-CRD were found to be negative for anti-EP procyclin (as expected), further 
supporting the identification of these cells as MCF or BSF. Interestingly, an anti-CRD 
positive cell (3 dpi) was found to be undergoing cytokinesis (Figure 4.5-C), thus 
confirming the possible presence of BSF-like forms in induced cells.  
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Figure 4.5. Detection of developmentally regulated surface glycoproteins in 
RBP6 overexpressor cells. (A) Western blotting of cell lysate equivalent to 107 PCF 
cells either uninduced (-) or induced (+), at 3 days post-induction, were probed with 
either anti-MISP, or anti-BARP or anti-CRD. Positive controls: recombinant MISP380 
(anti-MISP), recombinant BARP (anti-BARP) and purified soluble VSG (anti-CRD). 
(B) Immunostaining of induced (3 dpi) RBP6 overexpressor cells with anti-CRD (red) 
and anti-EP procyclin (green). (C) Immunostaining of a dividing (2K2N) BSF-like cell 
from a 3dpi RBP6-induced culture, probed with anti-CRD (red) and stained with DAPI 
(green). Scale bars = 5 µm.  
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4.2.5 Developmental expression of RBP6   
 
 It has been shown that RBP6 is involved in differentiation from PCF to MCF in 
vitro upon overexpression, but its role in the biological context of the tsetse remains 
unknown. The RNA expression of rbp6 was measured throughout the life cycle of T. 
b. brucei (strain AnTat 1.1 90:13, Figure 4.6) to identify the potential developmental 
regulation and to understand at which point its expression is naturally important to 
carry out its function. The RBP6 PCF overexpressor cells were used as control for 
detection, showing a ~2 fold up-regulation in induced cells compared to the uninduced 
ones. cBSF and MG procyclics from both 15 and 30 dpi, showed low levels of rbp6 
RNA which were comparable to that in PCF. rbp6 expression seems to remain stable 
in PV stages at 15 dpi, but then it is significantly increased in PV parasites at 30 dpi 
(~3-fold). A high expression of rbp6 seems to be maintained in SG parasites (~1.25-
fold higher than PV at 30 dpi). These results suggest that, in the fly, RBP6 probably 
plays an important role in trypanosome differentiation at (and beyond) the PV, 
including metacyclogenesis inside infected SGs. This is reminiscent of the 
differentiation pattern observed in vitro during overexpression of RBP6.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6. Developmental expression of RBP6 in T. b. brucei. RNA relative 
expression of rbp6 normalised to the expression of tert during the life cycle of T. b. 
brucei strain AnTat 1.1 90:13 as cultured forms (BSF and PCF) or in the tsetse MG 
and PV at both 15 and 30 dpi and SG at 30 dpi.   
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4.2.6 In vivo phenotype of RBP6 overexpression in the tsetse 
 
T. b. brucei Lister 427 29:13 RBP6 overexpressor cells (see Section 4.2.8.1 
and 4.2.8.5), whose infectivity in the tsetse is limited and cannot progress beyond the 
PV (and thus cannot establish SG infections), were used to infect tsetse in two ways 
(Figure 4.7-A). First, flies were infected with uninduced cells and induction with Dox 
was started at 15 days post infection when the parasites have already colonised the 
PV (see section 4.2.8.1). We hypothesised that, if a defect in differentiation is what 
prevents Lister 427 from progressing beyond the PV, the overexpression of RBP6 at 
that point would induce differentiation of those PF and allow progression towards the 
SG. The second experiment consisted in pre-inducing the RBP6 overexpressors in 
vitro for 3 days (time point with more diversity of forms, Figure 4.3) and infect the 
tsetse with a mixture of PFs, EMFs and MCFs, expecting a potential early 
establishment of PV and SG infections bypassing MG colonisation. First, both 
experiments failed to generate SG infection rates due to the overexpression of RBP6 
(Figure 4.7-B). MG infection rates did not greatly vary except for a slight increase in 
the proportion of heavy MG infections in experiment 1, probably due to the initiation 
of RBP6-induced differentiation into EMFs in the tsetse MG within the first days of 
infection. In experiment 2, however, PV infections were slightly increased as a 
consequence of inducing differentiation at 15 d.p.i. when the parasites had already 
migrated to the PV.   
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Figure 4.7. In vivo tsetse experiments with RBP6 overexpressors. (A) 
Experimental design for experiments 1 and 2. (B) Infectivity (percentage) of the RBP6 
overexpressors (strain Lister 427 29:13) either induced (Dox +) or uninduced (Dox-) 
in the tsetse midgut (MG), proventriculus (PV) and salivary glands (SG) at 30 dpi. 
Midgut infection level distribution is noted as heavy (H) or medium (M).   
 
 
4.2.7 Assessing the essentiality of RBP6 for parasite development in the tsetse 
  
 As shown in this thesis and by others (Kolev et al., 2012), RBP6 appears to 
be an important RBP for trypanosome differentiation during its transit between the 
fly’s PV and the SGs. To further study the essentiality of RBP6 for T. brucei 
development in the tsetse, a T. brucei mutant cell line (fly-transmissible strain AnTat 
1.1 90:13) was created to knockdown rbp6 via RNAi. A unique fragment of the rbp6 
coding sequence was cloned into the vector pALC14 (MacGregor et al., 2013) for the 
expression of a stem loop short-hairpin dsRNA to induce gene knockdown under 
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tetracycline control (Figure 4.8-A). Knockdown levels were determined in PCF by 
qRT-PCR, revealing a ~50% transcript reduction as the strongest downregulation 
found in several cell lines screened (Figure 4.8B). Induced PCF cells did not 
experience any morphology or growth defects compared to uninduced cells in vitro 
(Figure 4.8-C). Tsetse flies were then infected and dissected at 30 dpi to determine 
infection rates in MG, PV and SG (Figure 4.8-D). Compared to uninduced cells, the 
downregulation of rbp6 did not show a visible infection phenotype in the tsetse. Both 
groups of parasites were able to infect the MG (~80%) at comparable rates, and the 
PV at similar (or even slightly higher) rates than the control (~70%). Furthermore, no 
SG infections were observed in either group (very common for the PCF 29:13 clone), 
since the parental Lister 427 strain is known for showing very poor or no SG infections. 
Altogether, these results suggest that RBP6 is apparently not essential for parasite 
infection of the tsetse, although it cannot be ruled out that the weak gene knockdown 
(~50%) may not be enough to lead to a phenotypic change. 
 
 
 
 
Figure 4.8. RBP6 RNAi knockdown. (A) DNA construct used for the expression of 
a shRNA to target rbp6 for RNAi silencing. (B) RNA relative expression levels of rbp6 
in two PCF clones. (C) Growth curve of mutant PCF (clone 1) either induced RNAi 
(Dox +) or uninduced (Dox -). (D) Infectivity of RBP6 RNAi mutants (Clone 1) in the 
tsetse midgut, proventriculus and salivary glands (SG).     
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4.2.8 Identification of other T. brucei genes important to progress towards a SG 
infection and transmission 
 
4.2.8.1 Two T. b. brucei strains as a model of study 
 
 Having corroborated that RBP6 is involved in life cycle progression, I next tried 
to identify other genes whose expression is essential for T. brucei development in the 
tsetse. The gene identification was made using a comparative transcriptomics study 
between two T. b. brucei strains with very different tsetse infection phenotypes. The 
wildtype-like strain TSW-196 (Paindavoine et al., 1986) is pleomorphic and fly-
transmissible, while the monomorphic strain Lister 427 29:13, broadly used by the 
trypanosome community, is unable to progress beyond the tsetse PV and, therefore, 
it cannot generate SG infections. Thus, these phenotypic differences are likely 
consequences of changes in gene expression as a result of having been passaged in 
vitro for many years. Comparing whole gene expression between the two strains in 
PV parasites was the chosen approach to potentially identify expression of genes 
essential for SG infection. 
 
 First, the two T. brucei strains under study were fully characterised regarding 
tsetse infectivity and parasite development through the life cycle. There are many 
reasons by which the strain Lister 427 29:13 may be unable to progress beyond the 
tsetse PV. Three major possibilities were considered: 1) parasites are unable to 
differentiate into EMFs in the PV; 2) PV parasites are unable to migrate to the SG; 
and 3) parasites are unable to establish a SG infection and/or unable to undergo 
metacyclogenesis. Tsetse were infected with both strains separately and parasites 
from MG and PV were collected for analysis at 15 dpi and 30 dpi, and at 30 dpi from 
SGs (TSW-196 only) (Figure 4.9-A). Regarding their capability to infect and develop 
in the tsetse, both strains can establish ~100% MG infections at 15 dpi, which remain 
sustained until 30 dpi, as expected. Both strains efficiently infect (~80%) the PV at 15 
dpi and this is even increased with time when scoring infection at 30 dpi (~100%). 
Differentiation to long and short epimastigotes in the PV occurs for both strains 
(Figure 4.9-B). However, and as expected, while TSW-196 establishes normal SG 
infections at 30 dpi (~22%), infection of SGs by the Lister 427 are strikingly inefficient 
(<2%) (Figure 4.9-A). Importantly, the few SGs that were infected by Lister 427 
showed an extremely low number of parasites (<5 MCF cells found per SG pair), 
compared to the tens of thousands MCF cells found in SGs infected with TSW-196. 
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Lister 427 MCFs are morphologically indistinguishable to those from TSW-196 
(Figure 4.9-A inset). However, their motility appears to be compromised, which 
questions about their viability and whether they would be able to further propagate 
the infection in a mammalian host.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9. Comparison of wildtype T. b. brucei strains Lister 427 29:13 and 
TSW-196. (A) Infectivity rates of tsetse midgut, proventriculus and salivary glands 
(SG) at 15 and 30 dpi. The inset shows representative MCF cells of both strains 
stained with DAPI (magenta). Scale bars = 5 µm. (B) Proportion (percentage) of 
mesocyclics (MSC), long epimastigotes (EMFL) and short epimastigotes (EMFS) 
found in PVs either infected with Lister 427 or TSW-196 strains at 15 dpi or 30 dpi. 
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4.2.8.2 Differential gene expression analysis of T. brucei in the tsetse 
 
Tsetse flies were infected with both strains separately and whole gene 
expression was determined by RNA-seq in PV trypanosomes3. A differential 
expression (DE) analysis revealed 786 genes up-regulated and 867 down-regulated 
in PV parasites from the ‘competent’ TSW-196 strain compared with the ‘defective’ 
Lister 427 29:13 strain (Figure 4.10). Up-regulated TSW-196 genes may reflect 
defective expression of those in Lister 427, which may account for its inability to 
progress beyond the PV.  Using BLAST2GO, differentially expressed genes were 
annotated and searched for GO terms. Strikingly, a ~33% of up-regulated genes were 
related with ribonucleotide binding activity, ~30% with ATP-related processes, and 
~13% with biopterin transport (Figure 4.10). These putative functions, shared 
between most of the up-regulated genes, are related to essential cellular processes 
such as gene expression regulation, energy metabolism and folate import. Folate 
refers to several essential metabolites needed in the metabolism of nucleic acids, 
several amino acids and methylation (Fenech, 2012), and both T. brucei and tsetse 
are auxotrophic (Gibson et al., 2016; Sienkiewicz et al., 2008). Thus, both organisms 
rely on the folate produced by the tsetse bacterial symbionts (Wang et al., 2013). The 
top 5 up-regulated TSW-196 hits, summarised in Table 4.1, are: 1) hypothetical 
protein (4.9 log2 fold-change (logFC)), 2) folate transporter (4.4 logFC), 3) glutamate 
dehydrogenase (4.3 logFC), 4) folate transporter (4.2 logFC), 5) folate transporter (3.7 
logFC). Interestingly, rbp6 was found to be up-regulated in TSW-196, with a logFC of 
~2.0 in position 79 (top up-regulated). A defect in rbp6 expression may compromise 
cell differentiation of Lister 427 in some way. In addition, introducing rbp6 in the 
experimental validation was useful as a positive control for differentiation.  
 
 
                                            
 
3 Tsetse infections and dissections were done by Dr. Lee Haines and Dr. Alvaro Acosta-
Serrano (LSTM, UK). Transcriptomics performed at the Centre for Genomic Research by Dr. 
Alistair Darby (University of Liverpool, UK). Data analyses done by Ms. Janna Shamsani and 
Dr. Pegine Walrad (University of York, UK) 
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Figure 4.10. Differential expression gene analysis between Lister 427 29:13 and 
TSW-196 PV trypanosomes at 15 dpi. (A) MA-plot depicting the log2 expression fold 
change (logFC) of individual genes compared with the average counts per million 
(logCPM). Significant hits (p-value £0.05) in red and non-significant (p-value >0.05) 
in black; blue lines set the logFC=2 threshold. (B) Pie chart showing the distribution 
of the major categories of GO functional terms of genes up-regulated in TSW-196 
compared to Lister 427.  
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Table 4.1. Top up-regulated T. b. brucei genes in TSW-196 compared to Lister 
427 29:13 proventricular trypanosomes. Differential expression analysis performed 
on the RNA-seq data from T. brucei parasites from both strains infecting the tsetse 
PV at 15 dpi. Gene accession code in TriTrypDB (Gene ID), normalised expression 
from two biological replicates (1, 2) of TSW-196 (T) and Lister 427 29:13 (L), log2 fold 
change T/L (logFC), statistic p-value (p) and protein function.  
 
Gene ID T1 T2 L1 L2 logFC p Function 
Tb927.4.4670 558 474 18 12 4.95 3.23E-53 Hypothetical protein 
Tb927.8.3630 4428 3810 130 218 4.44 5.19E-79 Folate transporter 
Tb927.9.5900 730 386 36 14 4.31 1.52E-24 
Glutamate 
dehydrogenase 
Tb927.8.3650 3518 3066 130 200 4.19 2.47E-79 Folate transporter 
Tb927.8.3620 2836 2796 116 274 3.74 5.55E-39 Folate transporter 
Tb927.3.2390* 1338 1068 338 220 1.94 1.38E-14 
RNA-binding 6 
(RBP6) 
 
*Tb927.3.2930 occupies the position 79 of up-regulated genes. 
 
 
 
4.2.8.3 In silico analysis of top candidate proteins 
   
Basic in silico predictions were run on the candidate protein sequences to get 
more information about putative protein features and structure. The Tb927.4.4670 
hypothetical protein (483 residues, 54.1 kDa) was predicted to have a zinc finger 
MYND-like domain (Myeloid, Nervy, and DEAF-1) at C-terminus. This domain, 
consisting in a cluster of cysteine and histidine residues forming a zinc-binding motif, 
is not directly related with any particular function (Gross and McGinnis, 1996; Leinhart 
and Brown, 2011; Spellmon et al., 2015). Its structure was modelled using I-TASSER 
and found to be a globular protein that is structurally similar to Nup proteins forming 
the human nuclear pore complex (Figure 4.11) (Kosinski et al., 2016). No signal 
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peptide, transmembrane domain nor GPI-anchor peptide were found and its cellular 
localisation has not been yet described. The C-terminus was randomly used as the 
location for epitope tagging for subsequent microscopy analysis (see Section 4.2.8.5). 
  
The paralog genes (Tb927.8.3620, Tb927.8.3630, Tb927.8.3650) encode 
three isoforms of folate transporters (632 aa, 69.9 kDa), which share a 97.8% of 
protein sequence identity. In addition, a copy of the gene is found in the BES as the 
ESAG10, although it has been shown that it is not essential for BSF cells as most of 
the ESAG proteins (Gadelha et al., 2015). These proteins were recently shown to 
have folate transport activity (Dewar et al., 2016). Although there is no prediction for 
cellular localisation, it was shown that ESAG10 localises on the plasma membrane of 
BSF cells (Gadelha et al., 2015). Membrane localisation is also supported by the 
presence of 12 predicted transmembrane domains with both free ends facing the 
cytosolic side. No signal peptides were predicted. The structural model generated in 
I-TASSER shows a typical transporter barrel shape (Figure 4.11) in which the N-
terminus seems to be less involved in the overall folding. Thus the N-terminus was 
found to be the preferred end for protein tagging (see section 4.2.8.5). 
 
The gene Tb927.9.5900 encodes for a glutamate dehydrogenase (992 aa, 
112.1 kDa). This enzyme is broadly conserved in eukaryotes as it is responsible for 
the reversible catalysis of glutamate to form a-ketoglutarate in the mitochondrion 
(Smith et al., 2017). Hence, it might be a crucial enzyme for cells relying on amino 
acids as a source of carbon and energy (trypanosomes in the tsetse), because it links 
the amino acid catabolic pathway with the TCA cycle (Mantilla et al., 2017). In many 
species, the globular GDH (Figure 4.11) adopts a hexamer as quaternary structure 
by monomer binding through the N-terminus (Son et al., 2015), where a small signal 
peptide for mitochondrial localisation is predicted. Therefore, the selected tagging site 
was at protein C-terminus. 
 
Lastly, RBP6 (Tb927.3.2930, 239 aa, 27.1 kDa) was also included in these 
analyses. No predictions for signal peptides, GPI-anchor, or transmembrane domains 
were found. Its RNA-binding (AU-rich binding) domain was found to be at the C-
terminus, and although its cellular location cannot be inferred from the sequence, it is 
probably expressed in the cytosol. Protein structure modelling with I-TASSER 
(Figures 4.1 and 4.11) showed that the N-terminal end is more disordered and far 
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away from the RNA-binding domain at C-terminus, thus suggesting the N-terminal 
end is the preferred for tagging. 
          
 
 
 
Figure 4.11. 3D models of the candidate proteins. Models generated using I-
TASSER from the mature protein sequences of RBP6, the MYND-like hypothetical 
protein, folate transporter and glutamate dehydrogenase. Molecular surfaces in grey 
and protein secondary structures in cartoon representation, coloured from blue (N-
termini, N) to red (C-termini, C). The RNA-binding domain in RBP6 and the MYND-
like domain in the hypothetical protein are coloured in magenta. Proteins represented 
in their putative sub-cellular location.  
 
 
4.2.8.4 Assessing expression of the candidate genes  
 
 To validate the DE analysis, the RNA relative expression levels of each of the 
candidate genes were determined using qRT-PCR. This was determined for both 
TSW-196 and Lister 427 29:13 parasites isolated from the tsetse MG, PV and SG, at 
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two-time points of infection (15 dpi and 30 dpi) (Figure 4.12). Samples from wildtype 
PCF and cBSF were included. Samples from PCF RBP6 overexpressors either 
induced or not at 3 dpi were also analysed to investigate whether the RBP6-induced 
differentiation triggers any candidate gene expression changes.  
 
 
 
Figure 4.12. Gene expression of the candidate genes throughout the life cycle 
of T. b. brucei. RNA relative expression levels of the hypothetical MYND-like protein 
(MYND), the folate transporters (FT), glutamate dehydrogenase (GDH) and RNA-
binding protein 6 (RBP6), normalised to the expression of tert. Parasites from midgut 
(MG) and proventriculus (PV) at two different time points (15 and 30 dpi) from either 
TSW-196 or Lister 427 strains; TSW-196 salivary glands (SG). Additional samples 
from BSF and RBP6 PCF overexpressor cells either induced (+) or uninduced (-) 
(3dpi).   
 
 
The MYND-like hypothetical protein was found to have low expression in 
cBSF, PCF and MG procyclics, and not to be affected by RBP6-induced differentiation 
(Figure 4.13). However, gene expression was found to be consistently higher in TSW-
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196 parasites in MG and PV compared with Lister 427 trypanosomes, especially in 
PV infections (>9-fold up-regulation at 15 dpi and >7-fold at 30 dpi), in accordance 
with the transcriptomics data. MYND expression achieves its highest in PV infections 
at 30 dpi, and it is further down-regulated in SG parasites, suggesting it may function 
in late PV stages. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13. Gene expression of the hypothetical MYND-like protein during the 
life cycle of T. b. brucei. RNA relative expression normalised to the expression of 
tert. Same samples as in Figure 4.12.   
 
 
On the other hand, the folate transporters (expression of three paralogs 
analysed together) seem to be highly expressed in PV and SG parasites, especially 
at 30 dpi although high expression was observed in TSW-196 midgut procyclics at 15 
dpi (Figure 4.14). The expression of the folate transporters is consistently higher in 
TSW-196 compared with Lister 427, with a ~3 fold and ~11-fold up-regulation in PV 
trypanosomes at 15 dpi and 30 dpi, respectively. FT expression seems not to be 
altered upon RBP6 overexpression in vitro.  
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Figure 4.14. Gene expression of the three folate transporters during the life 
cycle of T. b. brucei. RNA relative expression levels normalised to the expression of 
tert. Same samples as in Figure 4.12.  
 
 
 
GDH showed the highest overall expression in the tsetse stages compared 
with the other candidate genes (Figure 4.15). No major differences were observed 
between strains except for TSW-196 MG procyclics (15 dpi) having ~4.5-fold more 
expression than Lister 427, and this being reverted as a ~6.5-fold down-regulation in 
PV infections. Interestingly, GDH was the only candidate gene that showed a 
significant change in expression upon RBP6 induction with a 14-fold up-regulation 
upon RBP6 induction (3 dpi). This suggests that RBP6 may be directly controlling the 
expression of GDH or, alternatively, the differentiation cascade of changes triggered 
by RBP6 did indirectly induce an up-regulation of GDH.  
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Figure 4.15. Gene expression of the glutamate dehydrogenase throughout the 
life cycle of T. b. brucei. RNA relative expression normalised to the expression of 
tert. Same samples as in Figure 4.12.  
 
 
The expression of RBP6, although analysed by the same means in section 
4.2.5, was here evaluated for the direct comparison of expression levels between T. 
brucei strains (Figure 4.16). As expected, RBP6 was found to be up-regulated in PV 
and SG parasites, but no major differences between strains were detected.    
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Figure 4.16. Gene expression of the RNA-binding protein 6 during the life cycle 
of T. b. brucei. RNA relative expression levels normalised to the expression of tert. 
Same samples as in Figure 4.12.  
 
 
 
4.2.8.5 Analysis of the overexpression of candidate genes in Lister 427   
 
 Candidate genes were found to be up-regulated in the competent TSW-196 
strain compared to Lister 427 in PV parasites. Thus, overexpressing these genes in 
Lister 427 (29:13 clone) PV trypanosomes may overcome their deficient expression 
and potentially lead to rescue the SG infection phenotype. Several DNA constructs 
were created for the ectopic overexpression of single candidate genes under a strong 
constitutive rDNA or procyclin promoter and tetracycline-controlled (Figure 4.17). 
Genes were fused with an HA epitope tag at either N- or C-terminal according to the 
preferred sites determined in section 4.2.5.8. After transfection, ectopic expression 
was determined using immunoblotting (Figure 4.18-A) and immunofluorescence 
(Figure 4.18-B). Transgenic PCF clones, showing high and homogeneous protein 
expression, and correct localisation, were further studied.  
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Figure 4.17. DNA constructs for the overexpression of the candidate genes. The 
plasmids pMS (MYND and GDH) or pDEX577 (FT) were used for the tetracycline-
inducible expression of ectopic candidate genes tagged with an HA epitope at either 
C- (MYND, GDH) or N- terminus (FT). All transcripts under the regulation of  the EP1 
procyclin 5’ UTR and the aldolase 3’ UTR.   
 
 
 The hypothetical protein MYND-like was found to be expressed in induced 
cells by immunoblotting with an apparent molecular size of ~50 kDa (54 kDa 
expected) and was observed to localise in the cytoplasm (although excluded from the 
nucleus) by immunofluorescence (Figure 4.18). MYND has not been endo-tagged in 
TrypTag for comparison. In addition, the folate transporter (Tb927.8.3630) localised 
evenly on the surface of PCF, consistent with its location as a surface transporter 
(Gadelha et al., 2015). Interestingly, TrypTag localises this protein in the cytoplasm, 
which is unlikely for a transporter with 12 transmembrane domains. However, it could 
not be detected by immunoblotting, possibly due to a solubilisation problem common 
in proteins containing several hydrophobic transmembrane domains. Lastly, the GDH 
fusion protein was detected by immunoblotting as migrating with an apparent 
molecular mass of ~100 kDa (112 kDa expected). Moreover, the protein localises in 
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the mitochondrion as shown by co-localisation with the mitochondrial marker, 
MitoTracker (Mantilla et al., 2017). In TrypTag, GDH only localises in the 
mitochondrion when tagged at C-terminus, although it also seems to accumulate in 
the kDNA, probably as a consequence of being fused to mNeonGreen.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18. Cellular localisation of ectopic candidate proteins. Ectopic GDH, FT 
and MYND localised by immunostaining in induced (Dox +) cells using DAPI (blue), 
probed with anti-HA (red), and co-stained (green) with either concanavalin A (cell 
surface) or MitoTracker (mitochondrion). DIC and fluorescence merged images 
shown. Scale bars = 5 µm.   
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4.2.8.6 Infectivity of PCF overexpressing candidate genes in the tsetse  
 
 After a basic characterisation of the PCF Lister 427 cell lines overexpressing 
several of the candidate genes, these cells were used to infect tsetse in order to 
determine whether any of these genes is able to rescue the SG deficient infectivity. 
Teneral tsetse were infected with equal amounts of parasites that were either 
previously incubated with Dox for 2 days (pre-induced) or with uninduced cells (as 
negative controls). Flies were dissected at 30 dpi and the infection levels scored in 
the MG, PV and SG (Figure 4.19). Remarkably, only the MYND-like protein 
succeeded to rescue SG infectivity in Lister 427 at rates equivalent to that in wild type 
strains (~13%). No major differences were observed in MG and PV infection rates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19. In vivo phenotype of PCF overexpressing individual candidate 
genes. (A)  Experimental design of infections. (B) Infectivity (percentage) of the 
overexpressors in the tsetse MG, PV and SG. MG infection levels are noted as high 
(H), medium (M), or low (L).  
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4.3 Discussion 
 
 Studies on T. brucei SG stages are scarce compared to those in BSF or PCF. 
The main reason is the ability to culture these parasite stages in vitro so an unlimited 
number of homogeneous cells can be obtained. In contrast, SG trypanosomes cannot 
be cultured in vitro and so they need to be extracted from infected tsetse. This process 
is time-consuming and yields a very reduced number of cells mixed with SG debris 
and saliva, thus making most downstream experiments extremely challenging or 
unfeasible. For instance, this applies to the studies on MISP and BARP presented in 
Chapter 3. Hence, a tsetse-independent alternative method to obtain T. brucei SG 
forms would be ideal to overcome these difficulties. In this Chapter, I present the setup 
of a published method to obtain MCF in vitro (Kolev et al., 2012) with a more detailed 
characterisation and with special focus on the usage of these cells in MISP and BARP 
studies. In addition, in this chapter I characterised a few genes identified as potentially 
essential for the parasite to become transmissible in the tsetse SG.  
 
 
4.3.1 Overexpression of trypanosomal RBP6: a tool to study T. brucei 
development in vitro 
 
 Since the original report on the role and properties of T. brucei RBP6 protein 
(Kolev et al., 2012), surprisingly, no work has been published using the same system 
by other groups. After having generated three independent RBP6 overexpressor lines 
with different characteristics (e.g. expression levels and tags), it seems unlikely that 
a lack of reproducibility is responsible for this. The new three lines of RBP6 
overexpressors generated in PCF responded well to doxycycline induction of the 
transgene and differentiated to EMF and MCF although with different dynamics. The 
cell line used to carry out the full characterisation had the RBP6 fused to three HA 
epitopes and a sfGFP reporter, which greatly eased the selection process without 
compromising functionality. Upon induction, despite the population being clonal and 
expressing the ectopic sfGFP-tagged RBP6, a few cells start the differentiation 
process to EMF. After a few days, MCF were generated from EMFs as it naturally 
happens in the tsetse. While MCF peaked at 3 dpi, EMF are found to be present 
during the entire time course of the experiment (10 days). However, it appears that 
most PCF do not differentiate upon addition of Dox, and that  replicating EMF 
eventually generate MCF, although it cannot be ruled out that PCF population may 
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differentiate at variable times. Unfortunately, this could only be figured out if individual 
cells could be isolated and tracked over time, for instance, using a microfluidics device 
with multiple chambers. One novel finding in all these new RBP6 cells is that upon 
induction, dividing BSF-like trypomastigotes also appear in culture after 3 dpi. Thus, 
RBP6 may also promote the differentiation from MCF to BSF. Although these BSF-
like parasites could not be maintained in culture, perhaps because they rapidly 
differentiated to PCF or the culture conditions were not favourable, they have been 
shown to be replicative and significantly bigger in size than MCF. In addition, these 
forms also express CRD epitopes but not EP-procyclins, all characteristic of BSFs. 
MCF in contrast, do not replicate (Matthews, 2005). Further immunodetection studies 
for the identification of the transferrin receptor exclusively expressed by BSFs 
(Tiengwe et al., 2017), for instance, could corroborate the identity of these BSFs. 
     
 Besides generating different parasite stages, induced RBP6 overexpressors 
also experience anomalies in growth. It can be observed that right after induction, 
cells grow slower than the uninduced controls at all times. Changes in growth rate, 
however, are not stable but greatly fluctuate, perhaps due to two main reasons. First, 
cell density must have an impact in the growth rates as cells divide faster during 
exponential phase (106 to 107 approximately) than in stationary phase (>107). Second, 
cell differentiation is likely to slow cell growth rates because of the number of cells 
undergoing differentiation.  
 
 The setup of the RBP6 overexpression system aimed to produce EMF and 
MCF for the study of MISP and BARP at a new level. It has been shown that these 
cells express MISP as in wildtype SG stages (Chapter 3), although the presence of 
BARP (Urwyler et al., 2007) could not be confirmed. In addition, the ion-exchange 
purification method (Fox et al., 1986) allows the enrichment of MCF and BSF-like 
forms from large volumes of culture. Although in this Chapter no studies on MISP and 
BARP were performed using the in vitro-differentiated cells, the production, 
purification and characterisation methods have been established for future work. 
  
 Although it has been shown that RBP6 promotes differentiation in vitro, the 
biological role of RBP6 remains unclear. Expression analyses confirmed that rbp6 is 
up-regulated in PV and SG trypanosomes, whereas it is negligible in PF and BSF 
(Christiano et al., 2017; Savage et al., 2016). This suggests it plays an important role 
in the development of late stages in the tsetse. In an attempt to validate this, the 
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knockdown of RBP6 did not compromise parasite development in the tsetse as 
expected. However, knockdown efficiency in several cell lines was proved to be low 
(perhaps because of the potential essentiality of RBP6) and remaining RBP6 may be 
able to support normal functionality. A conditional-null RBP6 mutant will be the 
ultimate tool to unequivocally determine essentiality of RBP6 and its biological role in 
the tsetse. Alternatively, RBP6 was overexpressed to understand the role of 
differentiation promotion in the tsetse, in a strain with potential differentiation defects. 
As seen in vitro, differentiation dynamics upon RBP6 induction are fast and complex. 
To translate and adapt these phenomena into the tsetse, two induction timing 
approaches were followed to either resemble the natural differentiation process in the 
PV at 15 dpi, or to provide the tsetse with a mixture of parasite stages, expecting an 
early establishment of PV or SG infection. Both approaches failed to rescue SG 
infectivity of this mutant strain, although it cannot be ruled out that induction timing 
may have not been accurate enough. 
  
 In summary, this chapter section has optimised and better defined an in vitro 
tool to generate T. brucei stages that resemble those in the tsetse SG for the study of 
MISP, among other proteins. It has also provided new insights into the biological role 
of RBP6 in vivo. 
 
 
4.3.2 Gene expression potentially important for T. brucei transmission 
 
 This chapter has also aimed to identify genes whose expression is important 
for T. brucei to establish an infection in the tsetse SGs. This is essential for 
metacyclogenesis and thus completing the transmission cycle. The study was based 
on the comparison of two T. brucei strains which, in principle, are genomically 
equivalent, but present a distinctive infection phenotype in the tsetse with regards 
migration or colonisation of SGs. A detailed characterisation showed that the impeded 
(Lister 427 29:13) strain undergoes a normal development in the PV compared to 
TSW-196 and it is even capable of generating SG infections, although inefficiently. 
This suggests that these parasites have a defect in either differentiation after the PV 
stages, migration to the SG or establishment of an infection in the SG, any of each 
potentially explained by the differential expression of key parasite genes, as 
suggested by transcriptomics analysis. The top up-regulated genes in proventricular 
trypanosomes from the competent strain were a hypothetical protein with a MYND-
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like domain, three folate transporters and the glutamate dehydrogenase. These genes 
were all found to be developmentally regulated and up-regulated in late PV and SG 
infections, suggesting their products are likely to carry out their function in those 
parasite stages. It was hypothesised that genes whose expression was down-
regulated by the impaired strain in the PV, might be responsible for its low infectivity 
in SGs. However, with the exception of the MYND-like protein, overexpression of any 
of the other candidate genes did not rescue the SG infection phenotype. There are 
multiple hypotheses to consider: 1) none of these genes (except MYND) is directly 
responsible for the infectivity defect (unlikely because of the ability of RBP6 to 
promote parasite development), 2) the defective phenotype is due to a combination 
of multiple genes, 3) the phenotype could be due to a gene or combination of genes 
up-regulated in the impeded strain, or 4) the defective phenotype is not a direct cause 
of changes in gene expression but due to physical factors such as motility within the 
vector, which may be more challenging to study.  
  
As mentioned above, the overexpression of the MYND-like candidate protein 
was able to rescue the SG infection phenotype yielding infection rates equivalent to 
that in wildtype strains. In addition, the overexpression of the protein in PCF in vitro 
triggered the formation of EMF (~10%) stages morphologically equivalent to those 
generated in the RBP6 in vitro system (preliminary observation). Although proteins 
with the MYND domain have been described to have RNA-binding properties 
(Spellmon et al., 2015), it cannot yet be assumed that this protein is a putative RBP, 
since other MYND-related functional properties such as protein-binding may also lead 
to cell differentiation by undetermined mechanism. Future studies using the cell line 
here created including RNA-seq, immunoprecipitation and gene knockout, could shed 
more light into the putative role of the MYND-like protein. 
 
 In summary, this chapter section has described a comparative study between 
two T. brucei strains to identify genes whose expression may be important for the life 
cycle completion of T. b. brucei in the tsetse vector. Four candidate genes were tested 
by ectopic protein expression in mutant cell lines, and assessment of their in vitro and 
in vivo phenotypes. Only the MYND-like candidate protein, whose function remains 
undetermined, promoted SG infection and therefore should be further investigated.  
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CHAPTER 5 
Studies on the N-glycosylation of Trypanosoma brucei tsetse stages 
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5.1 Introduction 
 
 The glycocalyx of T. brucei has been extensively studied mainly in two life 
stages, i.e. BSF and PCF. The cell surface of these two stages is known to be densely 
coated by two developmentally regulated major surface glycoproteins: VSGs and 
procyclins, respectively, which can be both N-glycosylated (Ferguson, 1997). Overall, 
the function of these glycosylations remains unclear. It has been shown that VSG N-
glycans play a role in the dense packing of the VSG coat (Mehlert et al., 2002), 
whereas glycosylation of EP-procyclins may be important (but not essential) for 
parasite colonisation of the tsetse midgut (Vassella et al., 2009). So far, nothing is 
known about the structures and function(s) of surface N-glycans from T. brucei EMF 
and MCF. It was hypothesised that, since N-glycans are post-translationally added to 
proteins, the ones found as part of the MCF glycocalyx could be invariable antigens, 
independent on the type of VSG polypeptide expressed, and thus potentially 
exploitable for transmission-blocking approaches.  
 In T. brucei, N-glycan structures vary from complex-type N-glycans mostly 
(containing poly-acetyllactosamine or aGal terminal residues) in VSGs to high 
mannose N-glycans on EP-procyclins (Man5GlcNAc2) (Ferguson, 1997; Izquierdo et 
al., 2009a). N-glycan structures are not directly encoded in the glycoprotein genes, 
but they are the result of multiple and complex interactions between glycosylation 
enzymes, donor substrates and acceptor proteins, among others (Varki et al., 2015). 
A key enzyme in the N-glycosylation pathway is the oligosaccharyltransferase (OST), 
which in T. brucei is composed by a single subunit (STT3) and whose function is to 
attach N-glycan precursors to nascent glycoproteins within the ER lumen (Izquierdo 
et al., 2009b). T. brucei has three paralog genes encoding for three STT3 isoforms 
(A-C), which appear to be developmentally regulated. They have different affinities 
for glycan substrates and acceptor sequences which have a direct impact in the 
resultant N-glycan structure (Izquierdo et al., 2009b). The expression of STT3 
isoforms has been determined in BSF and PCF, but it remains unknown which ones 
are preferentially expressed in the tsetse stages. 
In this chapter, I describe the expression profile of the three stt3 paralogs 
throughout the entire life cycle of T. brucei, including EMF and MCF, which provides 
new insights into the potential types of N-glycan structures found on the surface of 
these parasite stages. I also attempted to obtain structural information on the N-
glycans expressed by MCFs. Lastly, functional studies were performed to pinpoint the 
essentiality of N-glycosylation in all developmental stages of T. brucei in the tsetse.      
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5.2 Results 
 
5.2.1 Developmental expression of stt3 paralogs  
  
 Understanding how T. brucei regulates the expression of the three stt3 paralog 
genes during its life cycle is key to determine the structures and functions of parasite 
N-glycans. However, these studies have only been conducted in cultured parasites 
(i.e. BSF and PCF), so the expression pattern of stt3 in the tsetse stages remains to 
be investigated. The differential RNA expression levels of all the stt3 paralogs (stt3-
A, stt3-B, stt3-C) were determined from cDNA in all T. brucei life stages: cBSF, PCF, 
MG procyclics, PV forms and SG forms. Since the DNA sequence identity shared 
between paralogs is very high (~84% between stt3-A/B, ~96% between stt3-B/C, and 
~84% between stt3-A/C), it was virtually unfeasible to use quantitative real-time RT-
PCR. Semi-quantitative RT-PCR was the method of choice due to its increased 
flexibility in design. Primers were designed for the specific and unequivocal 
amplification of individual paralogs exploiting the gene regions with highest sequence 
diversity (Figure 5.1-A), producing amplicons of different sizes (686 bp for stt3-A, 538 
bp for stt3-B and 571 bp for stt3-C). PCR reactions were stopped at exponential phase 
and the products were analysed using gel electrophoresis. 
  
The analyses first confirmed what has been reported in BSF and PCF 
(Izquierdo et al., 2009b). BSFs express both stt3-A and stt3-B at similar rates, while 
PCFs primarily express stt3-B and little stt3-A. In addition, little expression of stt3-C 
was detected in PCF and in BSF it was found to be equivalent to that of stt3-A. When 
analysing the expression in the tsetse stages, little stt3-C was detected in MG 
parasites along with stt3-B, which was the only expressed paralog in PV and SG 
forms.  
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Figure 5.1. Developmental expression of the oligosaccharyltransferase 
paralogs in T. brucei. (A) Schematic of the three stt3 paralogs highlighting the 
domain with least sequence identity (top). Multiple sequence alignment of the DNA 
coding sequences of stt3-A, stt3-B, and stt3-C. Forward and reverse primers 
designed for the detection of the individual paralogs by RT-PCR are shown in boxes. 
(B) RNA relative expression levels of stt3 paralogs throughout the life cycle of T. 
brucei (strain AnTat 1.1 90:13), normalised to the expression of tert.  
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5.2.2 Functional studies on N-glycosylation 
 
5.2.2.1 Attempts to generating stt3 and rft1 conditional-null mutants 
 
 To study the role(s) and essentiality of T. brucei N-glycosylation during 
development in the tsetse, several T. brucei mutant cell lines defective in N-
glycosylation were created by targeting two key enzymes in the N-glycosylation 
pathway: the oligosaccharyltransferase STT3 and the putative flippase RFT1 
(Helenius et al., 2002). To generate a conditional-null mutant, I tried to knock out the 
two alleles of these genes by replacing the coding sequence with an antibiotic 
resistance marker, in separate rounds of transfection. Both 5’ and 3’ UTR sequences 
of the genes were used to target the insertion of the markers (Figure 5.2). Lastly, an 
ectopic HA-tagged copy (addback) of the knocked-out genes was introduced in an 
untranslated region of the genome (intergenic rRNA), whose expression is 
tetracycline-inducible. This versatile system allows to rescue the wildtype phenotype 
by inducing the addback with tetracycline in a KO-like cell line (-Tet), or to observe 
the KO phenotype in a wildtype-like cell line (+Tet) by removing tetracycline from the 
culture. There are three stt3 paralog genes (Tb927.5.890, Tb927.5.900, Tb927.5.910) 
and one pseudogene (Tb927.5.880) in chromosome 5 in an array disposition. The 
four genes were knocked-out by replacing the entire array with the antibiotic marker 
(Figure 5.2). In contrast, there is a single rft1 gene which was normally targeted for 
replacement (Figure 5.2). While knocking out stt3 alleles did not present much 
difficulties, the single KO rft1 cells were refractory to get the second allele removed in 
several attempts. To fix the issue, single KO rft1 cells were provided with the rft1 
addback whose expression was kept permanently on and indeed allowed the 
knockout of the second allele. 
 
A PCR approach was designed to genotype the generated mutant cell lines 
for the double KO of all stt3 and rft1, with an addback gene. Multiple primers were 
designed to target unique regions to unequivocally detect individual insertions and 
insertion sites (Figure 5.3). Results showed that all cell lines had successfully 
inserted the puromycin and blasticidin resistance markers in the expected loci and, in 
RFT1 lines, the ectopic addback was inserted in the genome too. However, all cell 
lines also showed that, despite having removed the two native alleles, at least one 
copy of the genes had remained in the genome, likely as a result of a gene duplication 
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event during the process (Emes and Yang, 2008). Consequently, none of the created 
mutants was found to be useful in the end for further studies on N-glycosylation.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. DNA constructs for the creation of conditional-null stt3 and rft1 
mutant trypanosomes. (A) Genetic approach for the knockout of the STT3 array and 
the addition of an ectopic HA-tagged stt3-B in T. b. b. AnTat 1.1 90:13. (B) Approach 
for the double knockout of RFT1 and the introduction of an ectopic RFT1 HA-tagged.  
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Figure 5.3. Genotypic analysis of conditional-null stt3 and rft1mutants. Primer 
design (red arrows) to identify the insertions for the double knockout of STT3 (A) and 
RFT1 with addback addition (B). (C) Electrophoresis results of mutant genotyping; 
parental (W), single KO (1) and double KO (2).  
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5.2.2.2 Creation of stt3 RNAi knockdown mutants 
 
 Having failed in generating the stt3 and rft1 conditional-null mutants, I then 
used RNAi to knockdown the expression of the stt3s. RNAi, although simpler and 
faster, it is not as definitive as the conditional-null knockout approach. A DNA 
construct was engineered for the overexpression of dsRNA to target the transcripts 
from the three stt3 paralogs (Figure 5.4-A). A 537 bp unique sequence fully 
conserved in stt3H, stt3A, stt3B and stt3C, was amplified by PCR and cloned in both 
sense and antisense directions flanking a stem loop sequence, under the expression 
of an EP-1 procyclin promoter and tetracycline-inducible. The construct was 
transfected in T. brucei PCF resulting in clonal cell lines expressing the short-hairpin 
dsRNA upon doxycycline induction to silence stt3 expression. The knockdown levels 
were first determined by RT-PCR using universal primers to detect all stt3 transcripts 
(Figure 5.4-B). Several clones were screened and the one with the strongest 
downregulation of stt3 (~65%) was selected for further experiments. 
 
 
5.2.2.3 Characterisation of stt3 RNAi knockdown mutants 
 
First, a phenotypic experiment was performed to measure the N-glycan levels 
on the cell surface and the effect of the stt3 RNAi on it. Uninduced and induced PCF 
were incubated with a fluorescent ConA which binds to high-mannose N-glycans 
attached to surface EP-procyclins (Acosta-Serrano et al., 2000). Thus, the levels of 
surface N-glycosylation were directly correlated with fluorescence intensity. To test 
the specificity of the ConA, the lectin was pre-incubated with sugar inhibitors (aMe-
Man and aMe-Glc) and to test the sensitivity, PCF were pre-incubated with 
tunicamycin, a known inhibitor of eukaryotic N-glycosylation (Takatsuki et al., 1971). 
Cell fluorescence was analysed using Flow-Activated Cell Sorting (FACS) (Figure 
5.4-C).  The lectin was found to be specific since cells stained with pre-inhibited ConA 
displayed fluorescence levels equivalent to unstained negative control cells. In 
addition, the pre-incubation with tunicamycin resulted in a partial inhibition of N-
glycosylation as cells showed increased fluorescence compared with unstained cells, 
but a 10-fold reduction compared with non-treated stained cells. When analysing the 
binding of ConA to stt3 RNAi mutants, uninduced cells showed fluorescence levels 
equivalent to that in wildtype stained cells. However, when the knockdown was 
  
188 
induced, cells displayed ~5-fold less fluorescence than uninduced cells, which proves 
the stt3 knockdown led to a partial reduction in surface N-glycosylation.   
 
 
  
 
 
Figure 5.4. Characterisation of stt3 RNAi AnTat 1.1 90:13. (A) DNA construct 
designed for the expression of a shRNA to downregulate all stt3 transcripts through 
RNAi. (B) RNA relative expression levels of all stt3 in RNAi cells either uninduced or 
induced state. (C) FACS analyses on stt3 RNAi cells. Top panel shows a histogram 
for ConA-FITC intensity of control wildtype cells tunicamycin-treated (tun.) and ConA 
inhibited (inhin.) compared to stained and unstained cells. Top panel inset shows a 
representative dot plot (FSC-A vs SSC-A) of the population of cells analysed (gated). 
Bottom panel shows a histogram for ConA-FITC intensity of RNAi cells either induced 
(Dox +) or uninduced (Dox -) compared to wildtype stained and unstained cells.  
  
189 
A different approach was used in addition to characterise the phenotype of 
stt3 RNAi cells.  Both immuno- and lectin blottings were performed to analyse the 
reduction of N-glycosylation in RNAi cells at a more detailed level. Procyclins from 
both uninduced and induced cells (and tunicamycin treated ones) were extracted with 
organic solvents and their migration analysed by western blotting using specific anti-
EP antibodies (Butikofer et al., 1997). The blotting revealed that procyclins from all 
samples migrated as single broad bands with an apparent molecular mass of ~50 kDa 
(Figure 5.5-A). However, procyclins from tunicamycin-treated cells showed a slightly 
faster migration, likely as a result of the loss of the N-glycans. Furthermore, procyclins 
from RNAi induced cells revealed the broadest band compared to both untreated 
wildtype and RNAi uninduced cells, probably as a result of having a mixture of 
glycosylated and non-glycosylated procyclins as RNAi only produced a partial 
knockdown. The same procyclin extracts were then analysed by ConA-blotting 
(Figure 5.5-B). Although less specific than anti-EP, the lectin reveals not only the 
glycosylated procyclins, but also the presence of other N-glycosylated proteins (likely 
contaminants in the procyclin preparations). Untreated wildtype cells showed a broad 
range of N-glycoproteins while tunicamycin-treated cells showed a massive reduction 
in signal, as expected due to overall N-glycosylation inhibition. The stt3 RNAi induced 
cells showed an equivalent reduction in detection, which is comparable to that from 
tunicamycin-treated cells. This shows that tunicamycin and stt3 RNAi not only 
affected the N-glycosylation of EP-procyclins, but had a general cellular effect. The 
results were also compared with the binding of ConA to chicken albumin (as a positive 
control for detection), as well as wildtype procyclins either treated or not with the 
glycosidase PNGase F, an enzyme that cleaves off N-glycans from proteins. 
Strikingly, there seems to be at least one protein resistant to PNGase F cleavage, but 
its identity was not further confirmed by mass spectrometry.  
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Figure 5.5. Characterisation of procyclins from stt3 RNAi cells. (A) Western 
blotting using anti-EP procyclin on extracted procyclins from wild type untreated (Tun. 
-) or tunicamycin-treated (Tun. +) cells, induced (+) or uninduced (-) RNAi cells, and 
cell lysate from BSF as negative control. (B) ConA blotting of extracted procyclins 
from wild type tunicamycin-treated or untreated cells, induced or uninduced RNAi 
cells. Commercial, glycosylated chicken albumin (C.A.) was used as positive control. 
Specificity controls: wild type procyclins either treated or not with PNGase F, pre-
inhibited ConA on wild type procyclins (Inh).  
 
 
5.2.2.3 stt3 RNAi cells show a partial infection phenotype in tsetse flies 
 
 The stt3 RNAi cell line has shown significant reduction in N-glycosylation 
activity. To study the role(s) and essentiality of N-glycosylation regarding infectivity 
and development in the tsetse, the stt3 RNAi cell line was pre-induced in culture and 
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used to infect tsetse to score MG, PV and SG infections. The rate of infection in non-
induced were 92% MG infection, 40% PV infection and 12% SG, which is comparable 
to that of wild type cells and indicated no “leakiness” in the inducible system (Figure 
5.6). This is in clear contrast to the results observed in induced cells, which showed 
an overall reduction in infectivity (i.e. ~15% and ~62% in MG and PV, respectively, 
and no parasites detected in SGs) (Figure 5.6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6. Essentiality of N-glycosylation for tsetse infection. Percentage of 
infection in MG, PV and SG at 30 d.p.i. of stt3 RNAi cells either uninduced (Dox -) or 
induced (Dox +).  
 
 
5.2.3 Systematic collection of T. brucei metacyclic cells for glycan structural 
analysis 
 
 The N-glycans in the MCF glycocalyx are expected to be predominantly 
attached to mVSGs as in BSF VSGs. After the findings in Chapter 3, however, more 
N-glycans could be expected to be found in MISP and BARP. Despite VSGs and 
mVSGs are assumed to be structurally equivalent, their respective attached N-
glycans may not have conserved structures as these depend in part on the STT3 
isoforms functioning in each stage of the parasite (Izquierdo et al., 2009b). As shown 
in section 5.2.1, BSF predominantly express stt3-B and stt3-C but also stt3-A. 
However, in SG parasites (mainly MCF) only expression of stt3-B could be detected, 
suggesting that the N-glycan structures in mVSGs may not be the same as in BSF. 
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To determine the structure(s) of MCF surface N-glycans, multiple tsetse infections 
were set up using either BSF from mouse infected blood, PCF or cultured BSF (strain 
AnTat 1.1 90:13). Parasites infecting the SG were collected at 30 days post infection. 
MCF (~95% of SG forms) were isolated from the SGs, washed in PBS to remove 
salivary proteins and snap-frozen until further use. The equivalent to ~250 SG-
infected flies (35 infection experiments, ~3,500 total flies) were pooled together to 
further perform a glycoproteomics analysis in order to determine the structure of the 
N-glycans and the proteins these belonged to. Although the sensitivity of these 
methods has greatly improved over the recent years, the required number of cells for 
these approaches is normally ~108-109. The estimated number of collected 
metacyclics during this thesis is ~2x106, considering an average number of 8x103 
MCF cells per infected fly. Consequently, due to time constrains and the impossibility 
to obtain the desired number of metacyclics for mass spectrometry analysis, the 
glycoproteomics analysis of T. brucei metacyclic, extracted from infected tsetse SGs, 
was never performed. However, an interesting observation can be made after 
performing the tens of tsetse infection for MCFs collection during a period of ~3 years. 
It became clear that flies infected with BSF from infected blood yielded higher SG 
infection rates (~27%) compared to infections carried out using either PCF (7.6%) or 
cultured BSF (0%) (Figure 5.7).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7. SG infection rates obtained in multiple tsetse infection for MCF 
collection. Comparison of the SG infection rates between tsetse infected with either 
BSF from mouse blood, PCF or cultured BSF (cBSF). Bar notes the mean; error bars 
show standard deviation. Each dot corresponds to an infection event of at least 100 
flies.   
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5.3 Discussion 
 
 The glycobiology of T. brucei has been widely studied over the years, mostly 
focus on BSF from animals and PCF due to the high number of cells that can be 
obtained from either stage. Besides structural studies which determined the major N-
glycan structures found on T. brucei (Ferguson, 1997), the study of the N-
glycosylation and GPI anchor pathways in this organism has provided a massive 
contribution to the entire field of glycobiology (Ferguson et al., 1988). However, little 
is known about the N-glycan structures found in advanced stages of the parasite in 
the tsetse (i.e. EMF and MCF) and the role of N-glycans regarding parasite 
development in the vector. This chapter provided more insights into the essentiality 
of parasite N-glycosylation in the vector.  
 
 
5.3.1 Developmental regulation of the trypanosomal STT3 
oligosaccharyltransferase isoforms  
 
 Understanding how the three stt3 paralogs are expressed throughout the life 
cycle of T. brucei is key to better understand the function and structure of parasite N-
glycans in response to adaption to the different environments. In particular, with the 
exception of procyclic cells, very little is known about the type of glycosylation present 
in most parasite stages developing within the tsetse. Here, the RNA expression of 
stt3-A, stt3-B and stt3-C was determined in all T. brucei stages. It was confirmed that 
BSF express both stt3-A and stt3-B isoform at similar rates while, in comparison, PCF 
mainly express stt3-B. This goes in agreement with a previous study on stt3 
expression (Izquierdo et al., 2009b) and with the reported N-glycan structures 
predominantly found in BSF (complex type as a result of stt3-A activity) or in PCF 
(high-mannose type as a result of stt3-B activity). While previous reports failed to 
detect any expression of stt3-C in neither BSF nor PCF, in this chapter I showed 
evidence of a significant expression of stt3-C in BSF, PCF and MG procyclics. This 
could be related to the use of strain AnTat 1.1, which is known to be pleomorphic and 
fly-transmissible. In contrast, previous studies used a transgenic clone of strain Lister 
427, which has been highly passaged in culture and is non-pleomorphic and not fly-
transmissible. Because it is unknown how STT3-C functions and considering the high 
sequence identity between STT3-A, STT3-B and STT3-C (~88%), it is possible that 
expression of STT3-C, in the Lister 427 strain, may have been repressed as a result 
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of culture adaptation and increased fitness. It was hypothesised that, because stt3-C 
was absent in both BSF and PCF, stt3-C could play its role in the tsetse stages, 
specifically in EMF since these are the most divergent to PCF and BSF. It could be 
also hypothesised that MCF would have similar expression patterns to BSF, as these 
cells re-express the VSG coat ready to be transmitted to the mammalian host (Tetley 
et al., 1987). This does not seem to be the case considering these results as it was 
found that MG procyclics, PV and SG stages predominantly express stt3-B. It is 
important to consider that the STT3 activity also depends on the residues flanking the 
N-glycosylation sequons (Izquierdo et al., 2009b; Jinnelov et al., 2017) and so the 
peptide sequence may influence the N-glycan structure output. STT3 specificity has 
been also determined in other parasites such as Leishmania ((Hese et al., 2009; 
Nasab et al., 2008) and Plasmodium (Samuelson et al., 2005), the latter transferring 
extremely truncated glycan precursors (GlcNAc only or a chitobiose core). The 
biological significance of this broad spectrum of OST subunits remains unclear.   
  
  Analyzing gene expression in tsetse stages is always challenging mainly due 
to two factors. First, the limited number of cells yields very low quantities of RNA, and 
second, the heterogeneity of parasite stages and tsetse cell debris in these samples 
may interfere with the results. It cannot be assumed that stt3-B is the only paralog 
expressed in the tsetse stages but the most abundant one. Some cell types, 
especially EMF in the PV (which represent 5-10% of the total PV population) or 
attached EMF in the SG (variable prevalence in SG, co-habiting with MCF), may have 
different expression patterns of stt3 but these could be masked by the predominant 
cell types.  
Lastly, it is interesting to notice that BSF have the overall highest expression 
of stt3, and the expression levels go down in the tsetse. This increased need for stt3 
expression in BSF could be attributed to the huge demand of N-glycans for VSGs. 
BSF keep a massive rate of continuous and fast production of VSGs, which indirectly 
implies that the N-glycosylation pathway needs to increase to meet the need.  
 
 
5.3.2 Functional studies on N-glycosylation in the tsetse stages 
 
 Attempts for generating conditional-null trypanosome mutants, defective in N-
glycosylation, were unsuccessful for two different genes. The genes of choice were 
the stt3s (stt3-H, stt3-A, stt3-B, stt3-C) and rft1 as they encode key enzymes in the 
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N-glycosylation pathway. The STT3 oligosaccharyltransferase transfers the N-glycan 
precursor to the protein, and the putative flippase RFT1 flips in the Man5GlcNAc2-PP-
dol precursor glycan from the cytosolic side of the ER into the luminal face during 
glycan assembly (Helenius et al., 2002). Remarkably, a double knockout of rft1 has 
been generated in T. brucei PCF (Jelk et al., 2013). In the case of rft1, both were 
knocked out but surprisingly, N-glycans were still being produced although with 
altered structures and in lower quantities (Jelk et al., 2013), suggesting that there may 
be an alternative flippase activity form either an unknown enzyme or by spontaneous 
diffusion through the ER membrane. On the other hand, trypanosomal stt3 genes 
could never be completely removed, being a single knockout enhanced with stt3 RNAi 
the best approach developed to deplete global N-glycosylation (Izquierdo et al., 
2009b). All these mutants were created in the Lister 427 strain (which is non-fly 
transmissible) making the tools unsuitable for studies in the tsetse. In this thesis, 
another attempt of generating stt3 and rft1 conditional-null mutants in AnTat 1.1 90:13 
was carried out. After multiple unsuccessful attempts, clonal cell lines were obtained 
resistant to the knockout antibiotic markers for both stt3 and rft1. A PCR-based 
strategy was designed to screen and genotype these cell lines for the identification of 
the insertion of resistance markers, addbacks and removal of the endogenous genes. 
Results from several cell lines showed that, despite having successfully inserted the 
two resistance markers and removed both alleles from the endogenous loci, all clones 
revealed the presence of at least one copy of the endogenous genes. Because a 
~96% of the total T. brucei proteins are N-glycosylated, it can be hypothesised that 
during the transfection processes, gene duplication events may have taken place as 
a result of applying pressure to deplete such important genes. This is not 
unprecedented as T. brucei glycosylation mutants have been described to recombine 
some of the stt3 isoforms after selection with cytotoxic carbohydrate binding 
molecules (Castillo-Acosta et al., 2016; Castillo-Acosta et al., 2013). Further analyses 
based on southern blotting could confirm this hypothesis and provide more 
information on when these events happened. In future attempts, an alternative 
strategy could consist on inserting the addback gene in first place and keep its 
expression active by default, so the enzymatic activity does not cease during deletion 
of the endogenous alleles, which may prevent gene duplication.  
  
 Having failed in creating conditional-null mutants, a second approach based 
on gene silencing through RNAi was considered. Stt3 silencing was preferred over 
rft1 since this proved to be effective in reducing N-glycosylation levels (Izquierdo et 
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al., 2009b) but not altering glycan structures (Jelk et al., 2013). The selected RNAi 
cell line showed acceptable downregulation of stt3 RNA, which indeed led to a 
reduction of EP procyclins glycosylation as proven by FACS and lectin blotting 
analyses, although not as effective as the reduction observed in tunicamycin-treated 
parasites. RNAi cells were then used to infect tsetse to study the impact of decreased 
N-glycosylation in parasite infectivity. Tunicamycin-treated cells were not considered 
in this experiment since the drug becomes lethal after a few days. Remarkably, a 
reduced overall N-glycosylation by the stt3 knockdown had a negative impact on 
parasite infectivity of the tsetse in MG, PV and SG. This is in contrast to published 
results showing that alteration of the parasite N-glycosylation after deletion of Alg3 
gene, does not affect infectivity of the tsetse MG (Manthri et al., 2008). The migration 
and infection of these tissues are naturally major bottlenecks for T. brucei 
transmission. The parasite is always more effective at infecting the MG (~90%) and 
infectivity rates decrease along with development in the PV (~40%) and SG (~10%). 
Therefore, the effect in infectivity due to a reduction of N-glycosylation is little in the 
MG and becomes greater in the PV and SG. Strikingly, the stt3 RNAi led to a complete 
absence of SG infections compared to the control.  
 
As to why N-glycosylation may be important for parasite progression through 
the fly is unknown, but one straightforward explanation is that surface N-glycans 
contribute to shield the parasite surface against the action of MG hydrolases (Acosta-
Serrano et al., 2001). In addition, recent evidence suggest that glycosylation mutants 
are unable to perform social motility (SoMo) in vitro, although whether SoMo also 
occurs in the tsetse remain to be proven (Imhof et al., 2015).  
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CHAPTER 6 
New methods for imaging African trypanosomes in the tsetse 
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6.1 Introduction 
 
T. brucei has been extensively studied and characterised in vitro. However, 
studies on vector-parasite interactions are scarce and, remarkably, one major 
bottleneck for these studies is the low quality of parasite imaging inside tsetse tissues.  
 
 Transmission and scanning electron microscopy were used many years ago 
in the firsts attempts to visualise T. brucei in the salivary glands of the tsetse (Gluenz 
et al., 2015; Sharma et al., 2008; Tetley et al., 1987; Tetley and Vickerman, 1985). 
On the other hand, light sheet microscopy was recently used to facilitate imaging of 
trypanosomes in the tsetse MG and PV (Schuster et al., 2017). However, access to 
this type of state-of-art microscope is difficult, including the possibility of imaging live 
or fixed pathogens in dedicated Cat 3 facilities. If higher magnification and detail is 
required, trypanosomes can be isolated from the tsetse, stained and imaged by 
regular fluorescence microscopy methods, but consequently the biological context is 
lost. In this chapter, I describe imaging methodologies based on confocal laser 
scanning microscopy. A series of staining and mounting methods were developed to 
allow the observation of either naïve or trypanosome-infected tissues from tsetse flies 
in their native context.   
 
Two examples of applicability of these methodologies are reported. First, I 
describe how the 3D reconstruction of several tsetse organs was used to study the 
tissue damage caused upon exposure to nitisinone, a powerful inhibitor of the tyrosine 
metabolism that kills all blood feeder insect vectors, including tsetse (Sterkel et al., 
2016) and (in preparation). Second, I greatly exploited these methodologies to study 
a novel route of colonisation of the tsetse gut by T. brucei.  
 
 
 
 
 
 
 
 
 
6.2 Methods 
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6.2.1 Tsetse nitisinone feeding and tissue processing 
  
 Teneral (<24h old) male tsetse were blood-fed on sterile defibrinated horse 
blood (TCS Biosciences) using standard silicon membrane feeding protocols. Three 
days later, flies were offered a second meal supplemented with 10 µg/mL wheat germ 
agglutinin (WGA)-rhodamine (Vector Laboratories) in either normal horse serum or 
IPL41 serum-free insect medium (Sigma), with or without 500 ng/mL (2-[2-nitro-4-
(trifluoromethyl)benzoyl]cyclohexane-1,3-dione (nitisinone) (Sigma). Tsetse were 
anaesthetised on ice 15 hours post feeding and the following tissues were dissected 
in ice-cold PBS: midgut (with attached proventriculus), flight muscle, fat bodies, 
Malpighian tubules and salivary glands. Tsetse survival was determined 72 hours post 
nitisinone feeding. Dissected tissues were immediately fixed in fresh 4% PFA for 1 
hour at RT, washed and stained with SiR-actin (1:1000 dilution in PBS, Cytoskeleton 
Inc.) for 3 hours at RT. Tissues were posteriorly incubated in 500 ng/mL DAPI for 10 
minutes at RT, washed and mounted in 1% low-melting agarose at <40°C mixed with 
Slowfade Diamond mounting oil in a contained (higher volume) area on a glass slide. 
Slides were imaged using a Zeiss LSM-880 and tissues reconstructed from a series 
of z-stacks as described in section 2.5.3. SiR has excitation and emission peaks at 
652 nm and 674 nm, respectively. 
  
 
6.2.2 Live staining of the tsetse peritrophic matrix 
 
 To stain the peritrophic matrix along the midgut, flies were fed every day with 
FBS supplemented with 15 µg/mL WGA-rhodamine. WGA is a lectin that binds to 
terminal linear GlcNAc residues. As proteins (peritrophins) in the tsetse PM are 
crosslinked with chitin fibres, WGA was used as a probe for staining of this tissue. 
This method is compatible with imaging of fluorescent (GFP) trypanosomes infecting 
the MG and PV.  Alternatively, to stain the PM at the synthesis site, flies were fed with 
FBS 15 µg/mL WGA-rhodamine for 10 minutes and the PV, still attached to the 
anterior midgut, was dissected out after 15 minutes post-feeding. Exceeding this time 
results in a loss of staining in the PV since the rate of PM synthesis and serum meal 
pumping are particularly fast (Lehane and Msangi, 1991). This method is also 
compatible with imaging of fluorescent trypanosomes infecting the PV and anterior 
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midgut. However, imaging of intact midgut is challenging because of the damage 
occurring due to the expansion caused by the blood/serum meal.  
 
 
6.2.3 3D reconstruction of trypanosome-infected tsetse proventriculus 
 
 To study the early infections of the tsetse PV by T. brucei parasites, tsetse 
control or infected with either T. brucei J-10 (GFP expressor) or AnTat 1.1. 90:13 
(mNeonGreen; this thesis) were fed every day on serum meals composed of FBS 
supplemented with 15 µg/mL WGA-rhodamine for PM staining as described in section 
6.2.2. At 5 dpi, the PV was immediately dissected after feeding and fixed in fresh 1% 
PFA at 0°C for 1 hour to preserve the trypanosome fluorescent protein fluorescence. 
Tissues were then stained with SiR-actin (1:1,000 dilution) for 4 hours on ice, stained 
with DAPI 300 ng/mL for 10 minutes, and mounted in 1% low-melting agarose (<40°C) 
mixed with Slowfade Diamond mounting oil, in a higher-volume contained area on a 
glass slide. Specimens were imaged and reconstructed using a Zeiss LSM-880 as 
described in section 2.5.3. 
 
 
6.2.4 Ex vivo 3D reconstruction of trypanosome-infected peritrophic matrices  
 
 Tsetse infected with T. brucei J-10 strain (GFP) were dissected at 9 days post 
infection to isolate the PM in PBS. The PM was washed several times in PBS and 
allowed to attach to poly-L-lysine slides. The PM was fixed in 1% PFA at 0°C for 1 
hour, washed and stained with 10 µg/mL WGA-rhodamine and 300 ng/mL DAPI for 
15 minutes. After washing, slides were mounted in Slowfade Diamond mounting oil 
and imaged and reconstructed using a Zeiss LSM-880 as described in section 2.5.3.  
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6.3 Results 
 
6.3.1 3D reconstruction of tsetse organs to investigate tissue damage upon 
nitisinone exposure. 
 
 The methods described in section 6.2.1 were applied to investigate the tissue 
damage caused after exposure to nitisinone (also referred as NTBC). Several groups 
of tsetse were fed with a fixed sub-lethal dose of NTBC (500 ng/mL) dissolved in either 
horse serum or IPL41 serum-free insect medium, supplemented with WGA-
rhodamine lectin for PM staining. Negative controls consisted only of horse serum or 
IPL41 medium. In previous experiments (unpublished data), the meal medium 
composition was shown to modulate toxicity of NTBC, the IPL41 medium being more 
effective in killing compared to serum using identical NTBC doses. It was therefore 
hypothesised that they would lead to “early” and “late” tissue damage phenotypes, 
respectively. At 15 hours post feeding, flies were dissected to collect the following 
organs (Figure 6.1-A): midgut (with attached proventriculus), flight muscle, 
Malpighian tubules, fat bodies and salivary glands. All of them were shown to be 
severely damaged upon NTBC exposure in previous experiments. In addition, flight 
muscle was of particular interest since paralysis is the first visible effect of NTBC, and 
flies show muscle detachment.  
 
Tsetse survival was determined 72 hours post-feeding to relate degree of 
tissue damage with death rates (Figure 6.1-B). The NTBC (serum) “early phenotype” 
group showed a survival rate of ~34% and thus proved to be a sub-lethal bloodmeal 
compared to the 0% survival of the NTBC (IPL41) “late phenotype” group. Both control 
groups had higher survival rates in comparison (92% serum, 52% IPL41), although 
the IPL41 itself seems to have an intrinsic toxic effect in some flies. However, the 
aspect of dead flies due to NTBC is clearly distinct from dead flies in the control 
groups. Control and affected tissues were then processed as described in section 
6.2.1 and imaged by LCSM for analysis. The tissues were reconstructed as a 3D 
overview model generated from several z-stacks combining DAPI and SiR-actin 
stainings. Detailed sections of the tissues were also imaged to analyse damage at 
cellular level. 
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Figure 6.1. Tsetse tissues investigated for damage upon NTBC exposure. (A) 
Schematic of a tsetse fly highlighting the organs dissected out for imaging. (B) 
Survival rates (percentage) at 72 hours post NTBC ingestion. 
 
 
After reconstruction, the tsetse anterior midgut (AM) was shown to be formed 
by an outer layer of muscle cells which are organised in longitudinal fibres (along the 
midgut length) and transversal fibres (around the midgut perimeter). The muscle 
fibres surround an inner layer made up by rounded epithelial cells. The control AMs 
could be dissected out intact and connected to the PV, crop and oesophagus, while 
the NTBC-treated tissues (early phenotype) appeared to be structurally damaged and 
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the AM disconnected from PV, crop and oesophagus (Figure 6.2). When observing 
the AM muscle fibres at higher magnification it could be observed that, while the 
longitudinal muscle fibres did not appear to be altered upon NTBC treatment, the 
transversal fibres were significantly fewer, thicker and less compact compared with 
the controls. It is reasonable to think that such alterations in tissue organisation make 
these important organs unfunctional, eventually leading to death. The same organs 
could not be isolated from NTBC-treated flies with “late phenotype”: at this stage, most 
organs have dissolved forming a single tissue mass in the abdomen which, after 
reconstruction, was shown to have unstructured remains of midgut tissue, Malpighian 
tubules and fat bodies (Figure 6.2).  
       
 
 
Figure 6.2. Midgut and proventriculus reconstructions. Bright field and 3D 
fluorescence reconstruction overviews (100x) of tsetse anterior midgut (AM), 
proventriculus, crop (C) and oesophagus (E) from control, NTBC-fed “early” and “late” 
phenotype flies. Fluorescence merges SiR-actin staining (green) and DAPI 
(magenta). Detail of either horizontal or vertical muscular fibres (630X) from the 
anterior midgut (AM). Scale bar = 200 µm (100X) and 20 µm (630X).  
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Also, the intensity of the SiR-actin staining was >10-fold less than the control 
and “early phenotype”, suggesting there has been an overall loss of actin due to cell 
death, which made it impossible to image muscle fibres in detail (also from flight 
muscle). In addition, a systemic darkening of the tissues, as a result of a systemic 
myelinisation process, was observed in NTBC-treated flies.  
 
The flight muscle was reconstructed to compare the architecture of the fibres 
and sarcomeres in detail between samples in equivalent areas of the muscle (Figure 
6.3). The overall structure of the muscles was not found to be altered in NTBC-treated 
flies. The “late phenotype” flies showed signs of muscle detachment, but the overall 
integrity of the fibres was maintained. When looking in detail at the level of single 
muscle fibres, the untreated samples showed well organised and straight fibres, with 
clearly defined sarcomeres. In ‘early phenotype’ flies, muscle fibres were still visible 
although in many areas the gaps between fibres and sarcomeres had increased in 
size, some fibres lost linearity and the nuclei became smaller. Samples from “late 
phenotype” flies showed a dramatic decrease in actin content, the fibres were more 
compacted, significantly thinner and the sarcomere unit was lost, suggesting these 
muscles completely collapsed and became unfunctional.   
 
The fat bodies, Malpighian tubules and salivary glands were also analysed to 
see the damage extent beyond the midgut and muscle. In previous experiments, 
NTBC was shown to make the Malpighian tubules collapse, preventing the tsetse from 
excreting NTBC in first instance. The fat bodies are known to be involved in 
detoxification (Arrese and Soulages, 2010) and thus were also taken in consideration 
for analyses. Lastly, although not directly involved in digestive processes, salivary 
glands were also analysed since they share the abdominal space with the rest of 
organs mentioned above. The fat bodies were slightly affected by NTBC exposure 
(Figure 6.4). While in untreated flies they can be isolated in mass containing 
hundreds of them, “early” phenotype flies contained less and smaller fat bodies, with 
a slenderer shape. Although oenocytes could still be found, SiR-actin staining in all 
cell types was also less abundance of actin. In “late” phenotype flies, remains of fat 
bodies were still recognisable but scarce and isolated within the mass of abdominal 
tissues, and oenocytes could not be found. The poor staining of SiR and DAPI showed 
areas of accumulation within the bodies, likely as a result of cell death processes. 
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Figure 6.3. Reconstruction of the tsetse flight muscle. Overview (100X), and 
detail of the muscle fibres (630X) from control and NTBC-treated “early” and “late” 
phenotype flies, in bright field and fluorescence reconstructions (SiR-actin in green, 
DAPI in magenta). Scale bars = 200 µm (100X) and 20 µm (630X). 
 
  
The Malpighian tubules were reconstructed to observe that the overall integrity 
is not compromised in “early” phenotype flies despite being unable to excrete 
digestion products. However, as seen in the other tissues, actin was greatly lost. 
Malpighian tubules in “late” phenotype flies could not be found (Figure 6.5). 
 
Lastly, the salivary glands were not found to be especially affected in NTBC 
“early” phenotype samples as they kept their integrity and the muscle fibres only 
seemed to be less tight compared with the control (Figure 6.6). Remarkably, in “late” 
phenotype flies salivary glands could not be found as they were probably dissolved 
or lost their integrity. 
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Figure 6.4. Tsetse fat bodies reconstructions. Overview (100X) and close detail 
(630X) of fat bodies from control and NTBC-treated “early” and “late” phenotype flies 
as bright field and fluorescence reconstructions (SiR-actin in green, DAPI in 
magenta). Fat bodies mass (FB) may contain Malpighian tubules (MT). Scale bars = 
200 µm (100X) and 20 µm (630X). 
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Figure 6.5. Malpighian tubules reconstructions. Overview (100X) and close detail 
(630X) of samples of Malpighian tubules from control and NTBC-treated “early” flies 
as bright field and fluorescence reconstructions (SiR-actin in green, DAPI in 
magenta). Malpighian tubules (MT) and hindgut (HG) noted in bright field. Scale bars 
= 200 µm (100X) and 20 µm (630X). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6. Tsetse salivary gland reconstructions. SG from control and “early” 
phenotype NTBC in bright field, DAPI and 3D fluorescence using SiR-actin (green) 
and DAPI (magenta). SG distal end pointed as ‘d’ in bright field. Scale bar = 100 µm.  
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6.3.2. Studies on T. brucei-tsetse interactions using imaging methods  
 
6.3.2.1 An overlooked T. brucei early infection of the tsetse proventriculus 
 
 It is well accepted that when the tsetse uptakes a T. brucei-infected 
bloodmeal, the parasite first colonises the MG and after 1-2 weeks it migrates towards 
the PV (Gibson and Bailey, 2003). However, here we observe that flies fed with 
infected rat blood contained a few parasites in the PV as soon as 2 d.p.i and 
developed a regular heavy PV infection from 3 dpi (Figure 6.7-A). Time course 
experiments showed that, while the infection in the MG remains stable during the first 
5 days post infection, PV infection rates rapidly increase from ~8% (2 d.p.i) to ~77% 
(5 d.p.i) (Figure 6.7-B). Interestingly, this capability of PV early infection seems to be 
lost upon parasite adaptation to culture. BSF blood parasites were put in culture and 
maintained for 9 days before fed to the tsetse. These recently-adapted BSF showed 
a dramatic decrease in PV infection rates (37%) at 5 d.p.i compared to BSF blood 
parasites (78%), and the early PV infection was totally lost in a BSF cultured cell line 
(0%) (Figure 6.7-C). PV infection rates at 15 d.p.i, however, are high and similar in 
all groups. This suggests that culture adaptation negatively affects PV invasion only 
at the early stages. It remains to be investigated what is the role of the early PV 
infection regarding parasite development or transmission. It can be thought that the 
early PV infection is somehow linked to the transmission index. Infection rates in SG 
were assessed in flies infected with the previous parasite groups. Blood BSF lead to 
the highest SG infection rates (22%) and these decreased in parasites recently-
adapted to culture for 9 days (8.7%). Cultured BSF are completely unable to develop 
a SG infection (0%) (Figure 6.7-D). Lastly, MG and PV parasites at 5 d.p.i and 15 
d.p.i were extracted for stage identification based on morphology, nucleus/kinetoplast 
relative position and cell length (Figure 6.7-E). Early PV parasites were found to be 
100% mesocyclics with same morphology, DNA relative position and cell length than 
those found at 15 d.p.i. However, early infected PVs do not contain EMF forms while 
at 15 d.p.i. they contain both long and short EMFs. This suggests that parasites 
infecting the PV at early stages are indeed proventricular forms and not procyclics 
that came in from the MG, so the development and invasion process could be 
equivalent to that at 15 d.p.i. with the exception of EMFs which are not yet formed.   
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Figure 6.7. T. brucei early infection of the tsetse proventriculus. (A) PV infection 
time course (0 to 5 d.p.i) in flies infected with T. b. brucei (strain J-10, constitutive 
GFP); scale bars = 200 µm. (B) Infection rates from time course in ‘A’, in MG and PV. 
(C) Infection rates (5 and 15 d.p.i) of MG and PV from tsetse infected with BSF (strain 
AnTat 1.1. 90:13) either from mouse infected blood (Blood), adapted to culture for 9 
days (Adapted) or cultured cells (cBSF). (D) Salivary gland infection rates of flies 
infected with the same groups in ‘C’ at 30 dpi. (E) Cell length of parasites stages found 
in the MG and PV at 5 and 15 d.p.i.    
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6.3.2.2 Imaging the early-infected tsetse proventriculus 
 
 It is also well established in the community that T. brucei, after 
colonizing the MG, needs to reach the ectoperitrophic space (ES; space between the 
peritrophic matrix and the MG endothelial cells) (Gibson and Bailey, 2003). It is 
assumed that the parasites cross the PM to do so, although there no direct evidence 
has been reported. Once in the ES, it is assumed that procyclic trypanosomes migrate 
towards the PV where the PM is synthesised. The discovery of the PV early infection 
challenges this dogma, since the time window is too short for the parasites to carry 
out the crossing and migration processes, and potentially suggests that reaching the 
ES could be a consequence of this PV early invasion.  
 
The early-infected proventriculus was stained with different markers to better 
understand the invasion process and interactions between parasites and tsetse 
tissue. The overall PV actin-based reconstruction was made using the same labelling 
and mounting method as in section 6.2.1 plus staining of the PM using the lectin WGA, 
DAPI to stain nuclei and GFP fluorescence from parasites. By analysing several z-
stack sections, orthogonal views were generated and used to determine the precise 
localisation of the parasites in the PV and AM.  In Figure 6.8-A it is depicted the areas 
of interest using a control and infected PV as example. Thanks to the different staining 
tools, it is clear to see the limits of the PV, the AM connected to it, the endothelial cells 
and the ES. A control and infected PV orthogonal views were analysed in detail 
(Figure 6.8-B-C). Parasites can be found in the PM lumen but also in the ES of the 
AM where they seem to gather in small areas along the ES. 
 
Sequentially added fluorescence channels in 3D reconstructed control and 
early-infected PV, at angles of 20° and 45°, help to understand how the PM is 
secreted inside the PV from multiple areas becoming a cylinder-shaped tube that 
goes along the MG. It also shows how the parasites invade the PV outside the PM 
(by the ES) but underneath the main section of PV columnar and muscular cells 
(Figure 6.9).  
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Figure 6.8. T. brucei localisation in PV and anterior midgut. (A) Examples of 
control and early-infected PV highlighting the areas of interest: PV, anterior midgut 
(AM), ectoperitrophic space (ES) and endothelial cells (EC). (B) Control and early-
infected PV (5 d.p.i) with labelled actin (SiR-actin), PM (Rhodamine), nuclei (DAPI) 
and T. brucei (GFP). In the merge channel the dashed-line square highlights the area 
analyzed in C. (C) Orthogonal views of control and early-infected (5 d.p.i) PV. Infected 
PV has two orthogonal sections, and the outer one without GFP fluorescence. Scale 
bars = 100 µm.  
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Figure 6.9. 3D reconstruction of infected proventriculus. Sequentially added 
fluorescent channels of control and early-infected PV. PM stained with WGA-
rhodamine (Rhod), T. brucei (GFP), nuclei (DAPI) and actin (SiR). Reconstructions 
rotated at 20° and 45° clockwise to facilitate visualisation. Scale bars: 100 µm. 
 
 
 
6.3.2.3 Imaging the tsetse T. brucei-infected PM ex vivo  
 
 Since in the orthogonal views of infected PV and AM it was observed that 
parasites formed small denser areas in the ES, the PM was dissected out and 
analysed on its own ex vivo. It could be observed that many parasites remained 
trapped in the PM after washes, suggesting they could be attached or trapped 
between PM layers. After PM staining with WGA and DAPI staining of nuclei along 
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with GFP fluorescence from parasites (Figure 6.10-A), it could be observed that the 
high-density areas corresponded to multiple parasites compartmentalised within the 
PM layer in a ‘pocket’-like structure. Several pockets were 3D reconstructed and their 
corresponding orthogonal views showed that indeed the parasites are trapped 
between PM layers (Figure 6.10-B). Considering the thickness of the fluorescence 
surrounding the pocket, it could be suggested that the parasites are trapped between 
layers 1 (thinnest layer facing the Pm lumen) and 2-plus-3 (thickest layer facing the 
ES). This was further confirmed in TEM images of MG sections (in preparation). In 
Figure 6.10-C, a schematic of an infected MG and PM sections simplifies the 
visualisation of parasite pockets in the PM.  
 
Besides finding parasites in pockets, single ones could also be found across 
the isolated PM. Using 3D reconstructions from z-stacks on single parasites it could 
be observed that some are attached either on the luminal or the ES side of the PM, 
and others are trapped between PM layers too (Figure 6.11-A). In a few 
reconstructions some parasites were seen in a ‘PM crossing-like’ event as the cells 
were transversally inserted in the PM (Figure 6.11-A) or between PM layers but not 
completely (Figure 6.11-B). It is difficult to prove they are crossing the three PM layers 
or only layers 2 and 3 which seem to be softer. It seems clear that the parasites found 
in the ex vivo stained PM are actively attached to it by some kind of interactive 
mechanism since they remain with the PM after many harsh washing steps. In 
addition, in most of the cases, the PM adopts the shape of the trypanosome attached 
to it. The biological role of this attachment to the PM remains unclear. Parasites found 
within PM layers either completely or partially trapped, or in a crossing-like event, 
could be either the result of being trapped in the PV where PM layers bind together, 
or that parasites can actively insert themselves mechanically within PM layers.  
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Figure 6.10. T. brucei trapped in PM ‘pockets’. (A) Control and T. brucei-infected 
(GFP) PM sections stained with WGA-rhodamine and DAPI, and high magnification 
image of a pocket; scale bars = 200 µm. (B) Orthogonal reconstruction of control and 
infected (pocket) PM sections stained with WGA-rhodamine and DAPI, T. brucei 
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express GFP; differential interference contrast (DIC), maximum intensity projection of 
z-stacks (MIP); scale bars = 20 µm. (C) Schematic of top views of control and infected 
midgut sections (left, grey cylinder) showing the endothelial cells (white cells with 
purple nuclei), PM (orange cylinder) and ES (grey area). Sections rotate 90 degrees 
clockwise on the X and Y axes (middle) showing the PM from the side. Detail of the 
PM edge containing a T. brucei pocket between layers 1 and 2-plus-3 (right).   
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.11. Single T. brucei cells interacting with the tsetse PM. (A) 3D 
reconstruction of an infected PM ex vivo with attached parasites in both luminal (L) 
and ES sides. An area with two parasites in a ‘crossing-like’ event is highlighted with 
a white rectangle (1). Two different perspectives of the two crossing parasites (2, 3) 
seen from the ES side. (B) A single parasite trapped within PM layers by DIC (1), 
maximum intensity projection and orthogonal view of GFP and rhodamine channels 
(2), rhodamine only (3), 3D reconstruction of the z-stacks for both channels (4), 
rhodamine only (5), GFP only (6). Scale bar = 5 µm 
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6.4. Discussion 
 
6.4.1 New imaging methodology to reconstruct tsetse tissues 
 
 Good quality imaging methods are essential in basic research to provide direct 
evidence of biological phenomena. Although a broad range of imaging methods 
exists, they sometimes require optimisation to be applied to specific models of study. 
Here, I have set up a methodology based on laser scanning confocal microscopy to 
help visualise structural changes in tsetse tissues or during the interactions between 
T. brucei and tsetse fly tissues. The same methodology could also be applied to other 
tsetse and African trypanosome species such as T. congolense, and even to other 
vector-pathogen systems.  
 
The structural staining relies on a commercial small drug conjugated to a far-
red fluorophore, with high affinity for actin which is very conserved across cell types 
and organisms. This makes the structural staining method suitable for any system, 
although the resultant staining pattern is unpredictable. Thanks to the confocal 
technology, the fluorescence from the specimen can be captured only at the focal 
plane, allowing the acquisition of series of z-stack images across the thickness of the 
specimen and further faithful 3D reconstruction with fine detail. The 3D 
reconstructions can ease visualisation of biological interactions by observing from 
different angles, and the orthogonal views resulting from a combination of the z-stacks 
allow the correct identification of an object’s position within the Z axis which is 
important, for example, to determine whether an object is either inside or outside a 
bigger one. The structural actin staining can be combined with more fluorescent 
markers to label different structures from both vector and pathogen. In the examples 
shown in the chapter, it was of great importance to visualise the nuclei of tsetse and 
trypanosome cells to identify DNA damage due to nitisinone exposure or for the 
identification of parasite stages, respectively. DAPI was chosen to stain DNA since it 
is easy to prepare, does not require cell permeabilisation and provides a strong clear 
signal in the blue range of light. There are other options available to consider, 
especially if live imaging for long periods of time is required, as DAPI intercalates into 
DNA strands and eventually leads to cell death. For instance, the commercial dyes 
DRAQ-5/7 allow DNA staining with high survival rates, although they emit light at 
similar wavelengths than SiR-actin which may give spectra overlapping issues. 
Additionally, the staining of the tsetse PM was of great importance to understand the 
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trypanosome infection dynamics in the MG and PV. The use of the fluorescent-tagged 
WGA lectin allowed the specific labelling of the PM (Schuster et al., 2017) since this 
is rich in chitin which is formed by long chains of N-acetylglucosamine residues 
(Lehane et al., 1996; Rose et al., 2014). Because the staining was intended for live 
imaging and the PM is constantly secreted by the PV (Lehane and Msangi, 1991), it 
was required to feed the tsetse with the lectin and dissect it out within a short period 
of time. PM staining within the PV is otherwise lost from 30 minutes after feeding the 
lectin. Lastly, a good fluorescence detection of trypanosomes was essential for the 
PV infectivity studies shown in this chapter. The expression of fluorescent proteins 
(FPs) by the parasite was the most convenient option for these experiments to avoid 
long immunostaining procedures and facilitate live imaging. The most used T. brucei 
cell line was the strain J-10 previously used by the community (Gibson and Bailey, 
2003), which strongly expresses eGFP under a procyclin promoter. Alternatively, I 
also created a T. brucei AnTat 1.1 90:13 cell line that expresses mNeonGreen under 
tetracycline regulation and driven by the same promoter. The mNeonGreen FP has 
improved brightness (~3-fold brighter than eGFP) and quantum yield (33% higher 
than eGFP) (Shaner et al., 2013), which has helped to overcome poor imaging of 
parasites inside more opaque tissue tissues. The imaging of FPs, however, becomes 
challenging when fixation of the specimen is required. Most standard fixation methods 
rapidly quench FP fluorescence as a result of small structural changes in the 
chromophore. It was required to optimise fixation of FP-expressing trypanosomes to 
allow imaging. Soft fixation with PFA under cold conditions was found to be optimal 
to preserve FP fluorescence. Alternatively, immunostaining with antibodies against 
surface proteins such as procyclins could be used to fluorescently label the parasites, 
although this is unsuitable for trypanosomes trapped within the PM as antibodies 
cannot penetrate through its layers.     
 
 
6.4.2. Assessing tsetse tissue damage upon nitisinone exposure 
 
 As previously described, the drug nitisinone, which is used to treat type-I 
tyrosinemia in humans, was shown to be very effective at killing Rhodnius prolixus 
(Sterkel et al., 2016), the vector of Chagas disease (Coura, 2015). It is suggested that 
nitisinone only affects hematophagous insects, so it can be used in the field to block 
transmission of virtually any vector-borne disease. Our group has recently shown that 
nitisinone is also effective in killing G. m. morsitans, the vector of sleeping sickness 
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(in preparation). In an attempt to further understand the cellular and molecular 
mechanisms that lead to the death of the tsetse upon exposure to nitisinone, I applied 
the developed method of 3D fluorescence tissue reconstruction to flies treated with 
the drug to search for specific patterns of tissue and cellular damage. In order to 
compare nitisinone-induced damaged at either “early” or the “late” stage, but also to 
perform tissue isolation and processing at the same time to prevent batch bias, flies 
were provided with the same dose of nitisinone mixed with different solutions (serum 
or medium), which was previously shown to lead to sub-lethal and lethal phenotypes, 
respectively. Overall, the “late” phenotype flies presented advanced damage of 
tissues that lost structural integrity and functionality. Actin and DAPI stainings were 
overall poor suggesting that cells lost actin and DNA content or condensation, 
probably due to cell death events. Imaging conditions required to be pushed to the 
limit to acquire low quality results. On the other hand, although actin and DAPI staining 
were somehow compromised in the early phenotype, it provided better results since 
all the analysed tissues conserved more or less their integrity, which allowed the 
examination of tissue and cellular damage in greater detail. For example, the salivary 
glands and Malpighian tubules are among the less affected tissues that could be 
analysed.  Apparently unaffected MT was a surprising result since nitisinone quickly 
blocks excretion, suggesting that tissue integrity may not be the cause of excretion 
failure. The fat bodies were also slightly affected and only minor variance in shape 
and size could be appreciated. Remarkably, a few still conserved their structure in 
late phenotype flies although looked severely compromised. The digestive tract (MG 
and PV) was shown to be severely damaged in “early” phenotype flies and completely 
disintegrated in the “late” ones. Not only the MG structure itself was affected but also 
the transversal muscle fibres seemed to have collapsed. Lastly, flight muscle fibres 
were also found to be highly affected upon nitisinone treatment, especially in “late” 
phenotype flies. Despite not revealing a precise mechanism by which the tsetse dies 
upon nitisinone ingestion, these series of imaging analyses helped to understand the 
scope of tissue damage in detail, which could not be determined by using 
conventional microscopy techniques. Further analyses to elucidate the molecular 
mechanisms of death induced by nitisinone are on their way, including untargeted 
metabolomics.    
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6.4.3. Studies on a novel alternative route of tsetse PV infection by 
Trypanosoma brucei 
 
 The methods presented in this chapter were of great usefulness to investigate 
a novel tropism of T. brucei in the tsetse. This observation describes an alternative 
route of early gut colonisation through the PV, which challenges the current 
understanding on how the parasite establishes an infection in the tsetse vector. It is 
thought that T. brucei first invades the ES from the MG by crossing the PM, and then 
it migrates to the PV and establishes an infection there. The alternative route suggests 
the parasites invade the PV as early as 3 days post infection, and parasites can 
access the ES from there or get trapped within PM layers since the PM is continuously 
synthesised in the PV. For both proving the hypothesis and describing the mechanism 
it was required to develop tailored imaging methods to visualise and determine the 
exact location of the parasites inside tsetse tissues with little alterations. After staining 
and mounting optimisations, the method allowed to image trypanosomes both within 
the MG and PV, and with the PM and ES well defined inside. This methodology 
complements recent imaging techniques of trypanosomes within the tsetse midgut 
(Schuster et al., 2017), although with simpler and quicker methodologies, and suitable 
to be used in any confocal  microscope.  
 
The early infection of the PV was first found by live confocal microscopy and 
detailed analyses showed that PVs contain normal proventricular parasite forms, 
except for the absence of epimastigote forms which appear to develop later. 
Experiments with tsetse showed that the tropism is shared by at least 3 different T. 
brucei strains, but it is lost when parasites are kept in culture for a long period of time. 
This also appears to have an impact in the transmission index, suggesting that an 
early PV infection may modulate parasite transmissibility.  
 
When analysing the localisation of trypanosomes in the reconstructed PV and 
AM with PM staining, it could be observed that they invade the ES in both PV and 
AM, and the distribution in those spaces was not always homogeneous but in high-
density patches. In addition, when the infected PM was analysed ex vivo, it could be 
observed that contained multiple trypanosomes attached to it on both sides of the 
matrix, but also trapped in between PM layers in cyst-like structures or ‘pockets’. 
Further analyses of multiple TEM images of infected PM revealed that parasites are 
always trapped between PM layers 1 and 2, although no PM crossing events were 
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ever observed by us or any other group. However, in a few confocal reconstructions 
of infected PMs it could be observed parasites partially trapped in the PM in crossing-
like events. It remains unknown whether these parasites actively crossed the three 
PM layers, or are only able to bury themselves within layers 2 and 3 (opposite to the 
midgut lumen). Alternatively, these parasites could have been trapped in the PV at 
the PM assembling site and dragged away because of PM excretion. 
 
Altogether, these imaging methods combined with TEM allowed us to define 
a novel tropism for the PV at early stages of infection, which is an alternative way for 
T. brucei to invade the ectoperitrophic space of the tsetse gut, and it is likely to 
modulate parasite transmission. 
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CHAPTER 7 
Overall discussion, reflections and future perspectives 
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This thesis first describes how a proteomics approach served for the 
identification of a new family of hypothetical T. brucei proteins found in salivary gland-
dwelling parasites. Based on in silico searches, the five predicted MISP isoforms in 
T. brucei can be GPI-anchored surface proteins, although this remain to be 
biochemically proven. Subsequent experimental work showed that misp expression 
is developmentally regulated, but mainly transcribed in salivary gland stages. This is 
similar to the expression pattern observed in BARP proteins in the fly. Thanks to the 
creation of a polyclonal antibody, MISP could be seen mostly expressed by metacyclic 
cells and localised evenly throughout the cell surface, in great contrast with the 
decreasing expression of BARP (Urwyler et al., 2007). Strikingly, live immunostaining 
of metacyclics showed that MISP epitopes were accessible to antibodies which 
suggests that may not be completely masked by the VSG coat. Further resolution of 
the MISP crystal structure and molecular modelling supported this hypothesis. While 
the core N-termini adopt a triple helical bundle structure, which highly resembles that 
of other unrelated trypanosome surface proteins, the random coiled C-termini with no 
fixed secondary structure of some isoforms is significantly longer than those in VSG 
and BARP, and therefore it may project the core over the VSG coat. More insights 
into the full structure of MISP could be obtained by performing NMR and small-angle 
X-ray scattering (SAXS) studies on the recombinant C-termini domains produced in 
this thesis. Altogether, these studies suggest that the glycocalyx of MCF cells is more 
permissive to the presence and exposure of invariant GPI-anchored proteins than in 
BSFs, probably due to the fact that MCF are not under pressure of the humoral 
immune system during the short time they reside in the mammalian host. The 
biological function of MISP cannot be inferred from in silico searches and it currently 
remains unknown. It can be hypothesised that they may be surface receptors since 
they display a hydrophobic molecular pocket at the distal end which may coordinate 
a ligand molecule. Interestingly, the residues around the pocket present the highest 
divergence among isoforms suggesting they may coordinate different ligands, 
potentially in different hosts. The results of the pulldown assays presented in this 
thesis may identify a putative partner in tsetse saliva, although more MISP isoforms 
should be screened in the future to get a more comprehensive outcome. This putative 
ligand may not necessarily be soluble but a surface molecule on a host cell for cell 
recognition or adhesion, including the possibility of MISP being actively shed as the 
high density of protease recognition sites at the C-termini suggests.  
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In this thesis I also attempted to determine the essentiality of MISP for parasite 
development in the tsetse using RNAi. Although gene knockdown was demonstrated 
in SG parasites for the first time, the absence of a clear phenotype and the mild gene 
down-regulation do not confidently prove that MISP is not important for parasite 
development in SGs. Gene knockout approaches would provide clear answers, 
although classic knockout by cassette replacement is virtually unfeasible due to the 
presence of unrelated genes in between misp, as previously explained. The recent 
CRISPR-Cas9 technology should be used to provide a technical solution to this 
problem, as it would specifically target only misp genes and without the need of using 
multiple selection markers. Tsetse infections with these knocked-out parasites would 
provide more insights into function of MISP in either development or during 
transmission. Furthermore, MISP are the ideal surface marker to determine the 
kinetics of transformation of MCFs into BSFs after transmission by an infected tsetse. 
Additional mice work would include immunisations with recombinant MISP to 
determine the potential protective role of MISP as a vaccine. Lastly, the creation of T. 
brucei BSF cells ectopically expressing MISP could become a powerful tool for the 
study of some aspects of MISP, including the measurement of the relative abundance 
of MISP in relation to VSGs, the localisation of specific MISP isoforms or determining 
the MISP N-glycan structures.  
  
 In order to continue our studies on MISP, a different approach was taken for 
increasing the yield of MCFs. A previously reported in vitro system for the generation 
of MCF upon overexpression of RBP6 (Kolev et al., 2012) was successfully set up 
and new aspects of it were characterised. Although differentiation was triggered 
significantly earlier than previously reported (likely due to differences in the 
expression levels of RPB6), the overall efficiency in the production of MCF and other 
stages was lower. Remarkably, I showed that differentiation events have an impact in 
cell growth speed and trigger the expression of MISP and mVSGs. Preliminary 
experiments also suggest that RBP6 promotes differentiation of MCFs into BSF-like 
cells. This was suggested by the presence of cells with a similar shape to MCFs, but 
bigger and having 2 nuclei and 2 kDNAs, and expressing CRD epitopes on the 
surface. Further investigations need to validate this novel stage formed during in vitro 
differentiation by detecting, for instance, expression of transferrin receptor (only 
expressed in BSFs) and by looking at the activation of canonical BES (Cross et al., 
2014). No further studies were carried out on these in vitro metacyclics due to the low 
yield of production, although this could be overcome in the future by using the ion 
  
224 
exchange purification step from large scale cultures. Additionally, I did some 
functional studies on RBP6 to understand its biological role during development in the 
tsetse, showing that it is mainly expressed in PV and SG parasites and that it appears 
not to be essential for development in the tsetse, although this should be further 
corroborated using conditional-null mutants. 
  
 In pursuit of the identification of genes important for promoting salivary gland 
infections, a comparative transcriptomics analysis was performed on two T. brucei 
strains. These strains differ in the ability to infect tsetse flies as one (Lister 427, 29:13 
clone) is unable to establish salivary gland infections. This revealed several genes 
involved in folate transport, amino acid metabolism and RNA binding, which were 
shown to be up-regulated in tsetse late infection stages and were further validated by 
overexpression in the deficient strain. None of the candidates altered the infectivity 
phenotype except for a hypothetical cytosolic protein with a predicted MYND-like zinc 
finger domain. This protein was found to be up-regulated in late proventricular 
infections in the competent strain only, and its overexpression led to the recovery of 
SG infections. The function of this hypothetical protein remains unknown and cannot 
be inferred only from the presence of the zinc finger domain, which has been found 
to be involved in very different binding functionalities. More studies should be carried 
out to understand the role of this hypothetical protein in parasite development, 
including gene knockout in a fly-transmissible strain and immunoprecipitation to 
identify interactive RNA and protein partners. 
 
 The cell surface of T. brucei is known to be heavily N-glycosylated, including 
the well-studied VSGs and EP procyclins (Ferguson, 1997). Other major surface 
proteins such as BARP or MISP, are also predicted to be N-glycosylated, especially 
considering that T. brucei OSTs are very processive enzymes. During this thesis, I 
attempted to collect MCF cells from multiple tsetse infections with the aim of 
performing mass spectrometry-based glycoproteomics for the structural 
determination of MCF N-glycans. Despite having set up a standard methodology for 
the tsetse infection and collection of MCFs, I failed to obtain enough number of cells 
to perform glycan structural analyses. However, from the functional point of view, I 
found that the OST STT3B isoform, which is the major contributor of high mannose 
N-glycans in BSFs and PCFs, is the only isoform detected in parasites from the tsetse 
midgut, proventriculus and salivary glands. However, it cannot be ruled out that low 
expression of other isoforms was missed in the analyses and their activity may be 
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reflected in changes in N-glycan structures in certain stages. More sensitive analyses 
could be performed in the future using higher amounts of tsetse-derived parasites or 
even using RBP6 cells, although the latter is the less preferred option as the correct 
developmental expression of STT3s may not follow the fast differentiation occurring 
in vitro. STT3 expression measurements by real-time RT-PCR are virtually unfeasible 
due to the high sequence conservation between isoforms. Studying the essentiality 
of N-glycosylation for the parasite during development in the tsetse was of great 
importance too. Despite failing in the creation of conditional-null mutants defective in 
parasite N-glycosylation, RNAi of stt3 genes showed a decrease in tsetse infectivity, 
similarly to previous reports (Izquierdo et al., 2009b). Infectivity was lower in the 
proventriculus compared with the midgut, and parasites were completely unable to 
infect the tsetse SG. These results point at any essential enzyme in the N-
glycosylation pathway as a target to explore in drug discovery approaches. 
  
 Lastly, I set up a method to reconstruct tsetse tissues in 3D for multiple 
purposes. Based on a combination of different staining methods using fluorescent 
probes, the methods proved to be useful for the study of insect tissue damage and 
the interactions between trypanosomes and tsetse. First, it was observed that the 
tyrosine metabolism inhibitor drug, nitisinone, causes tissue damage as shown by the 
total collapse of muscle fibres from different organs and tissues. Further investigations 
could include using other fluorescent molecular probes for determining, for instance, 
if the tissue destruction triggered by nitisinone occurs via apoptosis, necrosis or 
oxidative stress. Second, a novel tropism of T. brucei in the tsetse could be studied 
in more detail. T. brucei can invade the tsetse proventriculus earlier than expected, 
possibly as a parallel route for reaching the midgut ectoperitrophic space. Future work 
to elucidate the role of this tropism in transmission will also benefit from these 
methods, which could also be applied to study late stages of infection including those 
in the salivary glands or widely to study vector-pathogen interactions in other models. 
 
 In summary, the work carried out in this thesis has opened the door to study 
MISP as a vaccine candidate against sleeping sickness and potentially AAT caused 
by T. b. brucei, T. evansi and T. congolense, in addition to be a good candidate for 
xenodiagnoses in the field. It has also identified a new hypothetical protein with a 
MYND zinc finger domain, which may have importance in development of T. brucei in 
the tsetse. In addition, it has reported the developmental expression pattern of the 
oligosaccharyltransferase isoforms in the T. brucei and the potential essentiality of 
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parasite N-glycosylation in the tsetse stages. Lastly, it has also contributed for the 
development of novel imaging methodologies to study vector-parasite interactions, 
which are currently lacking in the field.   
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Primer Code Sequence 5' -> 3' 
3xHA_sfGFP_F_HindIII CGCAAGCTTATGTACCATATGATGTGCCTGAC 
3xHA_sfGFP_R_XhoI CGCCTCGAGCTATACCATATGATGTGCCCTGAC 
BARP_qPCR_F AAGCAAAGGTACAAGCAGAG 
BARP_qPCR_R CGAGTGTTGCTCTCACAG 
Cvar_F GCCGAAAGGACGGCAGAGACG 
Cvar_R GTGTATCCTCCTATAGATTCTGCATAGC 
FT_CDS_R_BamHI CGCGGATCCTCAGCGTCTGTCGCGTCTGCCGT 
FT_HA_CDS_F_HindIII CGCAAGCTTATG-[HA]-GCTTCGACAATCTACAATTTCAA 
GDH_CDS_F_XbaI CGCTCTAGAATGATGCGCCGTGCTTCTTA 
GDH_CDS_R_XbaI CGCTCTAGAAGAGATGTGCTTGGCCTGC 
MISP_-GPI_R_XbaI CGCTCTAGAGCTGCCGTCATTACCAAC 
MISP_-GPI_R_XhoI GCGCTCGAGGCTGCCGTCATTACCAAC 
MISP_-SP_F_NcoI GCGCCATGGACTCCATAATTGAGGAAGGG 
MISP_-SP_F_NdeI CGCCATATGGACTCCATAATTGAGGAAGGG 
MISP_C_F_NdeI CGCCATATGACGGAAGAAGCGGATGTTC 
MISP_qPCR_F GTGAGGAAGCAGAAGTTGG 
MISP_qPCR_R AAAGTGCTGCAAGAAGGATC 
MISP_RNAi_ANTI_F_NdeI CGCCATATGCACTACAGCAATTCGGGATAATC 
MISP_RNAi_ANTI_R_HindIII GCGAAGCTTGCCTCTCGCAATTCGTCTTG 
MISP_RNAi_SENSE_F_XhoI CGCCTCGAGCACTACAGCAATTCGGGATAATC 
MISP_RNAi_SENSE_R_BamHI GCGGGATCCGCCTCTCGCAATTCGTCTTG 
MISP360_CDS_R_BglII GCGAGATCTTTAAAAATGTGCGGCAGC 
MISP360_CDS-SP_F_XbaI GCGTCTAGAGACTCCATAATTGAGGAAGG 
mNG_CDS_F_HindIII  CGCAAGCTTATGGTCTCGAAAGGTGAGGAAG 
mNG_CDS_R_BamHI  CGCGGATCCCTACTTATACAATCGTCCATCCC 
MYND_CDS_F_HindIII CGCAAGCTTATGACAACTTCCCCATCCAC 
MYND_CDS_R_XbaI CGCTCTAGAGCTGAAGGCAGCGGACTTT 
RBP6_CDS_R_BamHI CGCGGATCCTCAACCAGCGGCACCGCGGGAAC 
RBP6_HA_CDS_F_HindIII CGCAAGCTTATG-[HA]-CTTTCTACCCCAACAGCCCGCA 
RBP6_RNAi_ANTI_F_NdeI CGCCATATGCAACAGCCGTATCATCCCTT 
RBP6_RNAi_ANTI_R_HindIII CGCAAGCTTACTCATTCGCTCCACAGCTT 
RBP6_RNAi_SENSE_F_XhoI CGCCTCGAGCAACAGCCGTATCATCCCTT 
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RBP6_RNAi_SENSE_R_BamHI CGCGGATCCACTCATTCGCTCCACAGCTT 
RFT1_3_F_XbaI  TCTAAGGTGGGAATAATG 
RFT1_3_R_SacI  AGCTTGGAGTCCATGAC 
RFT1_5_F_HindIII GGAAGCGCAATCATTCAGAG 
RFT1_5_R_EcoRI  CACACCAAAGGTACAGCTGC 
RFT1_CDS_F_HindIII ATGGACTTCAAACGACAGCTGGC 
RFT1_CDS_R_XhoI  CTACTCGCCCGTTG 
SST3B_RT_F GCGTCGAATGATGATTTCTTTG 
SST3C_RT_F GGCCTTCCTACGTCATC 
SST3C_RT_R TCATCGGCAAGAACCAAC 
STT3_3_F_XbaI  CGCTCTAGAACCCATGTTTCCGTCTTG 
STT3_3_R_SacI CGCGAGCTCCCCGCTATAAGCTACTTCTC 
STT3_5_F_HindIII  CGCAAGCTTGCGTATGTGCCTTGTTAGTG 
STT3_5_R_EcoRI  CGCGAATTCTTATGAAATGGGGATGAG 
STT3_RNAi_ANTI_F_NdeI  CGCCATATGGTGAGGGAGGGATGAGTAAG 
STT3_RNAi_ANTI_R_HindIII CGCAAGCTTCCATTGATCGCATCAGGTG 
STT3_RNAi_SENSE_F_XhoI CGCCTCGAGGTGAGGAGGGATGAGTAAG 
STT3_RNAi_SENSE_R_BamHI CGCGGATCCCCCATTGATCGCATCAGGTG 
STT3A_RT_F ATTGTGGCAAGTTTGCTTG 
STT3A_RT_R CATTGGGTAGATCAGTCACG 
STT3B_RT_R TATAATCTGGGGGCTCGAC 
TERT_qPCR_F AACAGTAAGTCCCGTGTGG 
TERT_qPCR_R GCCTTCAGTTTGTCCAAGAAG 
TERT_RT-PCR_F AACAGTAAGTCCCGTGTGG 
TERT_RT-PCR_R CAAAGTCGTACTTCAACATCAG 
 
